In the face of cancer
annual report 2015
Mission
The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

Vision
We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science.

We are Making Cancer History®.

Core values
Caring
By our words and actions, we create a caring environment for everyone.

Integrity
We work together to merit the trust of our colleagues and those we serve.

Discovery
We embrace creativity and seek new knowledge.
Contents

4 From our president

6 Patient care
   Our highest priority

18 Research
   Today’s discoveries are tomorrow’s treatments

32 Prevention
   A proactive approach to understanding and stopping the disease

46 Faculty

52 Board of Visitors

54 Donors

62 Financial and statistical data
In the face of cancer.

It’s a phrase that describes our patients, who, faced with a disease that is unpredictable and unforgiving, remain strong and determined.

It describes our doctors, researchers, educators and staff, who are relentless in their drive to stop a plague that robs us all of friends, family and loved ones.

At MD Anderson Cancer Center, we’re confronting cancer through innovations and advancements generated by the Moon Shots Program. We’re staring down the disease in laboratories, where new discoveries are leading to better understanding of a complex and elusive enemy. We’re training the next generation of scientists and clinicians in the Graduate School of Biomedical Sciences and the School of Health Professions. We’re harnessing and mining mountains of data to personalize treatments that best fit each patient. We’re helping them beat the disease, as well as deal with the complications of living through treatment. We’re supporting survivors and taking proactive steps to prevent cancer in the future.

We’re at the forefront of cancer treatment and discovery, and we’re on the front lines of this battle, standing shoulder to shoulder with our patients.
The Golden Era of Cancer Research and Care

When President Barack Obama called for a national moon shot to end cancer, the MD Anderson community and our patients cheered. For nearly 75 years, cancer has been our priority, and we are heartened to see it elevated to a true national priority.

At MD Anderson, our researchers and clinicians have moved us closer to meeting such a challenge, and we reinforced our commitment to doing so with the 2012 launch of our Moon Shots Program, an unprecedented effort to more rapidly convert scientific discoveries into lifesaving advances.

Our mission is clear. Our commitment is strong. And so is the support we receive, which is saving lives and accelerating progress in the years to come.

With a focus on patient care, research, prevention and education, we are discovering the causes of and cures for these devastating diseases. In the past year, we’ve made significant progress. We’re thinking big and creatively to make game-changing discoveries. We even expanded our program to 12 moons shots, adding six more of the most intractable cancers plaguing humanity for intensive focus. Our multidisciplinary teams, enabled by deep expertise and advanced technology, are ready to defeat our foe. And only three years after the launch, we’re already transitioning from an implementation phase to a results phase.

Giant leaps have been made to protect the future health of our children. Our cancer prevention and control platform, in collaboration with other organizations, continued its great work inspiring and educating legislators to enact valuable public health policies. During the 2015 Texas legislative session, this led to laws prohibiting access to and use of e-cigarettes by minors, the lifting of a hard-to-believe prohibition on children taking sunscreen to school, and implementation of a statewide strategic plan for preventing HPV-associated cancers.

New clinical trials bring to our patients innovative approaches to targeted therapy and immunotherapy. We’ve launched 125 immuno-oncology trials involving nearly 6,000 patients across all major cancer types, and our state-of-the-art immune system monitoring program — together with our big data framework — helps us understand who is helped by these drugs and why.

Speaking of immunotherapy, Jim Allison, Ph.D., a trailblazer in the field, who discovered a way to unleash the body’s immune system to attack cancer, received the Lasker-DeBakey Clinical Medical Research Award, the nation’s highest honor for clinical medical research. His findings led to the development of promising immunotherapy drugs that are benefiting patients around the world.

We’re using disruptive technologies and working smarter to more efficiently attack cancer on myriad fronts. We’ve developed the world’s most advanced data-generation, aggregation and analytics system to enable precision medicine for every patient. This platform, aptly named APOLLO for Adaptive Patient-Oriented Longitudinal Learning and Optimization, will revolutionize our ability to learn from each patient and dramatically accelerate translational research to a new level. Beyond our walls, our efforts to spread our knowledge and elevate the quality of care elsewhere continue with our development of a health care operating system that utilizes mobile devices, a secure cloud for data and IBM Watson cognitive computing.
Our ability to influence cancer care and share best practices throughout the world also is embodied in our Cancer Network, which continued to grow with the addition of our newest partner member, Baptist MD Anderson Cancer Center in Jacksonville, Florida, and three certified members, as well as the introduction of our first associate member, Hospital Israelita Albert Einstein in São Paulo, Brazil. With 20 Cancer Network members across the nation and around the world, we truly are making a difference in our collective fight to end cancer. These care-oriented collaborations join the 32 sister institutions in our Global Academic Program, which focuses on research and training opportunities in 23 countries.

As we prepare to celebrate MD Anderson’s 75th anniversary, we also must look back on the brilliant, innovative work of legendary faculty members such as Josh Fidler, D.V.M., Ph.D., and Emil Freireich, M.D., who celebrated his 50th year with the institution in 2015. Their work in understanding cancer metastasis and combination chemotherapy, respectively, is some of the most important in the war on cancer over the past 100 years. It has been an honor to serve as their colleague.

Today, our clinicians and researchers are working on tomorrow’s cancer care breakthroughs. Our clinical trials program — the world’s largest and most impactful — offers hope and help to patients who don’t respond to the current standard of care. The program’s more than 1,200 protocols demonstrate the direct line from research to clinical care, two of the pillars elevating this institution. Of note, MD Anderson is responsible for leading the trials for one-third of all new cancer treatments approved by the Food and Drug Administration.

The importance of research goes beyond clinical trials. Every day, in our Texas Medical Center labs and our research facilities in Bastrop County, scientists are learning what drives cancer, a complex and evasive disease. They’re hard at work to understand how cancer develops and grows, what fuels it and what its vulnerabilities may be. Those determinations are yielding pivotal discoveries, as evidenced by the more than 3,600 papers published by our faculty in scientific journals last year.

None of this would be possible without funding for research. This comes in many forms, such as tens of millions of dollars we have invested for shared core facilities, new granting mechanisms such as the Clark Fellows and Clinical Innovator Awards, an expanded Institutional Research Grant program and an ever-growing Graduate School of Biomedical Sciences. A most recent example is a transformational $30 million gift established by the Andrew Sabin Family Fellowship Program that will fund the brilliant ideas of world-class cancer researchers who push the boundaries in our quest to end cancer and will ensure the support of our faculty for decades to come.

You’ll read more about these and other inroads in the war on cancer in the pages of this Annual Report, which features many of our clinicians, researchers and brave patients on the front lines. These stories will explain why the institution is again ranked as the nation’s No. 1 hospital for cancer care, and why Chancellor William McRaven describes MD Anderson as “the crown jewel” of The University of Texas System.

We are a family of 21,000 cancer fighters, made stronger by the commitment of our patients, their families and everyone joining us in this fight to end cancer. We’re on a mission. Together, we are Making Cancer History.

Ronald A. DePinho, M.D.
Patient Care

Jim Boysen, 56
Leiomyosarcoma survivor

Being the first person to undergo a skull and scalp transplant gave Jim Boysen a new lease on life. Chemotherapy and radiation treatment for leiomyosarcoma — a rare cancer of the smooth muscle under the scalp — left Boysen with a deep head wound that immune suppression drugs kept his body from healing. He was taking the drugs to prevent his body from rejecting a transplant he received more than 20 years ago because of complications from diabetes. In turn, the open wound stood in the way of a much-needed second kidney and pancreas transplant.

Reconstructive plastic surgeon Jesse Selber, M.D., saw Boysen as an ideal candidate for a first-of-its-kind composite tissue transplantation in which the 56-year-old received a partial skull and scalp, a pancreas and a kidney, all at once.

“This has been a long journey, and I am so grateful to all the doctors who performed my transplants,” says Boysen, who is back at home in Austin and doing well. “I’m amazed at how great I feel, and I’m forever grateful that I have another chance to get back to doing the things I love and be with the people I love.”

From first-ever surgeries to translational research and drug discoveries that are yielding previously unheard of benefits for patients, MD Anderson’s faculty members and staff continue to improve and advance treatment options. Last year, the institution’s doctors, nurses and other cancer fighters cared for more than 267,000 patients in the Houston area and through its Cancer Network, which is making MD Anderson-quality care accessible to more people.

Read more about Boysen’s groundbreaking surgery on Page 9.
Patient Care

Reconstructive plastic surgeon Jesse Selber, M.D.
In 2015, surgical history was made
Collaboration and a unique opportunity led to the world’s first skull and scalp transplant
By Jacqueline Mason

After undergoing a first-of-its-kind surgery, music lover Jim Boysen is back home in Austin, doing the things he loves.

“I’m playing keyboards, riding my mountain bike and enjoying my favorite Tex-Mex foods,” says the 56-year-old software engineer, who’s also back at work and “feeling great.”

“That post-surgical diet was bland and boring. Give me enchiladas any day.”

Last May, doctors from MD Anderson and Houston Methodist Hospital performed the world’s first skull and scalp transplant on Boysen, whose treatment for a rare cancer of the scalp muscle left him with a deep head wound.

During the same surgery, he also received a kidney and pancreas transplant, making it the first time a patient has undergone a simultaneous craniofacial and solid-organ transplant.

Boysen’s first kidney-pancreas transplant was in 1992, a result of diabetes he's had since he was 5 years old. The immune suppression drugs he took to keep his body from rejecting his kidney and pancreas raised the risk of cancer and he developed leiomyosarcoma, a rare type of cancer affecting the smooth muscle under his scalp.

The drugs also prevented his body from repairing the wound caused by radiation therapy for his scalp cancer. To make matters worse, the transplanted organs he received 23 years ago were starting to fail.

However, doctors couldn’t perform a new transplant as long as he had an open scalp wound.

Jesse Selber, M.D., a reconstructive plastic surgeon at MD Anderson, saw a unique opportunity after first meeting Boysen several years ago. His solution was to give Boysen a partial skull and scalp, a pancreas and a kidney, all at once.

“Opportunity favors the prepared mind,” Selber says. “I've been deeply interested in composite tissue transplant since I was in surgical training. I read immunology textbooks and got up to date on this state-of-the-art procedure, which is a kind of subset of reconstructive microsurgery.”

From opportunity to orchestration of a world first
In composite tissue transplantation, doctors transfer skin, muscle, bone and nerve from a donor to a recipient. It’s less established than solid-organ transplants and free-flap procedures that use tissue harvested from the patient’s own body.

Fortunately for Boysen, MD Anderson has one of the most recognized microsurgery programs in the world.

Selber led Boysen’s microsurgery team, which included professors Matthew Hanasono, M.D., and Peirong Yu, M.D., and assistant professors Edward Chang, M.D., and Mark Clemens, M.D.

“While the approach seemed radical at first, in practice, we perform these techniques every day,” says Clemens. “By using them for Mr. Boysen, we helped him and, in the process, broke through certain surgical dogma and opened up a new reconstruction option for our cancer patients.”

The moment Clemens cherishes most is when blood flowed to Boysen’s scalp following hours of delicate surgery to connect blood vessels about half the diameter of a human hair.

“A blush of pink spread across the skin in a wave,” he recalls. “The surgery itself is very mechanical. But seeing that suddenly reminds you of the magnitude at hand and the stunning realization that it is possible.”

Chang, who performs more than 100 free-flap procedures a year, felt the enormity of this procedure resting on his shoulders.

“Every stitch I made seemed like a small step toward success, and even a little stumble or falter would mean failure.”

In the end, the successful procedure, which involved a team of about a dozen doctors and 40 health care professionals, created a gateway to more composite tissue transfers in the future.

“It certainly opens a lot of doors for patients who take immunosuppressive medications for organ transplants to undergo transplant of skin, muscle and skeletal structures as well,” Hanasono says.

Yu agrees.

“The experience really shows that by working together we can help many patients who need sophisticated multiple-organ transplantation.”
To be the No. 1 cancer hospital, you need the best and brightest physicians

By Laura Sussman

Patients know that choosing a world-class institution means they’ll be treated by world-class doctors. That’s why they choose MD Anderson. It’s where the next generation of outstanding physicians is caring for cancer patients today. Five of the institution’s best young physicians share what motivates them, why they chose to work in oncology and how they are constantly inspired by their patients.

Van Morris, M.D.
Assistant professor of Gastrointestinal Medical Oncology

During his residency, Van Morris noticed a unique quality about cancer patients that drew him to pursue a career as a medical oncologist.

“When patients first hear the word cancer, the mask of who they want you, as their doctor, to see comes off. From that point, the doors open to form an authentic doctor-patient relationship. And as a clinician, that’s most gratifying to me.”

The quickly evolving field of molecular oncology offers Morris a chance to work as part of a team in what he calls the most fascinating science in medicine. He was drawn to MD Anderson’s Fellowship Program because of its combined emphasis on high-quality patient care and patient-centered research.

Under the guidance of Scott Kopetz, M.D., associate professor of Gastrointestinal Medical Oncology, Morris secured multiple grants and wrote a clinical trial of colon cancer that’s driven by a mutation in the BRAF gene. Five to 10% of all colon cancer patients carry this mutation, which is associated with particularly poor outcomes. Under Cathy Eng, M.D., professor of Gastrointestinal Medical Oncology, Morris wrote and developed the first-ever Phase II clinical trial of the drug nivolumab for the treatment of anal cancer that spreads and resists treatment — a collaboration with MD Anderson’s immunotherapy platform.

These types of high-caliber mentorship opportunities for hematology and oncology fellows and junior faculty aren’t available elsewhere, he says.

Isabella Glitza Oliva, M.D., Ph.D.
Assistant professor of Melanoma Medical Oncology

Without a doubt, Isabella Glitza Oliva is a high-energy adventurer. She’s an avid world traveler who, so far, has pins in 49 countries on the map. She’s a car and motorcycle enthusiast and is passionate about diving. She’s also a gourmet cook who doesn’t have the patience for baking.

But when it comes to caring for patients, she knows how to gear down when the time is right.

“I tell them cancer is a journey that comes with fast as well as slow passages,” says Glitza Oliva. “I’ll always let them drive, but I’ll be in the passenger seat with the map in my hand to help navigate the way.”

A melanoma medical oncologist, Glitza Oliva chose her specialty because of the mentorship she received as a fellow at MD Anderson and rapid developments in the field of immunotherapy, where new drugs and therapies that boost the immune system’s ability to fight cancer are being designed and used.

Glitza Oliva is particularly interested in leptomeningeal disease, or LMD — a complication that arises when melanoma spreads to the membranes surrounding the brain and spinal cord. MD Anderson has been a leader in the treatment of this rare condition, using an immunotherapy approach that involves injections directly into the spinal fluid.

“Ultimately, I’m driven by my passion to help people. By choosing this field, I hope to offer long-term care, and that’s very important to me.”
Nishin Bhadkamkar, M.D.
Assistant professor of General Oncology

Nishin Bhadkamkar is a second-generation contributor to MD Anderson’s mission. His mom, Viju, has been involved in clinical research for more than 25 years.

“We talked about cancer at the dinner table. Obviously, as a kid, I didn’t fully understand it, but it piqued my interest in medicine.”

It was an MD Anderson summer program during college, working alongside physicians who would become his mentors, that solidified his interest in oncology.

Bhadkamkar calls oncology a great fit for his personality.

“Intellectually, it’s an interesting and satisfying specialty; there’s always new research on the horizon. There’s also the human aspect and chance to develop meaningful relationships with patients. That’s very important to me.”

As an MD Anderson fellow, Bhadkamkar enjoyed his work at Lyndon B. Johnson Hospital, where MD Anderson doctors provide cancer care to underserved patients.

At LBJ, Bhadkamkar also is training MD Anderson’s hematology and oncology fellows.

Delivering MD Anderson-quality care to those in need is a responsibility he and his LBJ colleagues take very seriously. He hopes to make MD Anderson’s therapeutic clinical trials more accessible to LBJ patients.

Terri Woodard, M.D.
Assistant professor of Gynecologic Oncology and Reproductive Medicine

Terri Woodard was groomed to be a geriatrician before she switched her focus to obstetrics and gynecology, and then reproductive endocrinology. She began seeing a number of cancer patients who were struggling with fertility issues, and found it rewarding to counsel them about their options for having children.

“There was this huge quality of life issue that was not being adequately addressed in the cancer population. I realized I could make a difference in these women’s lives.”

As MD Anderson’s first reproductive oncologist, Woodard has helped build the institution’s onco-fertility service — making patients aware of fertility options before and after cancer treatment.

Much like oncology, it’s an exciting time in reproductive endocrinology, says Woodard. Just four years ago, freezing a woman’s eggs was still considered experimental.

“We also have the possibility of freezing ovarian tissue and will soon open a research protocol,” she says. “If a young woman or girl needs chemotherapy right away, we can harvest ovarian tissue and place it back into her body if she has ovarian failure. In the future, we’ll be able to get immature eggs from the tissue and mature them in the lab.”

After three years at MD Anderson, Woodard is now beginning to see patients who’ve completed cancer treatment and are going on to have children, using the eggs or embryos they froze before treatment. Others have used gestational carriers, or even donor eggs.

Jianjun Zhang, M.D., Ph.D.
Assistant professor of Thoracic Head and Neck Oncology

Physician scientist Jianjun Zhang was always fascinated with physics and biology, but he turned his interest to cancer science after his father died of the disease when Zhang was still in high school. Following training in China, he traveled to the United States to continue his education, which included an oncology fellowship at MD Anderson.

“Although many new drugs have been approved during the past several years, the help we can offer our patients, especially in lung cancer, is still very modest,” he says. “That’s why we need more research.”

To maximize his impact, Zhang balances a career in both the clinic and the lab.

“I have to see patients so that I know I’m helping them. But I also feel it’s our obligation to conduct research to advance the field so we can potentially help even more patients,” he says.

Zhang’s research involves genomic profiling of specific subsets of lung cancers. He’s focused on understanding patients’ response to therapy, with the goal of finding better approaches to improve treatments. He’s also interested in immuno-genomics — applying genomic technologies to understand the immune system.

“We know the genomic profiles of cancers may be related to response to immunotherapy,” he explains. “We’re trying to use that as a tool to look at both the genomic profile of the cancer and the genomic profile of the immune cells to understand that relationship — and how to improve treatment efficacy.”
Curing leukemia without debilitating side effects

By Scott Merville

Jamie Whittington has an aggressive form of chronic lymphocytic leukemia, but you’d never know it.

“I haven’t experienced anything bad. No symptoms. No side effects, nothing,” she says. “I tell my granddaughter that my blood is sick, but I’m not sick.”

Whittington’s experience reflects a shift in the treatment for the disease known as CLL, from traditional chemotherapy to newer targeted therapies that attack cancer cells without harming normal cells — an area in which MD Anderson is leading the way.

“With these new targeted drugs, CLL patients are doing very well, maintaining normal lives and have no symptoms or signs of their disease. Only traces of leukemia — found by our most sensitive tests — remain,” says Jan Burger, M.D., Ph.D., associate professor of Leukemia and Whittington’s oncologist.

In people with CLL, the white blood cells — specifically B cells — that protect against disease and infection grow out of control. As they multiply, they crowd out healthy cells in the blood, bone marrow, lymph nodes, spleen and liver.

Through a clinical trial Whittington joined two years ago, she’s given ibrutinib, a drug that blocks a protein that aids B cells’ growth. The trial is part of the CLL Moon Shot, which taps the expertise of Burger and his colleagues who played leading roles in the early clinical trials of the drug.

“The Moon Shot Program is closely linked to the clinical trial she’s in, where we pursue a large number of laboratory studies to understand resistance to ibrutinib and develop new combination treatments with the goal to eradicate the leukemia,” Burger says.

Goal: Double the cure rate

Combination chemotherapy in which multiple drugs are given simultaneously, including a standard-of-care regimen developed at MD Anderson, has achieved a 35% cure rate for CLL, but comes with severe side effects that can force patients off treatment. CLL Moon Shot leaders think they can double the cure rate to 70% using ibrutinib and other targeted therapies.

Whittington’s CLL was caught by a routine blood test at her annual well-woman checkup in 2013. CLL usually progresses slowly and many patients are monitored for years before treatment becomes necessary.

“With these new targeted drugs, CLL patients are doing very well, maintaining normal lives and have no symptoms or signs of their disease. Only traces of leukemia — found by our most sensitive tests — remain,” says Jan Burger, M.D., Ph.D., associate professor of Leukemia and Whittington’s oncologist.

In people with CLL, the white blood cells — specifically B cells — that protect against disease and infection grow out of control. As they multiply, they crowd out healthy cells in the blood, bone marrow, lymph nodes, spleen and liver.

Through a clinical trial Whittington joined two years ago, she’s given ibrutinib, a drug that blocks a protein that aids B cells’ growth. The trial is part of the CLL Moon Shot, which taps the expertise of Burger and his colleagues who played leading roles in the early clinical trials of the drug.

“The Moon Shot Program is closely linked to the clinical trial she’s in, where we pursue a large number of laboratory studies to understand resistance to ibrutinib and develop new combination treatments with the goal to eradicate the leukemia,” Burger says.

“With these new targeted drugs, CLL patients are doing very well, maintaining normal lives and have no symptoms or signs of their disease. Only traces of leukemia — found by our most sensitive tests — remain,” says Jan Burger, M.D., Ph.D., associate professor of Leukemia and Whittington’s oncologist.

In people with CLL, the white blood cells — specifically B cells — that protect against disease and infection grow out of control. As they multiply, they crowd out healthy cells in the blood, bone marrow, lymph nodes, spleen and liver.

Through a clinical trial Whittington joined two years ago, she’s given ibrutinib, a drug that blocks a protein that aids B cells’ growth. The trial is part of the CLL Moon Shot, which taps the expertise of Burger and his colleagues who played leading roles in the early clinical trials of the drug.

“The Moon Shot Program is closely linked to the clinical trial she’s in, where we pursue a large number of laboratory studies to understand resistance to ibrutinib and develop new combination treatments with the goal to eradicate the leukemia,” Burger says.

CLL — the most common adult leukemia — is a malignancy of immune system B cells (white blood cells that normally produce antibodies against infection). The American Cancer Society estimates almost 19,000 new cases will be diagnosed in 2016 in the U.S., and about 4,600 people will die of CLL.

Drift thwarts rapid progression

Seven months after diagnosis, Whittington’s white blood cell counts rose to a level that prompted her oncologist to plan for chemo.

“I called Dr. Burger, came to MD Anderson and went on an ibrutinib clinical trial,” she says.

Her white count went up the first few weeks, which is common with ibrutinib because the drug pulls CLL cells into the bloodstream from the lymph nodes, spleen and bone marrow to die.

Her symptoms — night sweats, swollen lymph nodes and spleen, lack of energy — vanished in a week. “I’ve never had any side effects from the drug.”

After six weeks, her white blood cell counts began to plummet and her CLL went into remission. That was in October 2014. Now Whittington takes three ibrutinib pills a day, comes in every three months for blood tests and has an annual CT scan, bone marrow aspiration and biopsy. She’s never missed more than a day of work.

“I’m excited. I thank God every day because I couldn’t have a better care team,” she says.
Associate professor of Leukemia Jan Burger, M.D., Ph.D.
We’re putting the best cancer care within reach

To truly eliminate cancer, MD Anderson must expand its footprint in Houston and form relationships with hospitals and health systems around the world.

And MD Anderson Cancer Network™ is collaborating with community hospitals and health systems to provide the highest-quality and most advanced cancer care to patients in the communities in which they live.

“The National Cancer Institute estimates that only about 15% of U.S. cancer patients are diagnosed and treated at the nation’s major academic-based cancer centers,” says Margaret Row, M.D., vice president of operations for the Cancer Network. “Through our network, we can reach more people nationally and internationally.”

With objectives to improve access to specialized care and clinical trials, disseminate knowledge, deliver high-quality, multidisciplinary care and drive new discoveries, the network has been growing quickly. More than 115 million people now have access to MD Anderson care or best practices through its network members.

Close to home

In a unique partnership, MD Anderson joined forces with Memorial Hermann to create an integrated breast-screening program across the Houston area. The collaboration combines the cancer center’s expert breast screening and diagnostic services with the convenience of Memorial Hermann’s locations. In less than a year, the program, which began in five locations before expanding to 10, provided more than 77,000 patients with approximately 147,000 procedures. The program grew again in February, expanding to 15 sites.

MD Anderson also provides cancer care to the underserved at Harris Health’s Lyndon B. Johnson Hospital. In the past year, MD Anderson doctors have provided cancer care to 3,800 patients from underserved populations of Harris County.

Partnering to deliver care

MD Anderson’s collaborations bring extensive expertise and resources to communities across the nation as co-branded, multispecialty cancer centers. More than 22,000 newly diagnosed cancer patients sought diagnosis or treatment at MD Anderson’s network affiliates this year. Covering a population of more than 100 million people, these sites are strategically located to allow the institution to have the largest possible impact around the globe.

With partnerships at Banner MD Anderson Cancer Center in Gilbert, Arizona, MD Anderson Cancer Center at Cooper (Camden, New Jersey), Baptist MD Anderson Cancer Center (Jacksonville, Florida), an extension of the partnership of MD Anderson at Cooper with Summit Medical Group (Berkeley Heights, New Jersey), 14 current certified members across the country, as well as other national and international relationships in development, the care and knowledge that have made MD Anderson the nation’s top cancer hospital continue to have expanded worldwide reach.

Increasing access to MD Anderson quality and best practices

MD Anderson Cancer Network now has 14 certified members in 12 states, all of which take part in the MD Anderson quality improvement and best practices program. Through these sites, a population of more than 15 million people now has access to health systems and physicians certified by MD Anderson.

With a goal to more than double in size to over 30 member health systems by 2021, the number of potential patients who can receive oncology care that’s been shaped by MD Anderson will be increasing as well.

MD Anderson Breast Care with Memorial Hermann in the first year:

- 77,466 Patients served
- 146,781 Total procedures
- 107,591 Mammograms performed
- 293 Patients treated at MD Anderson locations following diagnosis
Sabin gift encourages research that tests the limits, delivers big impact

By Sarah Watson

Thanks to a $30 million commitment from New York-based Andy Sabin and his family foundation, promising young scientists at MD Anderson can independently pursue high-risk, high-impact research projects with one collective goal: to end cancer.

The Andrew Sabin Family Fellowship Program, through an endowment established by the Andrew Sabin Family Foundation, is designed to annually fund up to eight two-year research fellowships, at $100,000 each. The program encourages creative, independent thinking and impactful research. The MD Anderson grant is the foundation’s largest to date.

The gift will help MD Anderson researchers make substantial strides in the fight against cancer, says Ethan Dmitrovsky, M.D., executive vice president and provost of MD Anderson.

“Without the intellectual curiosity of leading young researchers who have the means to explore non-traditional solutions, progress in the fight against cancer will remain slow,” says Dmitrovsky. “The Andrew Sabin Family Foundation’s legacy gift will help advance research that results in real hope for cancer patients and their loved ones.”

Sabin has served on the MD Anderson Cancer Center Board of Visitors since 2005 and is president of Sabin Metal Corp., the largest privately owned precious metals refiner and recycler in the country. He devotes much of his time and energy to advocating on a national level for increased cancer research funding and is widely known as an avid environmentalist, conservationist and wildlife enthusiast.

Sabin says he hopes his gift will eliminate the need for highly qualified researchers at MD Anderson to spend “50 percent of their time fundraising to sustain innovative projects.”

“Through this program, they have the opportunity to focus instead on important work that can truly help people who suffer from cancer,” he says.
An immunotherapy drug to bolster a T cell surge
By Scott Merville

MD Anderson Melanoma Moon Shot researchers are combining two immunotherapies for the first time to double-team melanoma that has spread to other organs and resisted all forms of treatment.

Patients in a first-of-its-kind clinical trial will receive a vastly expanded dose of their own T cells — white blood cells that are the specialized warriors of the immune system — followed by a cancer immunotherapy drug known to promote the activation and survival of T cells.

“We’re excited about this combination because there’s no standard of care now for our metastatic melanoma patients if immune checkpoint blockade drugs fail,” says clinical trial leader Rodabe Amaria, M.D., assistant professor of Melanoma Medical Oncology.

Checkpoint blockade drugs allow the immune system to unleash T cells to attack tumors. The drugs work by blocking molecules on T cells that act as brakes, which prevent the immune system from launching an attack. To date, researchers have developed two types of drugs that target two separate brakes. Brake No. 1 is called CTLA-4 and brake No. 2 is named PD1. The drugs have revolutionized melanoma treatment, producing powerful and lasting responses in about 10% to 30% of patients who take one drug only, and in more than 50% of those who take both drugs combined.

That still leaves substantial numbers of patients in need of a new approach. For checkpoint blockade to work, there have to be T cells primed and willing to attack the cancer.

Enter T cell expansion and infusion. T cells that attempt to kill cancer are often found in tumors that are removed or biopsied. There just aren’t enough of them to succeed.

Patrick Hwu, M.D., head of Cancer Medicine and chair of Melanoma Medical Oncology, pioneered an approach that grows T cells on slices of a patient’s tumor in the lab, expands them to billions of cells over a few weeks, then infuses them back into the patient. The cells are called tumor-infiltrating lymphocytes, or TILs.

“We’ve treated about 100 patients with TILs. About 45 percent respond, and some of those responses last for years,” Amaria says. “There’s a lot of room for improvement.”

Patients in Amaria’s trial receive T cell expansion followed by a checkpoint blockade drug that blocks PD1. The trial is the first to combine TILs with a PD1 inhibitor.

This double-whammy combination may also stimulate small proteins that fire up the immune system, according to research conducted in Hwu’s lab by Weiyi Peng, M.D., Ph.D. In the clinical trial, 36 patients with metastatic melanoma will have surgery, so their tumor-attacking T cells can be expanded and then frozen. They’ll then be hospitalized and treated with chemotherapy to reduce their existing T cells before being infused with their TILs.

After that, they’ll receive interleukin-2, an immune stimulating protein, to bolster immune response. Three weeks later, they’ll receive the PD1 inhibitor drug Keytruda.

Patients’ tumors are biopsied once before and at least twice after treatment.

“Biopsies are a priceless learning opportunity,” Amaria says. “It’s so important to see what’s happening in tumors throughout the course of treatment so we can understand and improve how we manage disease.”
Bold advances require the latest technology
By Emily Watkins

To meet a growing demand for clinical, diagnostic and support services, ground was broken in 2013 for The Pavilion, an eight-story, 184,800-square-foot facility connected to the Main Building.

After more than 800,000 hours of construction work, the structure was completed in November 2015.

Among its many features, MD Anderson’s newest facility houses state-of-the-art surgical and interventional radiology suites that will allow MD Anderson to treat a greater number of patients at the highest level.

“The Pavilion is just an incredible facility,” says Ronald DePinho, M.D., president of MD Anderson. “It’s one of the most advanced infrastructures for surgery and interventional radiology in the world.”

The building’s six operating rooms, including one for intraoperative computerized tomography (IOCT), will open this spring. These ORs are designed to allow multiple teams to work simultaneously, aided by the latest innovations in navigation and image-guided technologies.

In the IOCT suite, a custom surgical table was created to optimize the patient’s position so that a CT scanner can move on rails and scan the patient in real time during surgery.

“This real-time imaging leads to a more effective and accurate surgery for the patient,” says Laurence Rhines, M.D., professor of Neurosurgery.

In addition to new operating rooms, The Pavilion houses a 27,000-square-foot Interventional Radiology facility that will allow multidisciplinary procedures and operations to be performed using robotic image guidance, reduced radiation doses for patients undergoing interventional procedures and real-time consultation with Pathology.

“The Pavilion is a great milestone in MD Anderson’s history,” says Robert Brigham, senior vice president for Hospital and Clinics. “Every time we get a chance to do an expansion like this, we do it not just to get larger and accommodate more, we do it to push the boundaries and transform the practice.”

The Pavilion serves as the new Main Building entrance and features state-of-the-art surgical suites, a new home for Interventional Radiology, an expanded Post-Anesthesia Care Unit and a larger space for sterile processing.

It also includes:

| Pre- and Post-Anesthesia Care Unit beds | 35 |
| New surgery suites on Floor 5 (5 more surgery suites will be added on Floor 7 in the future) | 6 |
| Interventional Radiology procedure rooms | 9 |
When Tatiana Demus’ leg started to hurt, her parents assumed a minor soccer injury was to blame. But when the pain got worse, a trip to the doctor and ensuing medical tests revealed she had osteosarcoma, the most common type of bone cancer in children.

Tatiana was referred to MD Anderson Children’s Cancer Hospital and placed on a lifesaving treatment plan: chemotherapy to shrink the cancer, followed by surgery to remove the tumor, then more chemo to kill any remaining cancer cells and minimize chances of the cancer coming back.

A year later, she’s finished with treatment and back in the game.

A straight-A honor student, Tatiana is doing well and enjoying her favorite things: Reading, video games, Chinese noodles and taking care of her guinea pigs, Bambi and Smores.

To help patients like Tatiana win their battles with cancer, MD Anderson researchers are developing leading-edge approaches to outwit the disease and, when possible, prevent it altogether.

At MD Anderson Children’s Cancer Hospital, studies are underway to:

- Identify the genes and chemical interactions that may lead to osteosarcoma
- Train the immune system to recognize and attack cancer cells
- Test an aerosolized, inhaled chemo for cancer that has spread to the lungs
- Develop a blood test that detects cancer in its earliest stages

To ensure MD Anderson remains a powerhouse of cancer research, a significant commitment has been made to explore, create and support all avenues of discovery. In the past five years, the institution has nearly doubled its support for research. Those investments are critical in order to improve the standard of care across many diseases. This steadfastness wouldn’t be possible without the generosity of donors and Board of Visitors members, and grants from the National Cancer Institute and the Cancer Prevention and Research Institute of Texas — all of which drive the engine of the nation’s largest clinical trials program.

At the Children’s Cancer Hospital, more than 770 patients have contributed tumor samples to a biobank — a repository of biological samples that will be used to advance research that will help pediatric and adult patients alike.
Professor of Cancer Biology Isaiah Fidler, D.V.M., Ph.D.
He took on the mystery of metastasis. Now he’s taking on brain cancer.

By Ron Gilmore

Few scientists have devoted as much of their career to understanding how cancer spreads as Isaiah Fidler, D.V.M., Ph.D.

From his days as the head of Metastasis Biology at the National Cancer Institute, to his current work at MD Anderson exploring new therapeutic approaches to challenging diseases such as brain cancer, his name has been heavily imprinted on the timeline of “firsts” in the quest to understand how cancer spreads.

Most recently, the professor of Cancer Biology published his team’s findings on a potential new therapeutic approach to treating glioblastoma, a fast-growing and incurable form of brain cancer. The study indicated that combining the oral chemotherapy drug temozolomide (TMZ) with macitentan, a drug originally approved for treating pulmonary hypertension, significantly reduced brain cancer cells in mice.

“In five separate studies, 96% of mice treated with both drugs had no evidence of disease,” says Fidler. “Whereas, all mice in other groups died.”

Fidler’s group previously showed that tumors that spread to the brain after originating elsewhere in the body tricked brain cells called astrocytes into protecting the cancer, making the tumors resistant to chemo. In this latest study, Fidler explored whether astrocytes — key to providing oxygen and nutrients to neurons — and brain endothelial cells, which form the inner lining of blood vessels, actually shield brain tumor cells from TMZ.

The results, Fidler believes, may very well represent a significant new therapeutic approach for treating glioblastoma.

An unlikely start

The path that Fidler followed — from his native Jerusalem via Oklahoma State University, where he earned his degree in veterinary medicine — did little to indicate his future as a pioneer of metastasis biology.

“I wanted to be a surgeon. But in Israel in the late 1950s and early 1960s, our education emphasized that we must ‘return to earth,’” he said in a 1999 profile that appeared in the Journal of the National Cancer Institute. “We had enough lawyers and doctors, and the nation encouraged people to be farmers. I compromised. If I couldn’t be a human surgeon, I might as well be a veterinarian.”

After working as a surgical oncologist at the University of Pennsylvania’s School of Veterinary Medicine, he earned a doctoral degree in human pathology at the university’s School of Medicine. Nine years later, Fidler joined the NCI, where he headed Metastasis Biology. The institute was the site of some of his early and innovative work in unraveling the riddles of how cancer spreads.

A new understanding

In cancer firsts, Fidler and Margaret Kripke, Ph.D., MD Anderson professor emerita of Immunology, are noted for their groundbreaking studies that demonstrated tumors are composed of different, unrelated cells.

Fidler, who joined MD Anderson in 1983, also showed that metastases are non-random biologic events whose outcomes depend on the interaction between tumor cells and the cellular environment in which they exist. This cellular environment is called a microenvironment and includes the normal cells, molecules and blood vessels that surround and feed a tumor. A tumor can change its microenvironment, and the microenvironment can affect how a tumor grows and spreads.

By uncovering the complex underpinnings of these biological processes, Fidler showed that metastasis isn’t random.

Thanks to the historical — and ongoing — work of Fidler and scientists like him, tumor microenvironments are now a field of intense investigation and a promising new incubator for innovative therapeutic solutions to some of the most deadly cancers.

Isaiah Fidler’s NCI work was based largely on the findings of English surgeon Stephen Paget, who identified the role of host-tumor cell interactions and is credited with developing the “seed and soil” hypothesis in 1889. He likened the spread of cancer to seeds spread by the wind. Not all seeds germinate, and not all cancer cells metastasize. Just as seeds need the right soil, Paget postulated that cancer cells needed the right “host.”
Graduating to big things before returning to MD Anderson

By Ronda Wendler

When Joya Chandra, Ph.D., joined the faculty of MD Anderson’s Pediatrics department in 2002, she felt an immediate kinship with the researchers, clinicians and, especially, with the students.

That’s because Chandra herself spent four years as a student at The University of Texas Health Science Center (UTHealth) Graduate School of Biomedical Sciences, located on the MD Anderson campus.

Nestled in the heart of the Texas Medical Center and located in MD Anderson’s George and Cynthia Mitchell Basic Sciences Research Building, the school is run by two institutions — MD Anderson and UTHealth. This unique partnership unites 580 faculty members from both institutions to teach students who conduct biomedical laboratory research. Two deans — one from each institution — work together to lead the school.

“I trained with some of the best scientists in the country,” says Chandra, who graduated in 1998 with a Ph.D. in Cancer Biology and Immunology.

After earning her Ph.D., Chandra, like many GSBS graduates, became a postdoc — a Ph.D. recipient who continues learning by conducting research in a mentor’s lab, typically for two to five years. This stint, called a postdoctoral fellowship, is frequently required to obtain tenure-track faculty positions, especially at research-oriented institutions.

Chandra completed not one, but two postdoctoral fellowships — the first at the Karolinska Institute in Sweden and the second at the Mayo Clinic. When she finished, she returned to Houston and joined the MD Anderson faculty.

“As a graduate student I was impressed by the culture of collaboration between clinicians and researchers,” says Chandra. “MD Anderson was at the top of my list when I was deciding where to begin my independent career as a translational researcher (a scientist whose laboratory findings will be translated into medical therapies for patients).”

Fourteen years later, Chandra is an associate professor at the Children’s Cancer Hospital where she studies how unstable molecules known as free radicals lead to cancer progression, resistance to chemotherapy and tissue damage. She encourages children with cancer to eat healthy foods that contain antioxidants — molecules that prevent free radicals from harming healthy tissue. In addition to her research, Chandra and colleagues created an online cookbook (mdanderson.org/recipes) filled with recipes taste-tested and approved by pediatric cancer patients and their families.

Patrick Dougherty, Ph.D.
Professor of Anesthesia and Pain Medicine

Education: Ph.D. in Biomedical Science, Graduate School of Biomedical Sciences, 1988

Why I joined MD Anderson: MD Anderson and the nearby institutions in the Texas Medical Center provide an outstanding biomedical science environment that fosters high-impact translational science unlike anywhere in the world. And Houston is a great place to live. It has all the amenities of a big city, but small, affordable neighborhoods in excellent school districts.

Key research: My research seeks a better understanding of the biologic mechanisms that cause peripheral nerve damage in patients undergoing chemotherapy. This research could allow current chemotherapies to be given in higher, more effective doses, and could help in the development of new chemotherapies with less severe pain-related side effects.

Ralf Krahe, Ph.D.
Professor of Genetics

Education: Ph.D. in Genetics, Graduate School of Biomedical Sciences, 1995

Why I joined MD Anderson: As a Graduate School of Biomedical Sciences alumnus, my decision to join the MD Anderson faculty was easy. I joined because of the exceptional research opportunities and environment, and outstanding colleagues in the Department of Genetics. My decision was facilitated by the unique institutional culture and the wonderful educational opportunities at the graduate school, which allow me to combine my passions for genetics research and education at my alma mater.

Key research: I identify and characterize disease genes and their mutations and variants, and am particularly focused on inherited cancers such as Li-Fraumeni syndrome, a rare disorder that leads to a higher risk of developing certain cancers at a younger-than-average age.
Peng Huang, M.D., Ph.D.
Professor of Translational Molecular Pathology

Education: Ph.D. in Pharmacology, Graduate School of Biomedical Sciences, 1990 (M.D., Zhongshan Medical College, Guangzhou, China, 1982)

Why I joined MD Anderson: Nothing compares to MD Anderson. The close interaction between scientists in the lab and patient-care professionals in the clinic provides a seamless pathway for translating laboratory findings into medicines and therapies for patients.

Key research: I’m investigating differences between leukemia cells and normal cells, which is research that provides a biochemical basis for the design of new drugs and strategies that will selectively kill cancer cells.

Dihua Yu, M.D., Ph.D.
Professor and deputy chair of Molecular and Cellular Oncology

Education: Ph.D. in Molecular and Cancer Biology, Graduate School of Biomedical Sciences, 1991

Why I joined MD Anderson: At MD Anderson, I’m privileged to work side by side with world-class biomedical scientists and physician-scientists. By pooling our knowledge, we’ve fast-tracked our laboratory research findings to clinical trials that are continually leading to new diagnostics and therapeutics to save cancer patients’ lives.

Key research: My laboratory research focuses on how and why cancer begins, spreads and resists various treatments, with an emphasis on breast cancer.

DEGREES AWARDED
Graduate School of Biomedical Sciences

<table>
<thead>
<tr>
<th>Degree</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Master of Science</td>
<td>15</td>
</tr>
<tr>
<td>Ph.D.</td>
<td>78</td>
</tr>
</tbody>
</table>

MOST DEGREES AWARDED

<table>
<thead>
<tr>
<th>Field</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Biology</td>
<td>28</td>
</tr>
<tr>
<td>Biomedical Sciences</td>
<td>18</td>
</tr>
<tr>
<td>Genes and Development</td>
<td>10</td>
</tr>
<tr>
<td>Medical Physics</td>
<td>9</td>
</tr>
<tr>
<td>Genetic Counseling</td>
<td>8</td>
</tr>
</tbody>
</table>

TOP FIVE COUNTRIES OF ORIGIN
Graduate School of Biomedical Sciences

- United States 57%
- China 13%
- India 12%
- Taiwan 5%
- South Korea 3%
The man who helped cure childhood leukemia

By Ronda Wendler

A trailblazing oncologist who took on childhood leukemia by introducing combination chemotherapy — in which anticancer drugs are given simultaneously rather than singly — retired in September after 50 years at MD Anderson.

Yet Emil J Freireich, M.D., 88, who achieved legendary status as a pioneer in the early history of oncology triumphs, still comes to work every day, attending meetings and participating in the center’s medical education program.

Retirement is “just a suggestion,” Freireich says. “I’m too motivated to lounge around the house like a dried-up old geezer.”

Freireich’s motivation to stop cancer was born back in 1955 when he was hired at the fledgling National Cancer Institute (NCI) in Bethesda, Maryland. Built “way out in the country” on the campus of the National Institutes of Health, the center was the first full-time, patient-oriented clinical research center in the world. It was there that Freireich would alter the course of childhood leukemia for millions of patients in the years to come.

Stop the bleeding

On his first day at the institute, Freireich was assigned to care for children in the leukemia ward — a job no one else wanted.

“Leukemia at that time was a horrible illness — a death sentence,” he says. “Most children lived only eight weeks after being diagnosed. Ninety-nine percent died within a year.”

His first order of business was to halt the nonstop bleeding that is the hallmark of the disease.

“Leukemia prevents blood from clotting,” he explains. “Children bled to death. The leukemia ward looked like a slaughterhouse. Blood covered the pillowcases, the floor, the walls … it was horrific.”

Early chemotherapy drugs were available, but patients bled to death before they could undergo treatment.

Freireich firmly believed his patients’ bleeding was caused by insufficient platelets — tiny blood cells that help the body form blood clots. Recent research revealed that the platelets of World War II atom bomb victims had been wiped out by radiation, and that those victims died from hemorrhaging. The connection was indisputable, Freireich believed. Yet the medical community dismissed his idea.

To prove them wrong, Freireich mixed platelets from his own blood with blood from leukemic children. Without fail, the bleeding stopped.

Further studies confirmed not only that Freireich had been right all along, but also his belief that platelets were useless unless they were obtained from fresh blood.

“Platelets in donated blood last only 48 hours,” he explains. “Because blood bank protocol demanded that the oldest blood be used first, the children all along had been getting blood that was too dated to contain platelets.”

With these discoveries, bleeding as a cause of death was essentially eliminated.

Combo chemo

With the bleeding problem solved, Freireich turned his attention to curing childhood leukemia. Another difficult-to-treat disease, tuberculosis, recently had been cured. He believed the TB treatment approach might work for leukemia as well.

“We knew that three drugs controlled tuberculosis, but you had to administer them all at once. If given separately, they didn’t work,” he says. “I had an inkling the same method would work for leukemia.”

So Freireich began combining chemo drugs instead of giving them one at a time.

First he administered two of the highly toxic drugs, then three. With each addition, children became seriously ill, and some were brought to the brink of death. When he upped the ante to four drugs in a 1961 trial, an outcry arose from the medical establishment.

“They said I was unethical and inhumane and would kill the children. Instead, 90 percent of them went into remission immediately. It was magical.”

Once children were in remission, Freireich continued their four-drug regimen for a full year to kill any residual cancer cells. That exact strategy, called early intensification, is still used today, and the cure rate for childhood leukemia is 92%.

Looking ahead

In 1965, Freireich and his NCI friend and colleague Tom Frei, M.D., were recruited by MD Anderson to launch a chemotherapy program. Until then, the cancer center had treated patients with surgery and radiation. The two doctors formed the Department of Developmental Therapeutics and hired brilliant young scientists who developed drug combinations that cured various cancers based on the same methods used to treat childhood leukemia. Today, nearly all successful chemotherapy regimens use this approach of administering multiple drugs simultaneously.

Curing cancer isn’t synonymous with eradicating cancer, Emil J Freireich points out.

Our bodies contain 70 trillion cells, and when one of them misbehaves, you can get cancer. With that many cells, he says, mathematically, there’s great potential for error.

“Cancer will always be around, but every day we’re curing more and more patients who live a long time and do great things after their disease.”
Legendary oncologist Emil J Freireich, M.D.
They want to fill the void left by less federal funding for research

By Allison Schaffer

In today’s economy, with government funding for cancer research difficult to come by, private philanthropy is essential.

Realizing this, four MD Anderson Board of Visitors members took matters into their own hands and personally endowed three new faculty research awards. Together, the awards funded by Bill Finneran, Jack Randall, Regina Rogers and Gary Stein will provide millions in support over several years for clinical research.

The Finneran Family Prize in Translational Research
Prostate cancer survivor Bill Finneran recalls the impeccable care he received at MD Anderson 21 years ago.

“The personal care and attention provided by the doctors and staff was phenomenal,” says Finneran, who divides his time between New York and Palm Beach, Florida. “I always found total commitment on every level of patient care, as well as the highest quality of research.”

He established the Finneran Family Prize, a $50,000 cash award given annually to a deserving faculty member. Christopher Logothetis, M.D., Finneran’s physician and chair of Genitourinary Medical Oncology, received the inaugural prize for his leadership and innovation in cancer care, particularly as co-leader of MD Anderson’s Prostate Cancer Moon Shot.

The Jack and Beverly Randall Prize for Excellence in Cancer Research
Jack Randall and his wife, Beverly, know it takes big ideas to get big results, and they established the Jack and Beverly Randall Prize for Excellence in Cancer Research to encourage innovative ideas and novel thinking among researchers.

“It takes creativity, passion and tenacity to have big breakthroughs,” says Jack Randall. “It’s only through original ideas and a willingness to take a chance on the most promising concepts that vision becomes a reality.”

The $100,000 cash prize is awarded annually and alternates between cancer research and patient care.

“We think it’s important to build on MD Anderson’s history of achievement by honoring, encouraging and advancing innovation,” says Beverly Randall. “This award is our way of supporting tomorrow’s leaders so they have the incentive and resources needed to make this happen.”

Andrew Futreal, Ph.D., chair ad interim of Genomic Medicine, is the inaugural recipient. Futreal is recognized for his groundbreaking research in large-scale systematic cancer genomics.

The Shirley Stein Scientific Endowed Research Award
Gary Stein teamed up with longtime family friend Regina Rogers to create the Shirley Stein Scientific Endowed Research Award in honor of his mother and Regina’s best friend, the late Shirley Stein.

“Mom was a force of nature,” says Stein. “She felt strongly that MD Anderson is one of Houston’s crown jewels and needs to be taken care of. This is one way we can honor her memory.”

Two faculty members will receive a $12,000 cash award each year to support outstanding clinical research performed with limited project resources.

The inaugural awards went to Alejandro Contreras, M.D., Ph.D., assistant professor of Pathology, and Yun Wu, M.D., Ph.D., associate professor of Pathology. Contreras’ research focuses on identifying genetic alterations believed to contribute to aggressive forms of breast cancer. Wu’s research focuses on identifying molecular biomarkers for breast cancer prognosis and targeted therapy.
Big data interchange: Where rivers of research and clinical data converge into one pool

By Satt Merville

A simple yet unprecedented goal drives the big data efforts of MD Anderson’s Moon Shots Program: to have every patient contribute to and benefit from the cancer center’s research.

“At every academic institution, research data is a separate universe from clinical data,” says MD Anderson President Ronald DePinho, M.D., “Clinical data are trapped in medical records and research data in different systems throughout an institution. We’re transforming how we do things in the future by integrating research and clinical data in one system.”

Academic medical institutions generate enormous amounts of research and clinical information. But making that data accessible to researchers has been a problem.

“We do a good job of capturing data, but it ends up being vaulted, padlocked and imprisoned in different ways,” says Andy Futreal, Ph.D., chair ad interim of Genomic Medicine. “What we’re trying to do with our big data interchange is liberate that data into a secure space where we can put it all together and learn from it.”

Data from almost 250,000 patients

As co-leader of the big data platform of MD Anderson’s Moon Shots Program, Futreal and a team of experts have worked to build such an interchange since 2012. Years of planning led to construction of the system architecture in 2015 and the initial loading of clinical data from nearly a quarter of a million patients treated since Jan. 1, 2012.

Research data from two other moon shots platforms — next-generation tumor genetic analysis by the Cancer Genomics Laboratory and immune cell monitoring data from blood and tumor samples gathered by the immunotherapy platform — are being added to the big data interchange. This will expand to include other research information over time, Futreal says.

Most research data now are scattered in various MD Anderson databases, in the computer hard drives of individual researchers, and in their papers published in academic journals.

Detailed clinical information found in patients’ medical records — treatments, side effects, pathology, test results, notes by oncologists, surgeons, radiation oncologists, images — will continue to live in MD Anderson’s clinical electronic health record (EHR) system while also being routed into the big data interchange.

Security and compliance experts have been engaged in the project since day one to build safeguards into the system.

More questions, faster answers

Researchers will be able to query the system, Futreal notes, “to facilitate and accelerate access to data and avoid the laborious searching, hunting, gathering” now required to obtain information.

For example, a laboratory scientist studying a specific molecular pathway could search the database for a specific mutation across various cancer types.

Or an oncologist might want to look at outcomes for all patients with a specific type of breast cancer who were treated with a specific regimen during a specific time frame.

Futreal is an expert in cancer genomics and led the team that discovered the BRAF mutation found in half of all melanoma cases. Patients with this mutation are now treated with targeted therapy that attacks cancer cells without harming normal cells.

But the genomic diversity of tumors is what makes them so hard to treat in advanced stages, he says. When a targeted therapy knocks down cells dependent on one mutation, surviving cells that lack that mutation — or ones that have acquired new ones — come back with a vengeance.

“Because every cancer is different, we need to build this infrastructure to learn as much as possible about every patient we care for. One treatment can produce 10 different outcomes among 10 patients,” Futreal says. “The knowledge for how to do it better next time lies in those individual patients. Until we build systems that capture data properly, integrate it, and empower the analysis of it, we’re missing a trick — an important one.”
The training ground for the next generation of scientists

By Gillian Kruse

It’s only been a short time since graduation, and already the first students to earn master’s degrees from the School of Health Professions are having a global impact.

When they enrolled in the new MS in Diagnostic Genetics program, the students were drawn to its unique features — access to state-of-the-art labs and classrooms that can only be found within a comprehensive cancer center, and the one-on-one support of a world-class faculty.

“We’re one of only four graduate clinical diagnostic molecular science programs in the country recognized by the NAACLS (National Accrediting Agency for Clinical Laboratory Sciences),” points out Peter Hu, Ph.D., associate professor in the School of Health Professions and director of the new program.

The three members of that first graduating class are taking what they learned about clinical molecular diagnostics such as genetic disorder testing, cancer genetics testing and bioinformatics around the globe. One has returned home to the Bahamas, one has gone to a cytogenetics lab in Peoria, Illinois, and one has taken a research role at Baylor College of Medicine.

Information gained from molecular testing helps MD Anderson’s physicians move closer to the goal of precision medicine tailor-made for each patient by providing the data needed to analyze each patient’s genome. Graduates are able to provide good laboratory results efficiently, and are armed with the skills and knowledge to create new, more accurate testing procedures as needs arise.

A new degree

The students spend two years in a program that combines diagnostic genetics theory with hands-on practice in clinical rotations. They also participate in research aimed at making advances in diagnostic genetics while learning about the world of academic medicine. (One of the students’ final research projects is being submitted for publication in a leading journal.)

After graduation

After receiving their diplomas, all graduates are eligible to take board exams in either molecular biology or cytogenetics — or in some cases, both — to become certified in one or both fields by the American Society of Clinical Pathology. Certification is required to work in a clinical diagnostic setting. Graduates’ clinical and research training prepares them for a number of career options, and their rotations through many collaborative clinical partners — including UTMB Galveston, Baylor College of Medicine and Texas Children’s Hospital — give them experience outside the world of cancer.

Looking to the future

The program is growing fast as word spreads about the unique opportunities students are offered in the cytogenetics and molecular genetics specializations within the master’s degree. The second graduating class has seven members, and nine new students joined the program in the fall of 2015.

“As one of very few institutions that offer this program at both the undergraduate and graduate level, we’re uniquely positioned to help guide the next generation of scientists through the study and creation of genetic testing,” notes Hu. “This field is quickly evolving and the clinical diagnostic information gained from genomics is becoming entwined with quality cancer care.”

EDUCATIONAL TRAINEES

<table>
<thead>
<tr>
<th>Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical</td>
<td>1,507</td>
</tr>
<tr>
<td>Research</td>
<td>1,890</td>
</tr>
<tr>
<td>Special programs</td>
<td>752</td>
</tr>
<tr>
<td>Student programs</td>
<td>817</td>
</tr>
<tr>
<td>School of Health Professions programs</td>
<td>303</td>
</tr>
<tr>
<td>Nursing programs</td>
<td>1,352</td>
</tr>
<tr>
<td>Total</td>
<td>6,621</td>
</tr>
</tbody>
</table>

TOP FIVE SOURCES OF ROTATING TRAINEES

- UT Health Science Center at Houston 56%
- Baylor College of Medicine 27%
- UT Medical Branch at Galveston 5%
- Methodist Hospital 2%
- San Antonio Uniformed Services Health Education Consortium 1%
SCHOOL OF HEALTH PROFESSIONS

Bachelor of Science degrees awarded 144

Diagnostic Imaging 29
Molecular Genetic Technology 27
Radiation Therapy 20
Medical Dosimetry 16
Clinical Laboratory Sciences 15
Cytogenetic Technology 15
Master of Science in Diagnostic Genetics 3
Histotechnology 14
Diagnostic Medical Sonography 7
Cytotechnology 1

Master of Science degrees awarded
Diagnostic Genetics 3

POSTDOCTORAL FELLOWS

- China 31%
- United States 16%
- India 10%
- South Korea 8%
- Japan 4%

TOP FIVE COUNTRIES OF ORIGIN
Clinical residents and fellows

- United States 70%
- Canada 4%
- South Korea 3%
- China 3%
- India and Lebanon 2%
Bottom line: Converting discoveries into new treatments at a faster rate

By Scott Merville

When a clinical trial for a new breast cancer drug launched recently, researchers estimated it would take at least two years to enroll the 20 patients needed to make the trial a success. However, within four months, half the patients had already enrolled — and the drug worked for all 10.

“That’s the power of the Moon Shots Program,” says Jennifer Litton, M.D., associate professor of Breast Medical Oncology and the trial’s principal investigator.

Accelerating the conversion of scientific knowledge into new treatments for patients is a priority of the program.

“What moon shots has done for my patients is cut the time it takes to go from a clinical trial idea to the time a person gets a new drug down from three years to about one. That’s huge,” says Litton, an experienced leader of clinical trials.

The drug, called talozoparib, is currently being tested in late-stage breast cancer patients who have BRCA1 and 2 gene mutations and whose disease has spread.

Those who test positive for BRCA mutations have a significantly higher risk of developing breast and ovarian cancers, as well as passing on the mutation to future generations.

Owned by Medivation Inc., talozoparib is what is known as a PARP inhibitor. PARP — short for Poly(ADP-ribose) polymerase — is an enzyme that helps repair damaged DNA. In cancer treatment, blocking PARP may prevent such repairs, causing the cells to die.

Litton’s trial uses a new targeted therapy for two months before proceeding to standard of care chemotherapy followed by surgery. The trial and accompanying moon shot studies will provide a detailed view of talozoparib in first-line use.

“In this and other studies, we’ve found that when companies know we have the moon shot behind us, we’ve been given access to drugs they won’t give to anyone else for investigator-initiated trials because we can promise them the trial will happen,” Litton says.

Not only does the moon shot provide funding for the study, it supplies a deep roster of scientists drawing on expertise from across the institution to provide the pharmaceutical corporation an unprecedented opportunity to learn about its drug.

“It’s low risk for them. And on top of that, they’re getting correlative study information they can’t get from other places now.”
Leading edge labs foster collaboration and ingenuity as research silos are torn down

By Andy Olin

In 2011, MD Anderson received a $150 million gift — the largest in its history — from the Khalifa Bin Zayed Al Nahyan Foundation for the construction of the Sheikh Zayed Bin Sultan Al Nahyan Building for Personalized Cancer Care.

The 12-floor, 615,000-square-foot facility is the home of the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research, which puts investigators with shared research vision into the same space to foster collaboration and encourage a cross-pollination of ideas.

“Our only goal is to do meaningful translational research in one disease — pancreatic cancer,” says Anirban Maitra, M.B.B.S., professor of Pathology and director of the center.

But traditional labs, which are built with walls, can be a hindrance to multidisciplinary problematic research. Literal walls become figurative walls that stifle collaboration, communication and creativity.

“No one lab can do everything or house the expertise required for this type of research,” Maitra explains. “In the pancreas center, because we have investigators with such diverse interests, we’re able to take on these multidisciplinary research initiatives where, for example, there’s a team that includes experts in imaging, metabolism and mouse models. Bringing these experts together in one space would not be possible in many research facilities.”

This is resulting in the creation of meaningful science and energizing researchers, which perpetuates the process. In the past two years, the footprint of the center has made a significant impact in terms of the big ideas and big grants being generated.

“I’ve seen the number of collaborations grow exponentially,” says Bettina Marble, director of Research Planning and Development for the center. “The excitement has grown and everyone is more engaged. There’s more buzz and unity.”

One such big idea is the development of a liquid biopsy that could be used to determine prognosis, guide targeted therapy and monitor treatment of pancreatic cancer.

Maitra’s research team found that pancreatic cancer tumors shed their complete DNA and RNA — wrapped inside protective lipid particles — into the bloodstream, essentially spilling their molecular secrets. This makes the tumors ripe for analysis with a noninvasive blood test.

The open-concept labs of the the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research place investigators from different specialties in the same space to promote collaboration, communication and creativity. The center’s director, Anirban Maitra, and its director of Research Planning and Development, Bettina Marble, say the layout of the facility is translating into excitement among MD Anderson scientists.
Prevention

Teresa Hall, 35
Colorectal cancer survivor

Teresa Hall has a family history of colorectal cancer, and at age 32, she learned she had the disease. Genetic testing at MD Anderson revealed she had a hereditary cancer syndrome known as familial adenomatous polyposis (FAP), which greatly increases the risk of the cancer. In fact, without treatment, people with FAP have a 100% chance of developing cancer. Because of the testing, Hall has been able to inform her family about their inherited genetic risk. In turn, they can get tested for FAP and, hopefully, catch any polyps before they become malignant and spread. Through the Colorectal Cancer Moon Shot, there is new focus being placed on improving early detection and prevention of the disease, as well as the development of personalized treatment with immunotherapies before surgery. MD Anderson researchers also are working to classify colorectal cancers by subtype based on integrated molecular and genomic analysis to improve targeted therapy.

Read more about Teresa Hall’s cancer experience on Page 35.
Prevention and early detection

Patient Teresa Hall and her daughter
Outsmarting cancer with genetic testing

By Clayton Boldt, Ph.D.

Teresa Hall’s visit to a gastroenterologist three years ago wasn’t the first time she’d sought help for troubling symptoms.

Over the span of a decade, she’d consulted three other doctors, and all had diagnosed her with irritable bowel syndrome. But the gastroenterologist told her otherwise.

At age 32, Hall learned her colon and rectum were riddled with polyps. Two were cancerous.

“All three of those doctors missed it. They never once said, ‘You know, maybe we need to do a colonoscopy on this girl,’” says Hall, despite the fact she shared her alarming family history with each doctor.

She told them about how her father’s colon and rectum were removed when he was 36 because of thousands of pre-cancerous polyps.

“If I’d had a colonoscopy, my cancer would’ve been caught very early. It probably wouldn’t even have been cancer at that point.”

Like her father, Hall had her entire colon and rectum removed, and she underwent chemotherapy. When doctors discovered the cancer had spread to her liver and lungs, she sought help from MD Anderson. After more rounds of chemo and several surgeries, she’s hanging tough.

Because of her young age and family history, Hall underwent genetic testing at MD Anderson. The test revealed she had a hereditary cancer syndrome known as familial adenomatous polyposis (FAP).

The lifetime risk of colorectal cancer for most people is 5%. For those with hereditary syndromes such as FAP or Lynch syndrome, it’s much higher. Lynch syndrome carries a lifetime cancer risk of 50 to 80%, and those with FAP have a 100% chance of developing cancer without treatment.

Although only about 5% of colorectal cancer is caused by hereditary syndromes, the incidence tends to be higher in those diagnosed at a younger age. To learn more about hereditary syndromes in adolescents and young adults, MD Anderson researchers studied nearly 200 colorectal cancer patients diagnosed at age 35 or younger. All were evaluated by the institution’s genetic counselors.

The study found that one-third of patients diagnosed before age 35 had hereditary-associated cancer.

“Based on our findings, patients younger than 35 must be evaluated by a genetic counselor,” says Eduardo Vilar-Sanchez, M.D., Ph.D., the study’s principal investigator. “They’re encouraged to share their genetic risk with their parents, siblings and other relatives, who can also get tested.”

Testing can identify relatives with high-risk mutations and allow them to take preventive measures, such as earlier screenings, explains Vilar-Sanchez, an assistant professor of Clinical Cancer Prevention.

Other than her father, Hall’s family history contains no colorectal conditions of any kind. However, her family members are now being tested.

Hall’s son doesn’t appear to have the mutation, and her daughter is still too young for testing. Her sister and nephew, however, both carry the harmful FAP mutation. Hall’s sister had her colon and rectum removed to reduce her cancer risk. Hall’s nephew is watched closely and may enter clinical trials when he’s old enough.

“My advice is, if you have symptoms, be an advocate for yourself, regardless of how embarrassing it can be,” says Hall. “Get a colonoscopy. If one doctor won’t do it, find another doctor. Getting tested saves lives. It really does.”

If you think you might be at risk for an inherited cancer, it’s a good idea to meet with a genetics counselor. They will review your family medical history, talk to you about the role of genetics in cancer and perform a hereditary cancer risk assessment.

Based on your results, the counselor may recommend genetic testing, which simply involves having a blood sample drawn. The findings may help determine if members of your family face higher risks for certain types of cancer.
Are you at high risk for pancreatic cancer?

By Scott Merville

A new clinic to identify and monitor those at high risk for developing pancreatic cancer continues to expand after opening last year.

The clinic’s goal is to find ways to detect the disease early, when a cure may be possible, says its director, Florencia McAllister, M.D., assistant professor of Clinical Cancer Prevention.

“Due to the location of the pancreas, early tumors can’t be seen or felt by health care providers during routine physical exams,” McAllister says. “Patients are usually diagnosed when the cancer cannot be surgically removed.”

Who’s at risk?
Pancreatic cancer risk is higher in those whose parents, siblings or children developed the disease, particularly at a young age, and in those who have any of 10 genetic mutations, including a mutation in the BRCA2 gene, better known for raising breast cancer risk.

Family history coupled with genetic mutations place a person in the high-risk category. Some genetic mutations alone place a person at an increased risk, even without a family history of pancreatic cancer. One example is a mutation in the STK11 gene, which can be found in people with Peutz-Jeghers Syndrome. The syndrome causes noncancerous growths in the gastrointestinal tract and puts people at a greatly increased risk of developing certain types of cancer, including cancer of the gastrointestinal tract, pancreas, cervix, ovaries and breast.

Other factors such as chronic inherited inflammation of the pancreas, called pancreatitis, are powerful and well-known risk indicators.

At MD Anderson’s high-risk clinic, patients are tested for a blood biomarker called CA-19-9, which can indicate cancer but also is prone to false positives. Magnetic resonance imaging and endoscopic ultrasound examinations follow, McAllister says.

Clinic participants are relatives of MD Anderson patients, referrals from other clinics, such as breast, or self-referrals — usually relatives of cancer patients.

Recent studies have found that about 1% of adult patients diagnosed with new-onset diabetes will also be diagnosed with pancreatic cancer within three years of the date of their diabetes diagnosis. The high-risk screening clinic will be expanding to screen new-onset diabetic patients during this three-year window.

Novel screening tests
To date, no screening test has been conclusively shown to lower the risk of dying from pancreatic cancer, and only about 6% of patients are alive five years after diagnosis.

Funded by the Pancreatic Cancer Moon Shot, researchers are working to change that by creating a blood test that signals the presence of cancer. When developed, the test will detect cells that are shed from tumors or other substances that are produced in response to tumors.

They’re also investigating new imaging techniques to detect precancerous pancreatic lesions called PanINs (pancreatic intraepithelial neoplasias), early precursors of pancreatic cancer.

“They are unlike precancerous lesions for melanoma or polyps for colon cancer, which can be easily observed,” McAllister notes. “PanINs are microscopic lesions that can’t be seen by MRI.”
We’re creating partnerships to detect a deadly cancer earlier

By Ron Gilmore

Building on MD Anderson research, a new company named Codiak Biosciences has formed to create therapeutic and diagnostic products using exosomes — small parts of cells that break away and float around the body.

Long thought to be a kind of trash collection bin for cells, it turns out exosomes are instead one of the main ways cells communicate with each other.

“This makes them medically useful in a number of ways,” says Raghu Kalluri, Ph.D., chair of Cancer Biology at MD Anderson.

Kalluri has found that exosomes from healthy cells can be used to safely deliver drugs to penetrate tumor cells. Building on his discovery, Codiak plans to develop a drug to treat pancreatic cancer, using exosomes as a delivery vehicle.

“This cellular-to-cellular transfer of drugs is a potent and safe delivery system for a number of therapeutic purposes,” Kalluri says.

He’s also discovered a potential method for detecting pancreatic cancer sooner. The secret lies in fragments of DNA, RNA and proteins inside and on the surface of exosomes that are specific to cancer cells. Kalluri discovered one particular protein that has been found to detect pancreatic cancer with 100% accuracy.

Codiak plans to use this protein to develop a diagnostic test that can identify pancreatic cancer in its early stages when it’s still treatable. The disease typically is detected so late that only 6% of patients survive five years after diagnosis.

“It’s a feather in our cap and a real turning point for MD Anderson’s growing collaboration with private industry,” says Ferran Prat, Ph.D., J.D., vice president for Strategic Industry Ventures. “Our ultimate goal is to bring innovative diagnostic and therapeutic solutions to our patients. The ability to add to our arsenal of cancer-fighting tools is greatly enhanced by ventures like Codiak.”
Let’s protect ourselves against HPV-related cancers with the ‘cancer vaccine’

By Laura Sussman

Kathleen Schmeler, M.D., vividly remembers the day a chance encounter on a flight to Amsterdam changed her life.

“The man sitting next to me happened to be reading the same novel I was, so we struck up a conversation,” says Schmeler, who at the time was a mechanical engineer with Procter & Gamble. “As it turned out, he was a colon cancer researcher and doctor in the Netherlands.”

Schmeler, who had always harbored an interest in medicine, chatted with her seatmate for six hours. The conversation led to a job offer.

“When we landed,” she says, “I called my parents to let them know I was quitting my job and moving to Amsterdam to work for a scientist doing cancer research.”

Twenty years later, Schmeler is an associate professor of Gynecologic Oncology and Reproductive Medicine and an impassioned advocate for women’s health. She’s on a mission to educate women — and men — about a vaccine that blocks transmission of the human papillomavirus (HPV), which causes 99% of cervical cancer. The virus also is linked to cancers affecting the middle throat and genital areas.

The HPV vaccine was approved by the Food and Drug Administration in 2006, and has the power to prevent all of these.

To the disappointment of Schmeler and others in health care, it’s been slow to gain wide acceptance.

“It’s disheartening,” Schmeler says. “We have to do a better job of getting it out there. It’s been slow, but we’re making strides.”

The Cancer Prevention Research Institute of Texas (CPRIT) awarded MD Anderson a $1.4 million grant to increase cervical cancer screenings and preventive treatments for underserved women along the Texas-Mexico border. CPRIT provides state funding for cancer research, prevention and product development programs. MD Anderson’s efforts target Cameron, Hidalgo, Willacy, and Starr counties, where the cervical cancer rate is 30% higher than anywhere else in the state, and 70% of the population is uninsured.

Last year, MD Anderson expanded its ambitious Moon Shots Program to include HPV-related cancers. Co-led by Schmeler, the moon shot’s goals include improving access and vaccination rates, developing HPV-related cancer screenings for men, developing targeted drugs that attack HPV-related cancers directly, and developing immunotherapies that rally the immune system to fight the virus.

“The moon shot has spurred us to organize our efforts and move our work benefiting patients to the next level. It’s not acceptable to make small, incremental improvements,” Schmeler says. “We must do something big and innovative on their behalf.”

Cervical cancer is the 14th most common cancer in the United States. Yet in Latin America, Africa and the Caribbean, it’s one of the leading causes of cancer deaths in women.

To bridge this gap, Kathleen Schmeler and colleagues run the Central America Oncology Education Program, or CONEP. The program brings gynecologists from MD Anderson and other institutions to Guatemala, Honduras, El Salvador, Costa Rica and Panama, where they make patient rounds and train local doctors. Since CONEP’s inception in 2009, more than 100 Central American medical residents and faculty have participated in each of the visits. The program recently expanded to Mozambique in Southeast Africa.
Breast cancer screening guidelines aren’t a one-size-fits-all solution
By Clayton Boldt, Ph.D.

It’s clear that breast cancer screenings save lives. But exactly when women at average risk of developing breast cancer should begin screening is much less clear.

Leading medical groups have conflicting guidelines. The American College of Obstetricians and Gynecologists (ACOG) and the National Comprehensive Cancer Network (NCCN) say starting at 40 is best. The U.S. Preventive Services Task Force (USPSTF) says women can wait until 50. And in October, the American Cancer Society (ACS) added to the confusion by revising its guidelines. For years, the ACS recommended women start mammograms at age 40, but the ACS now recommends starting at age 45, or at 40 if the patient chooses. The groups also vary on how often mammograms should be done. ACOG says annually, USPSTF says every two years, and the most recent ACS guidelines suggest getting annual mammograms between ages 45 and 54; after that, they say every two years is OK.

“My concern is that there is a lack of clear direction for women and their doctors to best protect their health,” says Therese Bevers, M.D., medical director of MD Anderson’s Cancer Prevention Center.

To clarify the issue, Bevers urges a closer look at the new ACS guidelines. Although they recommend annual mammograms starting at 45, the guidelines suggest women should still have the opportunity to begin at 40.

“The guidelines still affirm the importance of annual screening for women in their forties and continuing for as long as they are in relatively good health,” says Bevers.

Additionally, the ACS now recommends against clinical breast exams for women. Given a lack of new data supporting this change, Bevers feels it’s premature to recommend against this important clinical practice.

“Annual clinical breast exams are a chance for women to meet with their doctors to discuss screening, risk and healthy lifestyles to reduce their breast cancer risk.”

In line with the ACOG and the NCCN guidelines, MD Anderson continues to recommend annual screening and clinical breast exams beginning at 40.

“Our mission is to save lives, and data has shown this approach to be the best way to do that,” says Bevers.

Screening for women at elevated risk
The above recommendations, however, apply only to women at average risk of breast cancer — not to those at elevated risk.

“There are many factors that may increase a woman’s risk, including family history, hereditary cancer syndromes, previous cancers, age when first giving birth and age at first menstrual cycle,” says Jennifer Litton, M.D., associate professor of Breast Medical Oncology.

Unfortunately, for those at high risk, there’s no single answer for screening.

“Screening recommendations for women at increased risk depends on why they are at increased risk,” explains Litton.

Depending on the situation, it may be appropriate to get screened earlier, more often or in different ways. Women should talk to their doctor to determine their risk, as well as individualized recommendations for screening or risk reduction. Risk assessment tools also are available from MD Anderson and the ACS.

Michelle Baumann

Baumann asked to get her first mammogram before she was 40 because her grandmother had breast cancer. As the mother of two young boys, she wanted to start her annual screenings early.

Her doctor agreed and nine months before her 40th birthday she was diagnosed with Stage 1 breast cancer. Because her cancer was caught early, Baumann’s treatment consisted of a bilateral mastectomy and reconstruction.

“The thought of waiting until 45 for screening is scary,” says the elementary school principal. “I would’ve been six years into my cancer by that point. You have to trust your gut, advocate for yourself and become a part of the process.”
Roxana Lopez

Lopez, an aspiring nurse, was diagnosed with Stage 2 breast cancer during a clinical breast exam when she was 25, two decades younger than the ACS’ recommended screening start date for women at average risk of cancer. But Lopez wasn’t average. After genetic testing confirmed she carried a BRCA1 mutation, she urged her twin sister, Ana, and two brothers to get tested. Turns out all three also have the mutation that increases the risk of breast and ovarian cancers in women. That wasn’t entirely a surprise; their mother was diagnosed with breast cancer at 47, and died four years later.

After completing chemotherapy, Lopez will undergo a double mastectomy to reduce the risk of recurrence. Her sister is also having a preventive double mastectomy to reduce her risk of developing breast cancer.

“I still have a goal of going to nursing school. I look forward to getting all my treatments done and getting better, and then being able to move on with my life.”

Nancy Lombard

Lombard is an advocate for early detection. She began having her annual mammograms at age 40. Three decades later, when she was 70, she decided to have a 3D mammogram for the first time. With this technology, doctors caught a Stage 1 cancer in her left breast, one that a standard mammogram would have missed.

Following her surgery, a CT scan revealed a small tumor in her lung that required a lobectomy. By catching both cancers early, Lombard successfully overcame breast and lung cancer in just a year.

With no family history of cancer she could have elected less-frequent screening, but she believes it’s important to be vigilant. Lombard says she’ll be sure to emphasize the importance of yearly mammograms to her two daughters and four granddaughters.

“I think screening is very important,” she says. “Based on my experience, why take the chance? If these cancers hadn’t been caught early, they would probably have already spread to other parts of my body.”
The Year of the Dragon

More than 1,300 patients, family members and staff worked for five months with artist Ian Cion to bring Okoa the Wave Rider to life. An open art studio was sent up in The Park area of MD Anderson’s Albert B. and Margaret M. Alkek Hospital where visitors were invited to draw on paper dragon scales, create watercolor paintings that were used to represent waves, and make and paint paper flowers.

A contest was held to name the sculpture, which stretches 21 feet and stands 9 feet tall, and Okoa — a Swahili word that means rescue, save, redeem or deliver — was selected.

Created in 2010, The Arts in Medicine Program creates art with patients and their families in both one-on-one sessions and in art groups. Pediatric patients and their families are invited to work with the program while in treatment during both inpatient stays and outpatient visits.
Leaders prepare and plan today to prevent disease tomorrow

By Clayton Boldt, Ph.D.

Working on his family’s farm as a boy in Puerto Rico, Joxel Garcia learned the importance of planning ahead to prevent hardships.

“We had to be ready for a drought or a flood, because both made our cows’ milk production decrease,” he says. Either could spell disaster for the family, so Garcia learned to prepare and guard against the worst.

Those lessons learned years ago still apply today in Garcia’s career as a medical leader focused on disease prevention. He joined MD Anderson in August to further the institution’s cancer prevention efforts.

“While efforts to develop new cancer treatments and therapies are important, it’s preferable to prevent the disease in the first place,” says Garcia, a medical doctor and executive director of MD Anderson’s cancer prevention and control platform, which promotes community programs to prevent cancer, particularly among the poor and underserved.

Ernest Hawk, M.D., vice president and head of Cancer Prevention and Population Sciences, and Mark Moreno, vice president for Governmental Relations, led the platform’s early efforts, which have achieved a number of successes.

MD Anderson’s tobacco-free hiring policy is a direct result of the platform’s EndTobacco program.

Platform experts have advised Texas legislators on various public health measures, including laws to restrict minors’ access to indoor tanning devices and electronic cigarettes.

MD Anderson is lending its expertise to the Coordinated Approach to Child Health (CATCH) program, school-based lessons that help students and their parents adopt healthy lifestyle choices through nutrition and exercise. With MD Anderson’s participation, the program now includes sun safety lessons to prevent skin cancer. CATCH has been introduced in 10,000 schools, preschools and after-school programs throughout the nation.

Project ECHO (Extension for Community Healthcare Outcomes) uses a Skype-like video conferencing program to connect MD Anderson experts with health care providers in underserved areas, teaching them how to screen for and treat cervical cancer.

Garcia, who formerly served as U.S. Assistant Secretary for Health, U.S. Representative to the World Health Organization and a four-star Admiral for the U.S. Public Health Service, says the platform prioritizes those Moon Shots Program targets that’ll be most influenced by prevention and cancer control, including lung, melanoma and human papillomavirus (HPV)-related cancers.

“We’ll increase genetic counseling and testing for patients with increased cancer risks, such as those with BRCA1 and 2 mutations; we’ll increase screenings and identify biomarkers for the early detection of lung cancer; and we’ll work with health departments and legislators around the nation to advocate for the HPV vaccine and for restricting tanning bed and electronic cigarette use by minors,” Garcia says.

He intends to use big data to develop more personalized risk assessments and targeted interventions.

The platform is not meant to remain local, but to be shared with leadership at local, state, federal and international entities, he explains.

“Houston is our base, our home, and we want it to be as healthy as possible, but we have a global responsibility as well.”

Executive director of MD Anderson’s cancer prevention and control platform Joxel Garcia, M.D.
What would you say to cancer?

By Andy Olin

In 2015, MD Anderson launched its “Confronting Cancer” campaign, which gave patients, caregivers, supporters, physicians and researchers the opportunity to confront the disease directly.

What did they say?

Physician and researcher Sapna Patel, M.D., warned, “My team will get you, cancer.”

Survivor Gail Morse told the disease it didn’t get the best of her: “You made me stronger, cancer.”

“No more hiding, cancer,” cautioned researcher Michael Curran, Ph.D.

And Board of Visitors member Tom Rushing split no hairs in his prediction: “MD Anderson will destroy you, cancer.”

The campaign, which included online, mobile, television, print and radio placements, began in Houston in July before going national in August.

“This campaign has caught the public’s attention and inspired even greater confidence in us,” MD Anderson President Ronald DePinho said during his state of the institution address in October. “They are the heroes on the front lines of our fight, and their real thoughts and emotions drive the campaign. The approach is bold, emotional and engaging.”

The goal of the effort is to raise national awareness of the institution, and by all measures, it succeeded. In 2010, MD Anderson had only 6% awareness nationally. Today, with the new campaign, that awareness has seen a boost to 13% in the final quarter of last year — a significant milestone for the MD Anderson brand.

The campaign has also increased philanthropic efforts, attracting additional support for the institution’s mission to end cancer.

**MD Anderson is confronting cancer by investing in and collaborating with local community organizations to support cancer patients and survivors, as well as educating people about ways to reduce their cancer risk by making healthy choices.**

In FY15, those investments and collaborations included:

- Working with 409 local schools, churches, employers and community organizations.
- Participating in 1,128 programs and events to support local community fundraising and education efforts.
- Implementing 176 education programs targeted specifically for Hispanics, Asians and African Americans in Houston and the surrounding area to educate them on the importance of cancer screening exams and ways they can improve their health to lower their risk of cancer.
ADMINISTRATION

OFFICE OF THE PRESIDENT
Ronald DePinho, M.D.
President
Weldon Gage
Senior Vice President and Chief Financial Officer
Brad Gibson
Vice President, Revenue Cycle and Treasurer
Mark Moreno
Vice President, Governmental Relations
Patrick Mulvey
Vice President, Development
Tadd Pullin
Senior Vice President, Institutional Advancement

OFFICE OF ADMINISTRATION
Dan Fontaine, J.D.
Executive Vice President, Administration
Amy Hay
Vice President, Business Development
Ferran Prat, Ph.D., J.D.
Vice President, Strategic Industry Ventures
Sherri Magnus
Vice President and Chief Audit Officer
Steven Haydon, J.D.
Vice President and Chief Legal Officer
Allyson Kinzel, J.D.
Vice President and Chief Compliance Officer
Spencer Moore
Vice President and Chief Facilities Officer
Shibu Varghese
Vice President and Chief Human Resources Officer
Chris McKee
Vice President, Business Operations
Margaret Row, M.D.
Vice President, Operations, MD Anderson Cancer Network

OFFICE OF STRATEGY AND INNOVATION
Leon Leach, Ph.D.
Executive Vice President and Chief Business Officer
Chris Belmont
Vice President and Chief Information Officer
Rebecca Kaul
Vice President and Chief Innovation Officer

OFFICE OF THE PROVOST AND EXECUTIVE VICE PRESIDENT
Ethan Dmitrovsky, M.D.
Provost and Executive Vice President
Helen Piwnica-Worms, Ph.D.
Vice Provost, Science
George Wilding, M.D.
Vice Provost, Clinical and Interdisciplinary Research
Robert C. Bast Jr., M.D.
Vice President, Translational Research
Oliver Bogler, Ph.D.
Senior Vice President, Academic Affairs
Maureen Cagley
Vice President, Academic Operations
Diane Bodurka, M.D.
Vice President, Medical Education
Aman Buzdar, M.D.
Vice President, Clinical Research Administration
Ernest Hawk, M.D.
Vice President, Cancer Prevention
Mien-Chie Hung, Ph.D.
Head, Division of Cancer Prevention and Population Sciences

OFFICE OF THE EXECUTIVE VICE PRESIDENT AND PHYSICIAN-IN-CHIEF
Thomas Buchholz, M.D.
Executive Vice President and Physician-in-Chief
Robert Brigham
Senior Vice President, Hospitals and Clinics
John Bingham
Vice President, Performance Improvement and Chief Quality Officer
Wenonah Ecung, Ph.D.
Vice President, Clinical Administration
Lewis Foxhall, M.D.
Vice President, Health Policy
Joel LaJeunesse
Vice President, Pharmacy
Paul Mansfield, M.D.
Vice President, Acute Care Services
Alma Rodriguez, M.D.
Vice President, Medical Affairs
Frank Tortorella, J.D.
Vice President, Clinical Support Services
MD ANDERSON FACULTY

DIVISION OF ANESTHESIOLOGY AND CRITICAL CARE

DEPARTMENT OF ANESTHESIOLOGY AND PERIOPERATIVE MEDICINE
PROFESSOR AND CHAIR
Tom F. Rahlfs, M.D.

DEPARTMENT OF CRITICAL CARE
PROFESSOR AND CHAIR
Kristen J. Price, M.D.

DEPARTMENT OF PAIN MEDICINE
PROFESSOR AND CHAIR
Salahadin Abdi, M.D., Ph.D.

DIVISION OF CANCER MEDICINE

DEPARTMENT OF BREAST MEDICAL ONCOLOGY
PROFESSOR AND CHAIR
Debasish Tripathy, M.D.

DEPARTMENT OF GENERAL ONCOLOGY
PROFESSOR AND CHAIR AD INTERIM
Robert A. Wolff, M.D.

DEPARTMENT OF GENITOURINARY MEDICAL ONCOLOGY
PROFESSOR AND CHAIR
Christopher J. Logothetis, M.D.

DEPARTMENT OF GASTROINTESTINAL MEDICAL ONCOLOGY
PROFESSOR AND CHAIR
James C. Yao, M.D.

DEPARTMENT OF INVESTIGATIONAL CANCER THERAPEUTICS
PROFESSOR AND CHAIR
Funda Meric-Bernstam, M.D.

DEPARTMENT OF LEUKEMIA
PROFESSOR AND CHAIR
Hagop M. Kantarjian, M.D.

DEPARTMENT OF LYMPHOMA/MYELOMA
PROFESSOR AND CHAIR
Robert Orlowski, M.D., Ph.D.

DEPARTMENT OF MELANOMA MEDICAL ONCOLOGY
PROFESSOR AND CHAIR
Patrick Hwu, M.D.

DIVISION OF CANCER PREVENTION AND POPULATION SCIENCES

DEPARTMENT OF BEHAVIORAL SCIENCE
PROFESSOR AND CHAIR
Paul M. Cinciripini, Ph.D.

DEPARTMENT OF CLINICAL CANCER PREVENTION
PROFESSOR AND CHAIR
Powel H. Brown, M.D., Ph.D.

DEPARTMENT OF EPIDEMIOLOGY
PROFESSOR AND CHAIR AD INTERIM
Ernest Hawk, M.D., M.P.H.

DEPARTMENT OF HEALTH DISPARITIES RESEARCH
PROFESSOR AND CHAIR AD INTERIM
Sharon Hermes Giordano, M.D., M.P.H.
DIVISION OF DIAGNOSTIC IMAGING

DEPARTMENT OF CANCER SYSTEMS IMAGING
PROFESSOR AND CHAIR
David Pismica-Worms, M.D., Ph.D.

DEPARTMENT OF DIAGNOSTIC RADIOLOGY
PROFESSOR AND CHAIR
Wei Tse Yang, M.D.

DEPARTMENT OF IMAGING PHYSICS
PROFESSOR AND CHAIR
John D. Hazle, Ph.D.

DEPARTMENT OF INTERVENTIONAL RADIOLOGY
PROFESSOR AND CHAIR
AD INTERIM
Michael J. Wallace, M.D.

DEPARTMENT OF NUCLEAR MEDICINE
PROFESSOR AND CHAIR
Homer A. Macapinlac, M.D.

DIVISION OF INTERNAL MEDICINE

DEPARTMENT OF CARDIOLOGY
PROFESSOR AND CHAIR
Edward T.H. Yeh, M.D.

DEPARTMENT OF DERMATOLOGY
PROFESSOR AND CHAIR
Ronald P. Rapini, M.D.

DEPARTMENT OF EMERGENCY MEDICINE
PROFESSOR AND CHAIR
AD INTERIM
Kumar Alagappan, M.D.

DEPARTMENT OF ENDOCRINE NEOPLASIA AND HORMONAL DISORDERS
PROFESSOR AND CHAIR
Steven I. Sherman, M.D.

DEPARTMENT OF GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION
PROFESSOR AND CHAIR
AD INTERIM
Marta Davila, M.D.

DIVISION OF NURSING

DEPARTMENT OF NURSING
ASSOCIATE PROFESSOR AND CHAIR
AD INTERIM
Joyce E Dains, Dr.P.H., J.D.

DIVISION OF PATHOLOGY AND LABORATORY MEDICINE

DEPARTMENT OF HEMATOPOATHOLOGY
PROFESSOR AND CHAIR
L. Jeffrey Medeiros, M.D.

DEPARTMENT OF LABORATORY MEDICINE
PROFESSOR AND CHAIR
Elizabeth A. Wagar, M.D.

DEPARTMENT OF PATHOLOGY
PROFESSOR AND CHAIR
Victor Prieto, M.D., Ph.D.

DEPARTMENT OF TRANSLATIONAL MOLECULAR PATHOLOGY
PROFESSOR AND CHAIR
Ignacio Ivan Wistuba, M.D.

DIVISION OF PEDIATRICS

DEPARTMENT OF PEDIATRICS
PROFESSOR AND CHAIR
AD INTERIM
Cindy Schwartz, M.D.

DEPARTMENT OF PSYCHIATRY
PROFESSOR AND CHAIR
Alan D. Valentine, M.D.
DIVISION OF RADIATION ONCOLOGY

DEPARTMENT OF EXPERIMENTAL RADIATION ONCOLOGY
PROFESSOR AND CHAIR
Junjie Chen, Ph.D.

DEPARTMENT OF RADIATION ONCOLOGY
PROFESSOR AND CHAIR
Stephen Hahn, M.D.

DEPARTMENT OF RADIATION PHYSICS
PROFESSOR AND CHAIR
Geoffrey Ibbott, Ph.D.

DIVISION OF SURGERY

DEPARTMENT OF BREAST SURGICAL ONCOLOGY
PROFESSOR AND CHAIR AD INTERIM
Kelly K. Hunt, M.D.

DEPARTMENT OF GYNECOLOGIC ONCOLOGY AND REPRODUCTIVE MEDICINE
PROFESSOR AND CHAIR
Karen H. Lu, M.D.

DEPARTMENT OF HEAD AND NECK SURGERY
PROFESSOR AND CHAIR
Randal S. Weber, M.D.

DEPARTMENT OF NEUROSURGERY
PROFESSOR AND CHAIR
Randal S. Weber, M.D.

DEPARTMENT OF ORTHOPEDIC ONCOLOGY
PROFESSOR AND CHAIR
Valerae O. Lewis, M.D.

DEPARTMENT OF PLASTIC SURGERY
PROFESSOR AND CHAIR
Charles E. Butler, M.D.

DEPARTMENT OF SURGICAL ONCOLOGY
PROFESSOR AND CHAIR
Jeffrey L. Lee, M.D.

DEPARTMENT OF THORACIC AND CARDIOVASCULAR SURGERY
PROFESSOR AND CHAIR
Ara A. Vapariyan, M.D.

DEPARTMENT OF UROLOGY
PROFESSOR AND CHAIR
Colin P. Dinney, M.D.

EXTERNAL ADVISORY BOARD

MD Anderson's External Advisory Board is composed of highly regarded scientific advisors who consult with MD Anderson faculty leaders on research programs and initiatives.

Carolyn “Bo” R. Aldigé
Prevent Cancer Foundation

Frederick Appelbaum, M.D.
Fred Hutchinson Cancer Research Center

Leslie Bernstein, Ph.D.
City of Hope

Monica Bertagnolli, M.D.
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Elizabeth Blackburn, Ph.D.
University of California at San Francisco

Paul A. Bunn, Jr., M.D.
University of Colorado Cancer Center

Steven K. Clinton, M.D., Ph.D.
The Ohio State University

Graham A. Colditz, M.D., Dr.PH.
Washington University School of Medicine

Nancy E. Davidson, M.D.
University of Pittsburgh Cancer Institute

Keith T. Flaherty, M.D.
Massachusetts General Hospital

Judy E. Garber, M.D., M.P.H.
Dana-Farber Cancer Institute

Levi A. Garraway, M.D., Ph.D.
Harvard Medical School

Gad Getz, Ph.D.
Broad Institute

Lauren E. Hackett, M.P.A.
Vanderbilt-Ingram Cancer Center

Lee J. Heilman, M.D.
Clinical Research Center for Cancer Research, National Institutes of Health

Lydia Kavraki, Ph.D.
Rice University

Quynh-Thu Le, M.D.
Stanford School of Medicine

Caryn Lerman, Ph.D.
Abramson Cancer Center, University of Pennsylvania

David N. Louis, M.D.
Harvard Medical School
Massachusetts General Hospital

Tak Wah Mak, Ph.D.
University of Toronto

Elaine Mardis, Ph.D.
Washington University School of Medicine

Monica Morrow, M.D., F.A.C.S.
Memorial Sloan Kettering Cancer Center

Harold Moses, M.D.
Vanderbilt-Ingram Cancer Center

William G. Nelson, M.D., Ph.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Giovanni Parmigiani, Ph.D.
Harvard School of Public Health
Dana Farber Cancer Institute

Antoni Ribas, M.D., Ph.D.
UCLA Jonsson Comprehensive Cancer Center

Robert Schreiber, Ph.D.
Washington University School of Medicine
Department of Pathology and Immunology

Norman E. “Ned” Sharpless, M.D.
Lineberger Comprehensive Cancer Center,
University of North Carolina

Yang Shi, Ph.D.
Boston Children's Hospital

Ellen Sigal, Ph.D.
Friends of Cancer Research

David R. Spriggs, M.D.
Memorial Sloan Kettering Cancer Center

Craig B. Thompson, M.D.
Memorial Sloan Kettering Cancer Center

Daniel Von Hoff, M.D., F.A.C.P.
TGen

Ralph Weissleder, M.D., Ph.D.
Massachusetts General Hospital
Harvard Medical School
BASIC SCIENCE DEPARTMENTS

Helen Piwnica-Worms, Ph.D.
Vice provost for science

DEPARTMENT OF IMMUNOLOGY
PROFESSOR AND CHAIR
James P. Allison, Ph.D.

DEPARTMENT OF BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
PROFESSOR AND CHAIR
John N. Weinstein, M.D., Ph.D.

DEPARTMENT OF MOLECULAR AND CELLULAR ONCOLOGY
PROFESSOR AND CHAIR
Mien-Chie Hung, Ph.D.

DEPARTMENT OF BIOSTATISTICS
PROFESSOR AND CHAIR
Kim-Anh Do, Ph.D.

DEPARTMENT OF SYSTEMS BIOLOGY
PROFESSOR AND CHAIR
Gordon B. Mills, M.D., Ph.D.

DEPARTMENT OF CANCER BIOLOGY
PROFESSOR AND CHAIR
Raghu Kalluri, M.D., Ph.D.

DEPARTMENT OF VETERINARY MEDICINE AND SURGERY
PROFESSOR AND CHAIR
Peggy T. Tinkey, D.V.M.

DEPARTMENT OF EPIGENETICS AND MOLECULAR CARCINOGENESIS
PROFESSOR AND CHAIR
Sharon R. Dent, Ph.D.

DEPARTMENT OF VETERINARY SCIENCES
PROFESSOR AND CHAIR
Christian Abee, D.V.M.

DEPARTMENT OF GENETICS
PROFESSOR AND CHAIR
Guillermina Lozano, Ph.D.

SCHOOL OF HEALTH PROFESSIONS
PROFESSOR AND DEAN
Shirley Richmond, Ed.D.
MD Anderson Cancer Center Board of Visitors

The MD Anderson Cancer Center Board of Visitors is an appointed board of people committed to helping MD Anderson achieve its mission of eliminating cancer. Board programs emphasize private fund development, public relations and outreach on behalf of the institution.

Executive Committee

CHAIR
Mr. Melvyn N. Klein

MEMBERS
Ronald A. DePinho, M.D. 
President, MD Anderson
Mr. James J. Mulva 
Chair-Elect
Mr. Harry J. Longwell 
Immediate Past Chair
Mrs. Marsha Shields 
Vice Chair
Mr. David T. Herr 
Chair, Development Committee
Mr. Pierre F. Lapeyre, Jr. 
Chair, Bylaws Committee
Mr. Mac Tichenor, Jr. 
Chair, Events Committee
Mr. W. Robert Nichols III 
Chair, Government Relations Committee
Mr. Barry G. Andrews 
Chair, Government Relations Committee

Mr. Tom Johnson 
Chair, Public Affairs Committee
Mrs. Patricia Bodin 
Chair, Cancer Control Advisory Group
Mrs. Linda Mays McCaul 
Chair, Cancer Control Advisory Group
Mr. James L. Gallogly 
Chair, Cancer Control Advisory Group
Mr. Patrick C. Oxford 
Chair, Cancer Control Advisory Group
The Honorable Donald L. Evans 
Chair, Cancer Control Advisory Group

Life Members

The Honorable James A. Baker, III
Mrs. Barbara Bush
The Honorable George H. W. Bush
Mr. Charles Butt
Mr. Ernest H. Cockrell
Mr. Edwin L. Cox
Miss Lyda Hill
Dr. Charles A. LeMaistre
Mr. L. Lowry Mays
Mr. Red McCombs
Mr. W. A. “Tex” Moncrief, Jr.
Mr. T Boone Pickens

Senior Members

Mrs. Linda L. Addison
Mr. Richard C. Adkerson
Mr. John D. Alexander, Jr.
Mr. Stanford J. Alexander
Mrs. Judy Ley Allen
Mr. Robert J. Allison, Jr.
Mr. Michael G. Bartolotta
Mr. Lawrence E. Bathgate II
Mrs. Sally B. Berry
Mr. Giorgio Borlenghi
Mr. Joel Brochstein
Mr. Kyle C. Brooks
Mr. Philip J. Burguiere
Pastor Kirbyjon H. Caldwell
Mr. Clarence P Cazalot, Jr.
Mr. Gus H. Comiskey Jr.
Mrs. Anne P. Connally
Mr. John B. Connally III

At-Large Members

Mr. Mark W. Albers
Mr. William R. Bush
Mr. Clarence P Cazalot, Jr.
Mr. Ernest H. Cockrell
Mr. G. Steven Farris
Mrs. Lily C. Garfield
Mr. Wayne Gibbens
Mr. David M. Grimes II
Mrs. Maureen Hackett
The Honorable Kay Bailey Hutchison
Mr. David H. Koch

Mrs. Nancy B. Loeffler
Mr. Jeff B. Love
Mr. R. Drayton McLane, Jr.
Mr. Joseph Neubauer
Mr. A. R. “Tony” Sanchez, Jr.
Mr. Marc J. Shapiro
Mr. Charles W. Tate
Mrs. Sue S. Timken

Mr. Rufus Cormier, Jr.
Mrs. Shirley Coskey
Mr. James D. Dannenbaum
Mrs. Charline Dauphin
Mrs. Myrna J. Deckert
Mrs. Linnet F. Deily
Mr. Ben A. Donnell
Mr. John H. Duncan, Sr.
Mr. G. Steven Farris
Mr. Stephen L. Feinberg
Mr. Alan D. Feld
Mr. Dillon J. Ferguson
Mr. Jerry E. Finger **
Mr. George A. Finley III
Mrs. Patsy S. Fourticq
Mr. Steve L. Fox
Mr. Michael E. Frazier
Mr. Gibson Gayle, Jr.
Mr. Wayne Gibbens
Mr. Gary F. Gibson
Mr. Terry M. Giles
Mr. Thomas S. Glanville
Mr. F. O’Neil Griffin
Mr. Ben A. Guill
Mrs. Gloria Hicks
Mr. Yerger Hill III
Mr. Jeffrey C. Hines
Mr. Forrest E. Hoglund
Mr. D. Alter Holand
Mrs. Desiree Lyon Howe
Mr. Woody L. Hunt
Mrs. Barbara R. Hurwitz
Mr. Charles E. Hurwitz
Mrs. Judith Jaynes

** Deceased
<table>
<thead>
<tr>
<th>Members</th>
<th>Associate Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mrs. Peggy Brunet Ahuja</td>
<td>Dr. Durga D. Agrawal</td>
</tr>
<tr>
<td>Mr. Mark W. Albers</td>
<td>Mrs. Nita Ambani</td>
</tr>
<tr>
<td>Mr. Barry G. Andrews</td>
<td>Mr. Andrew M. Baker *</td>
</tr>
<tr>
<td>Mr. Glynn Andrews</td>
<td>Mr. Lee Barberito</td>
</tr>
<tr>
<td>Mr. Matthew Anthony</td>
<td>Mr. David J. Beck</td>
</tr>
<tr>
<td>Laura E. Arnold</td>
<td>Mr. G. Alex Bernhardt, Sr.</td>
</tr>
<tr>
<td>Mr. John W. Barnhill, Jr.</td>
<td>Mr. J. Robert Brown *</td>
</tr>
<tr>
<td>Mr. Paul E. Begala</td>
<td>Mr. I. Jon Brumley</td>
</tr>
<tr>
<td>Mr. Brent Alan Benoit</td>
<td>Mr. William R. Bush</td>
</tr>
<tr>
<td>Mrs. Kelli L. Blanton</td>
<td>Mr. Tony Chase *</td>
</tr>
<tr>
<td>Mrs. Patricia Bodin</td>
<td>Mr. David A. Cockrell</td>
</tr>
<tr>
<td>Dr. W. E. Borsarge, Jr.</td>
<td>Mr. Ted Collins, Jr.</td>
</tr>
<tr>
<td>Mr. Robert T. Brockman</td>
<td></td>
</tr>
<tr>
<td>Mr. Rick J. Calhoon</td>
<td></td>
</tr>
<tr>
<td>Mr. Michael J. Cerno</td>
<td></td>
</tr>
<tr>
<td>Mr. Albert Y. Chao</td>
<td></td>
</tr>
<tr>
<td>Ms. Lois Chiles</td>
<td></td>
</tr>
<tr>
<td>Mr. Arthur Ciocca</td>
<td></td>
</tr>
<tr>
<td>Mrs. Cindy Citrone</td>
<td></td>
</tr>
<tr>
<td>The Honorable Peter R. Coneway</td>
<td></td>
</tr>
<tr>
<td>Mrs. Nadine Craddick</td>
<td></td>
</tr>
<tr>
<td>Mrs. Cheryl Creuzot</td>
<td></td>
</tr>
<tr>
<td>Mrs. Rose S. Cullen</td>
<td></td>
</tr>
<tr>
<td>Mrs. Patricia Hamilton Dewhurst</td>
<td></td>
</tr>
<tr>
<td>Mr. Jerry Dickman</td>
<td></td>
</tr>
<tr>
<td>Mr. Walter W. Driver, Jr.</td>
<td></td>
</tr>
<tr>
<td>Mrs. Jan E. Duncan</td>
<td></td>
</tr>
<tr>
<td>Mr. Raymond A. Eckstein, Jr.</td>
<td></td>
</tr>
<tr>
<td>Mr. Jay S. Eisenberg</td>
<td></td>
</tr>
<tr>
<td>Mrs. Elizabeth G. Epley</td>
<td></td>
</tr>
<tr>
<td>The Honorable Donald L. Evans</td>
<td></td>
</tr>
<tr>
<td>Mrs. Christine Gaylord Everett</td>
<td></td>
</tr>
<tr>
<td>Mr. James H. Everest</td>
<td></td>
</tr>
<tr>
<td>Mr. Jason B. Few</td>
<td></td>
</tr>
<tr>
<td>Mr. William B. Finneran</td>
<td></td>
</tr>
<tr>
<td>Mr. Andersen C. Fisher</td>
<td></td>
</tr>
<tr>
<td>Mr. James L. Gallogly</td>
<td></td>
</tr>
<tr>
<td>Mrs. Lily C. Garfield</td>
<td></td>
</tr>
<tr>
<td>Dr. Marie Goradia</td>
<td></td>
</tr>
<tr>
<td>Mr. Steven L. Gordon</td>
<td></td>
</tr>
<tr>
<td>Mr. Richard W. Gray III</td>
<td></td>
</tr>
<tr>
<td>Mr. David M. Grimes II</td>
<td></td>
</tr>
<tr>
<td>Mr. Felo Guerra</td>
<td></td>
</tr>
<tr>
<td>Mrs. Maureen Hackett</td>
<td></td>
</tr>
<tr>
<td>Mrs. Janelle Hail</td>
<td></td>
</tr>
<tr>
<td>Mrs. Katherine C. Hatcher</td>
<td></td>
</tr>
<tr>
<td>Ms. Adrea D. Heebe</td>
<td></td>
</tr>
<tr>
<td>Mrs. Becky Bradfield Heiser</td>
<td></td>
</tr>
<tr>
<td>Mr. John A. Holland</td>
<td></td>
</tr>
<tr>
<td>The Honorable Brenda L. Johnson</td>
<td></td>
</tr>
<tr>
<td>Ms. Luci B. Johnson</td>
<td></td>
</tr>
<tr>
<td>Mr. Tom Johnson</td>
<td></td>
</tr>
<tr>
<td>Mrs. Danielle Kavanagh</td>
<td></td>
</tr>
<tr>
<td>Mr. T. Mark Kelly</td>
<td></td>
</tr>
<tr>
<td>Mr. Melvyn N. Klein</td>
<td></td>
</tr>
<tr>
<td>Dr. Demos T. Kyrazis</td>
<td></td>
</tr>
<tr>
<td>Mrs. Julie Kyte</td>
<td></td>
</tr>
<tr>
<td>Mr. Pierre F. Lapeyre, Jr.</td>
<td></td>
</tr>
<tr>
<td>Mr. Stephen A. Lascher</td>
<td></td>
</tr>
<tr>
<td>Mrs. Helen H. Laughery</td>
<td></td>
</tr>
<tr>
<td>Mr. Michael C. Linn</td>
<td></td>
</tr>
<tr>
<td>Ms. Janiece Longoria</td>
<td></td>
</tr>
<tr>
<td>Mr. Harry J. Longwell</td>
<td></td>
</tr>
<tr>
<td>Mr. Angel Losada</td>
<td></td>
</tr>
<tr>
<td>Ms. Mary Ralph Lowe</td>
<td></td>
</tr>
<tr>
<td>Mrs. Karen R. Matthews</td>
<td></td>
</tr>
<tr>
<td>Mrs. Linda Mays McCaul</td>
<td></td>
</tr>
<tr>
<td>Mr. R. Drayton McLane, Jr.</td>
<td></td>
</tr>
<tr>
<td>Mr. Howard M. Meyers</td>
<td></td>
</tr>
<tr>
<td>Mrs. Denise D. Monte Leone</td>
<td></td>
</tr>
<tr>
<td>Mr. William C. Montgomery</td>
<td></td>
</tr>
<tr>
<td>Mr. James J. Mulva</td>
<td></td>
</tr>
<tr>
<td>Mr. Joseph Neubauer</td>
<td></td>
</tr>
<tr>
<td>Mr. Marvin Odum</td>
<td></td>
</tr>
<tr>
<td>Mrs. Vicky M. Pappas</td>
<td></td>
</tr>
<tr>
<td>Mrs. Roseann Park</td>
<td></td>
</tr>
<tr>
<td>Mrs. Melinda Hill Perrin</td>
<td></td>
</tr>
<tr>
<td>Mr. Ralph Ponce de Leon</td>
<td></td>
</tr>
<tr>
<td>Mrs. Sheila Reese</td>
<td></td>
</tr>
<tr>
<td>Mr. Scott E. Rozzell</td>
<td></td>
</tr>
<tr>
<td>Mr. Thomas V. Rushing</td>
<td></td>
</tr>
<tr>
<td>Mr. Michael S. Samis</td>
<td></td>
</tr>
<tr>
<td>Mr. A. R. “Tony” Sanchez, Jr.</td>
<td></td>
</tr>
<tr>
<td>Mrs. Maria J. “Tani” Sanchez</td>
<td></td>
</tr>
<tr>
<td>Mr. Christopher Sarofim</td>
<td></td>
</tr>
<tr>
<td>Mr. John C. Schweitzer</td>
<td></td>
</tr>
<tr>
<td>Mr. Milton L. Scott</td>
<td></td>
</tr>
<tr>
<td>Dr. Thomas Seitz</td>
<td></td>
</tr>
<tr>
<td>Mr. John H. Shields II</td>
<td></td>
</tr>
<tr>
<td>Mrs. Marsha Shields</td>
<td></td>
</tr>
<tr>
<td>Mrs. Jan A. Levit Silver</td>
<td></td>
</tr>
<tr>
<td>Mr. Doyle Simons</td>
<td></td>
</tr>
<tr>
<td>Mr. Herbert D. Simons</td>
<td></td>
</tr>
<tr>
<td>Mr. Walter J. Smith</td>
<td></td>
</tr>
<tr>
<td>Mr. Gary W. Stein</td>
<td></td>
</tr>
<tr>
<td>Mrs. Louise Stephenson</td>
<td></td>
</tr>
<tr>
<td>Mr. Charles W. Stiefel</td>
<td></td>
</tr>
<tr>
<td>Mrs. Gayle B. Stoffel</td>
<td></td>
</tr>
<tr>
<td>Mrs. Sue S. Timken</td>
<td></td>
</tr>
<tr>
<td>Mr. Tony Vallone</td>
<td></td>
</tr>
<tr>
<td>Mr. William M. Webster IV</td>
<td></td>
</tr>
<tr>
<td>Mr. Herbert D. Weitzman</td>
<td></td>
</tr>
<tr>
<td>Mrs. Michel H. Williams</td>
<td></td>
</tr>
<tr>
<td>Mrs. Sheridan Williams</td>
<td></td>
</tr>
<tr>
<td>Mr. John H. Wilson III</td>
<td></td>
</tr>
<tr>
<td>Mr. Don M. Woo</td>
<td></td>
</tr>
<tr>
<td>Mr. Eric S. Zorn</td>
<td></td>
</tr>
</tbody>
</table>

*New member

Mr. James F. Justiss, Jr.
Mrs. Glenda R. Kane
Mrs. Nancy G. Kinder
Dr. Henry A. Kissinger
Mr. David H. Koch
Mr. Gregory A. Kozmetsky
Ms. Neda Ladjevardian
Mr. Eric S. Lane
Mrs. Elyse Lanier
Mr. C. Berdon Lawrence
Ms. Marty V. Leonard
Mrs. Mary V. Lester
Mr. Max S. Levit
Mr. Michael R. Levy
Mrs. Nancy B. Loefller
Mr. Jeff B. Love
Mrs. Marlene A. Malek
Mr. Rodney H. Margolis
Mr. Kade L. Matthews
Mrs. Mary Anne McCloud
Mrs. Stacie McDouglas
Mr. Michael D. McKinnon
The Honorable Thomas F. McLarty III
Mrs. Soncera Messiah-Jiles
Mr. Allen A. Meyer
Mr. Steven L. Miller
Mrs. Kit Moncrief
Mr. Henry G. Musselman
Mr. W. Robert Nichols III
Mr. Dennis E. Nixon
Mrs. Kay M. Onstead
Mrs. Pamela K. Onstead
Mr. Paul F. Orefice
Mr. Patrick C. Oxford
Mrs. Jan R. Pickens
Mr. Jack P. Randall
Ms. Regina J. Rogers
Mr. William E. Rosenthal
Mrs. Helen Lho Ryu
Mr. Andrew E. Sabin
Mr. Federico Sada
Joan Weingarten Schnitzer
Mrs. Nancy M. Seliger
Mrs. Peggy Sewell
Mr. Marc J. Shapiro
Mr. Lester H. Smith
Mr. H. Leighton Steward
Mr. Charles W. Tate
Mr. Mac Tichenor, Jr.
Mr. Robert B. Tudor III
Mr. Steven H. Wasserman
Mrs. Margaret Alkek Williams
Mr. Melvyn L. Wolff
The Honorable Joseph Zappala

53
Partners in Making Cancer History

MD Anderson gratefully acknowledges the following individuals, foundations, organizations and others who made commitments of $1,000 or more from Sept. 1, 2014, to Aug. 31, 2015.
Mr. and Mrs. Joe H. Anderson, Jr.
John Henry and Dora Anderson
Karen and Charles Anderson
Mr. and Mrs. Kenneth W. Anderson
Mr. and Mrs. Marcus A. Anderson
Mr. Richard E. Anderson
Mrs. Rita Anderson
Mr. Robert W. Anderson
Mr. and Mrs. William L. Anderson, Jr.
Mrs. Adela W. Anding
Mr. and Mrs. Barry G. Andrews
Mr. Glynn Andrews
Mr. and Mrs. Richard L. Andrews
Andrews Distributing of North Texas, Ltd.
Glynn Andrews Family Foundation
Andrews Foundation
A. W. and Juan Angela Foundation
Anonymous
The Honorable and Mrs. Hushang Ansary
Mrs. Joyce A. Antes
Mr. and Mrs. Matthew Anthony
Ms. Samuel Ella Antoine
Aon Foundation
Aplastic Anemia & MDS International Foundation, Inc.
Aptose Biosciences Inc.
Aqua Water Supply Corporation
Mr. Rich Aram
Dr. and Mrs. Roberto J. Aranbar
Arbella Charitable Foundation, Inc.
Actor Car Wash
James B. Archer and Lois R. Archer Charitable Foundation
Ms. Susan E. Archer
Mrs. Bonnie Ardoin
Mr. and Mrs. George E. Ardoin
Mrs. Pam Ardoin
The Arena Energy Foundation
Ms. Michele Argo
Arkansas Community Foundation
Mr. and Mrs. William J. Arkwright
Mr. and Mrs. Charles F. Armbrust
Mr. and Mrs. David S. Armbruster
Dan and Mary Armour
Mr. and Mrs. Rick D. Amett
Mr. and Mrs. James W. Arnold
Mr. and Mrs. Truman Arnold
Arnold Foundation
Mr. and Mrs. Robert B. Arnot
Arnot Oil Company, LLC
Mr. Zane W. Arrott
Lovee and Bob Arum
Mr. and Mrs. Vijay K. Arya
Mr. and Mrs. Gerry Aschinger
Mr. and Mrs. Juan Jose Asencio
Mr. G. Ash
Mary Kay Ash Charitable Foundation
Mr. Frank A. Ashley, Jr.
Mr. and Mrs. John K. Ashley
Ashley Collins Studio Ltd.
Mr. and Mrs. Kenneth J. Aspromonte
AT&T
Employees of AT&T
AT&T Political Action Committees
Mr. and Mrs. Urul Ataman
Dr. Russell P. Atchley
Ms. Christie Atkinson
Atlantic Casino Resort Spa - Reno, Nevada
Dr. Michelle Aucoin and Dr. B. Michael Aucoin
Dr. and Mrs. Arthur I. Auer
Dr. Charles H. Aurand
Wayne B. and Jeanette Aurih
Austin Community Foundation
Mr. and Mrs. James Avery
Dr. and Mrs. Andrew Avillo

Bank of America Foundation
Bank of America Merrill Lynch
Bank of America Philanthropic Management
The Bank of San Antonio
Mrs. Barbara Banker
Mr. and Mrs. R. Clifford Banks
Mr. and Mrs. Larry G. Babour
Mrs. Ann K. Barfield
Mr. and Mrs. John N. Banneke III
John and Lee Barker
Estate of Bruce A. Barkhurst
Mr. and Mrs. C. L. Barlow
Barnard Partnership
Mr. and Mrs. Leroy R. Barnes, Jr.
Mr. James C. Barnett
Barney Family Foundation
J. H. Baroco Foundation, Inc.
Mr. and Mrs. Beverly Barr
Mr. and Mrs. Kenneth J. Barr
Mr. Laurence Barr
The Kenneth J. and Cora Barr Foundation
Ms. Elisabeth G. Barranco
Ms. Colleen C. Barrett
Michael Barrett
Barriere Construction Co., L.L.C.
Linda and Tommy Barrow
Mr. Herbert W. Barter
Sally and Jim Bartlett
Mr. and Mrs. Benny M. Barton
Bass Energy Company
Mr. and Mrs. Thomas B. Bastian
John and Nellie Bastian Memorial Foundation
Ms. Julie A. Baterman
Dale and Kay Bates
Mr. Lyle Bates
Jane and Alan Batkin
Baton Rouge Area Foundation
Mr. Joe Batson
Mr. and Mrs. James A. Baudin
Mrs. Evelyn M. Baum
Mr. and Mrs. Philip J. Baumann
Mr. and Mrs. Scott W. Baxter
Baxter International Inc.
Dr. Roberto J. Bayardo
Mr. and Mrs. Kenneth L. Bazzle
Employees of BBVA Compass
BCH Management LLC
BCM & Associates, Inc.
BDT Capital Partners
Mr. and Mrs. Bill Beach
Beacon Hill Show Stables, Inc.
Ms. Rebecca S. Beal and Mr. James I. Wimsatt
Mr. and Mrs. David S. Beall
Mr. and Mrs. Michael A. Beam
Mrs. Barbara Beard
Mr. and Mrs. Robert C. Beard
Mr. Stephen M. Beard
Mr. John W. Beasley
Beasley Family Foundation
Mr. Wayne Beason
Mr. and Mrs. Robert H. Beavers
Betheil Group Foundation
Mr. and Mrs. David J. Beck
John and Sharon Beck
Mr. Robert Beck
Beck Bros., Inc.
Mr. Allen J. Becker
Mr. Donald A. Becker
Mr. and Mrs. Harry G. Beckner
Mr. and Mrs. Elton G. Beebe
Mr. and Mrs. Louis A. Beecher, III
Ms. Sheryl Beeceoff
Mr. David C. Beeman
Mr. and Mrs. Paul E. Begala
JoAnna and Robert Behl
Martin and Kathleen Beine
Mr. and Mrs. William H. Belden, Jr.
The W. and Jeanne G. Belden Philanthropic Fund
Mr. and Mrs. Robert A. Belfer
Robert A. and Renee E. Belfer Foundation
Mrs. Billie B. Bell
Mr. and Mrs. Brian M. Bell
Mr. James Michael Bell, Jr.
Mr. and Mrs. Linda Bell
Bella Vita Belles
Mr. and Mrs. James Bellingier, Jr.
Mr. and Mrs. John W. Bellingier
Ms. Yvonne M. Bellingier
Ms. Maria Bellon
Mr. and Mrs. David S. Bellows
Mr. and Mrs. Dewey Bellows
Mr. and Mrs. Steve Bell
Mr. Gonzalo Beltran
Benefit Concepts, Inc.
Dr. and Mrs. Robert S. Benjamin
Mr. Edwin Bennett
Mr. Robert B. Bennett
Mr. and Mrs. Brent Alan Beno
Ben’s Supermarket, Inc.
Mr. Edmond B. Bentley
Bentley & Associates, PC.
Mrs. Betty V. Benton
Dr. Laura Beretta
Mr. Brian K. Berg
Mr. and Mrs. Bruce M. Bergquist
Mr. and Mrs. Steve Bergstrom

HARRY CAROTHERS WIESS DISTINGUISHED UNIVERSITY CHAIR FOR CANCER RESEARCH
Robert C. Bast, Jr., M.D.

OLGA KEEF AND HARRY CAROTHERS WIESS DISTINGUISHED UNIVERSITY CHAIR IN CANCER RESEARCH
Ethan Dmitrovsky, M.D.

THE ROBERT A. WELCH Distinguished University Chair in Chemistry
Andrew Futreal, Ph.D.

FREDERICK F. BECKER Distinguished University Chair for Cancer Research
Stanley R. Hamilton, M.D.

SAMSUNG DISTINGUISHED UNIVERSITY CHAIR IN CANCER MEDICINE
Hagop M. Kantarjian, M.D.

SHEIKH KHALIFA BIN ZAYED AL NAHYAN DISTINGUISHED UNIVERSITY CHAIR IN CANCER RESEARCH
Anirban Maitra, M.B.B.S.

OLGA KEEF WIESS DISTINGUISHED UNIVERSITY CHAIR FOR CANCER RESEARCH
Gordon B. Mills, M.D., Ph.D.

THE JOHN BROOKS WILLIAMS AND ELIZABETH WILLIAMS DISTINGUISHED UNIVERSITY CHAIR IN CANCER MEDICINE
Randal S. Weber, M.D.

SHEIKH ZAYED BIN SULTAN AL NAHYAN DISTINGUISHED UNIVERSITY CHAIR OF MEDICAL ONCOLOGY
Robert A. Wolff, M.D.

As of September 1, 2015

55
Endowed Distinguished Chairs

VIVIAN L. SMITH DISTINGUISHED CHAIR IN IMMUNOLOGY
James P. Allison, Ph.D.

JOHN CHARLES CAIN DISTINGUISHED CHAIR IN CANCER PREVENTION
Powel H. Brown, M.D., Ph.D.

HUBERT L. AND OLIVE STRINGER DISTINGUISHED CHAIR IN ONCOLOGY IN HONOR OF SUE GRIBBLE STRINGER
Thomas A. Buchholz, M.D.

PAMELA AND WAYNE GARRISON DISTINGUISHED CHAIR IN CANCER RESEARCH
Junjie Chen, Ph.D.

ALANDO J. BALLANTYNE DISTINGUISHED CHAIR OF HEAD AND NECK SURGERY
Gary L. Clayman, M.D., D.M.D.

JANE AND JOHN JUSTIN DISTINGUISHED CHAIR IN LEUKEMIA RESEARCH IN HONOR OF DR. ELIHU ESTEY
Jorge E. Cortes, M.D.

NATHAN W. LASSTTER DISTINGUISHED CHAIR IN UROLOGY
Bogdan A. Czerniak, M.D., Ph.D.

W. A. "TEX" AND DEBORAH MONCRIEF, JR. DISTINGUISHED CHAIR IN UROLOGY
Colin P. N. Dinney, M.D.

R. E. "BOB" SMITH DISTINGUISHED CHAIR IN CELL BIOLOGY
Isaiah J. Fidler, D.V.M., Ph.D.

WAUN KI HONG DISTINGUISHED CHAIR IN TRANSLATIONAL ONCOLOGY
Elizabeth A. Grimm, Ph.D.

GILBERT H. FLETCHER MEMORIAL DISTINGUISHED CHAIR
Stephen Hahn, M.D.

Mrs. Sue M. Brown
Mr. Tad Brown
Mr. W. Lawrence Brown
Mr. Wiliard B. Brown
Mr. William C. Brown
Mr. and Mrs. William R. Brown
Brown and Oritz, PC

The Brown Foundation, Inc.
H. L. Brown, Jr. Family Foundation
Mr. and Mrs. James R. Browning
The Samuel B. and Lorena J. Bruce Charitable Trust
Mr. and Mrs. D. Forrest Brunbaugh
Mr. and Mrs. Michael W. Brunnerhop
The Brunetti Foundation
Fred J. Brunner Foundation
Mr. and Mrs. Jeremy J. Brusser
Mr. Jonathan B. Brusser
Mr. Ralph C. Bruson
Mr. and Mrs. Charles J. Bryan
Fred and Lynn Bryla
Mrs. Laura L. Bucholz

Mr. Jason Buck
Buck Kreiths Marine Repair, LLC
Ms. Carol M. Buckley
Mr. W. F. Buckthal
Mr. and Mrs. I. David Bufkin

Mr. and Mrs. William T. Buída
Dr. Rosaria A. Bulgarella
Bull Shits
Ms. Sherry W. Bullock
Estate of Roberta Bunch
Mr. and Mrs. James Bunge
Dr. and Mrs. John F. Bunk
Mr. and Mrs. Thomas Allen Bunkley III
Bunnell-Lammons Engineering Inc.

Mr. and Mrs. Dean L. Buntrock
Burberry Americas
Burberry - Galería
Mr. and Mrs. Joe Tom Burch
Mr. and Mrs. Ralph R. Burchenal
Penny Burch
Mr. and Mrs. C. Scott Burchard
Mr. Thomas V. Burchford
Mr. Arthur Burke
Ms. Sherrill Burke
Tom and Cathy Burke
Mr. and Mrs. William A. Burke
Gale and Jean Burkett
Estate of Harry Burkett III
Mr. Robert Burleson
Mr. George K. Burnett
Sue and Rusty Burnett

Ms. Veronica Burnett
Mr. and Mrs. James L. Burns
Mrs. Susan E. Burns
Mr. Thomas W. Burnside
Sarah Lu Burrowes
Mr. Gerald G. Burton
Mr. Charles Burton
Mr. Charles A. Burton
The Naomi Burton Charitable Remainder Trust
Mrs. Bille Burwick

The Honorable and Mrs. George H. W. Bush
Mr. and Mrs. William R. Bush
Mrs. Robert Bushman
Business Connections, Inc.
Mr. and Mrs. John B. Butler
Mr. and Mrs. Kevin O. Butler
Charles Butt
Mr. Herbert H. Butt
Mr. and Mrs. George T. Byers
Mr. and Mrs. Lloyd Peter Byler
Mr. Gerald R. Byrd
Mrs. Jamie Broach Byrd
Mr. and Mrs. Jason C. Byrd
Mr. James E. Byrns
Ms. Phyllis K. Bywaters

As of September 1, 2015
As of September 1, 2015

Endowed Chairs

PAUL AND MARY HAAS CHAIR IN GENETICS IN HONOR OF AMANDA MARIE WHITTLE
Michael Andreeff, M.D., Ph.D.

BEN F. LOVE CHAIR IN CANCER RESEARCH
Richard B. Behringer, Ph.D.

FRANK T. MCGRAW MEMORIAL CHAIR IN THE TREATMENT OF CANCER
Eduardo Bruera, M.D.

CHARLES B. BARKER CHAIR IN SURGERY
Charles E. Butler, M.D.

ROBERT C. HICKEY CHAIR IN CLINICAL CARE
Richard E. Champiun, M.D.

ANN RIFE COX CHAIR IN GYNECOLOGY
Robert L. Coleman, M.D.

MARY BETH PAWELEK CHAIR IN NEUROSURGERY IN HONOR OF DR. AND MRS. SAMUEL DICKENS BUGG AND MR. AND MRS. ALBERT F. PAWELEK
Franco DeMonte, M.D.

J. RALPH MEADOWS CHAIR IN CARCINOGENESIS RESEARCH AT SCIENCE PARK- RESEARCH DIVISION
Sharon Y. R. Dent, Ph.D.

WILLIAM C. LIEDTKE, JR. CHAIR IN CANCER RESEARCH
Lee M. Ellis, M.D.

REBECCA MEYER BROWN AND JOSEPH MELLINGER BROWN CHAIR IN BASIC SCIENCE RESEARCH
Varsha V. Gandhi, Ph.D.

DR. KENNETH B. MCCREDIE CHAIR IN CLINICAL LEUKEMIA RESEARCH
Guillermo Garcia-Manero, M.D.

CHARLES AND DANIEEN STIEFEL CHAIR IN CANCER RESEARCH IN HONOR OF MERRILL KIES, M.D., DAVID ROSENTHAL, M.D., AND RANDAL WEBER, M.D.
Ehab Y. Hanna, M.D.

BERNARD W. BIEDENHARN CHAIR IN CANCER RESEARCH
John D. Hazle, Ph.D.

DAVID BRUTON, JR. CHAIR
John V. Heymach, M.D., Ph.D.

DALLAS/FORT WORTH LIVING LEGEND CHAIR FOR CANCER RESEARCH
Geoffrey S. Ibbott, Ph.D.

DALLAS/FORT WORTH LIVING LEGEND CHAIR FOR CANCER RESEARCH II
V. Craig Jordan, Ph.D.

JOHN G. AND MARIE STELLA KENEDY MEMORIAL FOUNDATION CHAIR
J. Jack Lee, Ph.D.

IRVING AND NADINE MANSFIELD AND ROBERT DAVID LEVITT CANCER RESEARCH CHAIR
Jeffrey E. Lee, M.D.

MATTIE ALLEN FAIR RESEARCH CHAIR
Guillermina Lozano, Ph.D.

NELLIE B. CONNALLY CHAIR IN BREAST CANCER
Funda Meric-Bernstam, M.D.

FRANK T. MCGRAW MEMORIAL CHAIR IN THE STUDY OF CANCER
Bruce Minsky, M.D.

LARRY AND PAT McNEIL CHAIR IN RADIATION ONCOLOGY HONORING DR. JAMES D. COX
Radhe Mohan, Ph.D.

FERENC AND PHYLLIS GYORKEY CHAIR FOR RESEARCH AND EDUCATION IN PATHOLOGY
Victor G. Prieto, M.D., Ph.D.

HOWARD FOSTER SMITH AND LEE DENNIS SMITH CHAIR FOR CANCER RESEARCH IN THE FIELD OF HEMATOLOGY
Elizabeth J. Shpall, M.D.

SUE AND RADCLIFFE KILLIAM CHAIR
Louise C. Strong, M.D.

CHRISTOPHER AND SUSAN DAMICO CHAIR IN VIRAL ASSOCIATED MALIGNANCIES
Erich M. Sturgis, M.D.

MOSE TALPAZ ENDOWED CHAIR IN IMMUNOLOGY
Shao-Cong Sun, Ph.D.

DALLAS/FORT WORTH LIVING LEGEND CHAIR FOR CANCER RESEARCH III
David Tweekard, M.D.

M. G. AND LILLIE A. JOHNSON CHAIR FOR CANCER TREATMENT AND RESEARCH
Ara A. Vaportizian, M.D.

JOSE M. TRUJILLO CHAIR IN LABORATORY MEDICINE
Elizabeth A. Wagar, M.D.

HUBERT L. STRINGER CHAIR IN CANCER RESEARCH
John N. Weinstein, M.D., Ph.D.

ANDERSON CLINICAL FACULTY CHAIR FOR CANCER TREATMENT AND RESEARCH
Ignacio Wistuba, M.D.

BETTY B. MARCUS CHAIR IN CANCER PREVENTION
Xifeng Wu, M.D., Ph.D.

MARGARET AND BEN LOVE CHAIR IN CLINICAL CANCER CARE IN HONOR OF DR. CHARLES A. LEMAISTRE
W. K. Alfred Yung, M.D.

As of September 1, 2015
Texas 4000 riders made a stop at MD Anderson Children's Cancer Hospital on their 70-day, more than 4000-mile bike ride from Austin, Texas, to Anchorage, Alaska. The group of students from The University of Texas at Austin played games, created pottery and made art with patients and their siblings. Since 2007, Texas 4000 has contributed $1.52 million to MD Anderson's research and patient care programs. This June, the group presented MD Anderson with $130,000 and Houston mayor Annise Parker declared June 3, 2015, to be "Texas 4000 Day."

Cure Fur Cancer
Curefest, Inc.
CureSearch for Children's Cancer
Mr. Robert A. Curley, Jr.
Mr. Jack T. Curve
The Curve Fund
Jim and Marion Currow
Joan and Keys Curry Foundation
Ms. Dennis P. Curtin
Mrs. Carolyn Ruth Curtis
Mr. and Mrs. Robert C. Curtis
Christy and Lou Cushman
CustomMilk LLC
Ms. Teresa Cvitanovich
CWS Apartment Homes, LLC
Cypress Bayou Casino & Hotel
Cypress Planning & Development LLC
Cypress-Fairbanks ISD
Mr. and Mrs. James S. Cyrus

D

D.E. Harvey Builders, Inc.
Mr. Richard M. Dadeks
Dadeks Machine Works Corp.
Mr. Raymond Dahman
Mr. and Mrs. William P. Dahquist
Mr. Michael W. Dale
Mr. and Mrs. Carl L. Dalio III
An Anonymous Fund of The Dallas Foundation
Dallas Jewish Community Foundation
Mr. and Mrs. Carol L. Dalton
Mr. and Mrs. Daniel W. Daly III
Susan and Christopher Darnico
Mrs. Shilpa C. Damle-Mogri
Susan and Christopher Damico
Mr. and Mrs. Mark A. Delaney
Dr. Nancy J. Delboy
Mr. Michael L. Delcambre
Del Management Inc.
Mr. William B. Beline
Mr. and Mrs. Michael S. Dell
Michael & Susan Dell Foundation
Dell Inc.
Employees of DeLottle & Touche
Deloitte Services, LP
Mr. Benno J. Deltz
Mr. and Mrs. Willie G. Dement
Mr. and Mrs. Seth A. Denbow
Mr. Jason Alexander Dentby
Mr. Theodore J. Dengier
Mr. and Mrs. Lawrence DeNino
Mr. William C. Denker
Denman/Newman Foundation
Ms. Margret Dennett
Mr. and Mrs. Benjamin L. Denny
Hayden and Sandy Dent
Mr. Leet E. Denton
Ms. Gabrielle I. Dentraygues
The Denver Foundation
Mrs. Charlotte J. Der Garry
Desroches Partners LLP
Estate of Mrs. George S. Deutsch
Mr. and Mrs. David DeVido
DEW Foundation
Mr. and Mrs. Robert L. Dewar
The Honorable and Mrs. David H. Dewhurst III
Devitt and Associates LLC
DialAmerica, Inc.
Chris P. Dialynas Family Foundation
Mr. and Mrs. George Diamantis
Diamond Doctor
Ms. Alyson Dias
Allyson K. Dias Foundation
Dr. and Mrs. Eduardo M. Diaz, Jr.
Mr. and Mrs. Christopher Dickens
Mr. Ronald J. Dickens
Mr. and Mrs. Peter H. Dickerson
Mr. Ernest J. Dickinson
Mr. and Mrs. Chester E. Dickson
Mr. and Mrs. Peter U. Diebold
Ms. Elizabeth Diehl
Martin W. Dies III
Mr. and Mrs. Timothy W. Dietrich
Mr. and Mrs. Alfred G. Diggles
Digitec Office Solutions
Mr. and Mrs. Scott A. Dillard
Dr. Nancy Hiatt Dilley and Dr. Jim Dilley
Mr. Robert P. Dillingham
Mr. Perry A. Dillon, Jr.
Mr. and Mrs. Nicholas DiMeglio
Ronnie James Dio
Discovery Toys
Ms. Donna De La Paz
The de Moya Group
Dena Family Foundation
Mr. and Mrs. John A. Deakins
Deal Sikes & Associates
Dr. James R. Dear
The DeBerry Group
DeCesare/Prout Cancer Foundation
Mrs. Elizabeth A. Decker
Myna and Ray Deckert
Mr. and Mrs. Michael W. Deeds
Deerfield Episcopal Retirement Community, Inc.
Mr. Brad G. Deffenbaugh
Mr. Bill Deffebach
Mr. Anthony J. DeFrancesco III
Mrs. Linnet F. Deily
Rafael del Barro
Del Sol Food Co., Inc./Brianas
Mr. and Mrs. Mark A. Delaney
Dr. Nancy J. Delboy
Mr. Michael L. Delcambre
Dei Management Inc.
Mr. William B. Beline
Mr. and Mrs. Michael S. Dell
Michael & Susan Dell Foundation
Dell Inc.
Employees of DeLottle & Touche
Deloitte Services, LP
Mr. Benno J. Deltz
Mr. and Mrs. Willie G. Dement
Mr. and Mrs. Seth A. Denbow
Mr. Jason Alexander Dentby
Mr. Theodore J. Dengier
Mr. and Mrs. Lawrence DeNino
Mr. William C. Denker
Denman/Newman Foundation
Ms. Margret Dennett
Mr. and Mrs. Benjamin L. Denny
Hayden and Sandy Dent
Mr. Leet E. Denton
Ms. Gabrielle I. Dentraygues
The Denver Foundation
Mrs. Charlotte J. Der Garry
Desroches Partners LLP
Estate of Mrs. George S. Deutsch
Mr. and Mrs. David DeVido
DEW Foundation
Mr. and Mrs. Robert L. Dewar
The Honorable and Mrs. David H. Dewhurst III
Devitt and Associates LLC
DialAmerica, Inc.
Chris P. Dialynas Family Foundation
Mr. and Mrs. George Diamantis
Diamond Doctor
Ms. Alyson Dias
Allyson K. Dias Foundation
Dr. and Mrs. Eduardo M. Diaz, Jr.
Mr. and Mrs. Christopher Dickens
Mr. Ronald J. Dickens
Mr. and Mrs. Peter H. Dickerson
Mr. Ernest J. Dickinson
Mr. and Mrs. Chester E. Dickson
Mr. and Mrs. Peter U. Diebold
Ms. Elizabeth Diehl
Martin W. Dies III
Mr. and Mrs. Timothy W. Dietrich
Mr. and Mrs. Alfred G. Diggles
Digitec Office Solutions
Mr. and Mrs. Scott A. Dillard
Dr. Nancy Hiatt Dilley and Dr. Jim Dilley
Mr. Robert P. Dillingham
Mr. Perry A. Dillon, Jr.
Mr. and Mrs. Nicholas DiMeglio
Ronnie James Dio
Discovery Toys
Shanon and Lori DiSorbo
Di-Trol Systems, Inc.
DKG Foundation
DNAtrix, Inc.
Mr. and Mrs. Robert J. Doan
Mr. and Mrs. Porter Dobkins
Mr. Randall W. Dobbs
Dobbs Consulting
Mr. and Mrs. Scott Dodds
Dodge Stores
Mrs. Judy Dodson
Mr. and Mrs. Samuel R. Dobson III
Dawn and Phil Doganes
Mr. and Mrs. Edward D. Doherty II
Ed and Susan Doherty Advised Fund
Mrs. Beverly Dolsky
Rickey and Ed Dominguez
Don McGill Toyota
Don McGill Toyota of Katy
Mr. David M. Donald
Eva and Tom Donalson
Donastic
Ms. Corean Donegan
Mr. James R. Donnelly and Mrs. Nina H. Donnelly
Nina H. Donnelly
Ms. Ellen Donnelly
Mr. and Mrs. Michael S. Donoho
Ms. Mary E. Donohue
Mr. and Mrs. Thomas J. Donohue
Mr. William P. Donohue
Don’s Specialty Meats II, Inc.
Mr. and Mrs. Jeffery D. Dooley
Sally and Rhee Dooley
Ms. Maddie Doran
Mr. and Mrs. Eddie E. Dore
Mr. and Mrs. William J. Dore, Sr.
The Dore Family Foundation
Mr. Brad Dorsey
Mr. and Mrs. Richard Parr Doss, Jr.
Mr. Joe A. Dotterweich
Mr. and Mrs. Patrick Doucette
Mr. and Mrs. Vince Doucette
The Dow Chemical Company Foundation
Mrs. Bobby (Sue) Dowd
Mr. and Mrs. Dan M. Dowdley
Mr. and Mrs. Greg Dowell
Mrs. Linda Downey
Downman Family Foundation
Mr. and Mrs. Jimmy Doyle
Mr. and Mrs. Robert J. Doyle
Jeff and Ann Drabing
Estate of Margaret L. Draper
Mr. and Mrs. William H. Draper III
Mr. and Mrs. Harold M. Draughon
Mr. and Mrs. Alan W. Dreeben
Ms. Trudy M. Dreier
The Richard H. Driehaus Charitable Lead Trust
The Driehaus Trust Company, LLC
Mr. and Mrs. Walter W. Driver, Jr.
Dr. and Mrs. Richard J. Drozd
DuaneBerg Central School
Alfonso and Mary Young Duarte
Mr. Melvin Dube
Oscar and Loretta Dube
The Honorable and Mrs. Kenneth M. Duberstein
Ms. Mary Dubitzky
Mr. Jack M. Dubose
Dubose Family Foundation
Mr. and Mrs. Craig J. Duchossois
Mr. Richard L. Duchossois
The Duchossois Family Foundation
Ducket, Bouligy and Collins, L.L.P.
Mr. and Mrs. Fritz L. Duda

60
Endowed Distinguished Professorships

BIRDIE J. AND LYDIA J. RESOFT DISTINGUISHED PROFESSORSHIP IN GASTROINTESTINAL ONCOLOGY

Robert Bresalier, M.D.

ANNIE LAURIE HOWARD RESEARCH DISTINGUISHED PROFESSORSHIP

Paul M. Cinquepini, Ph.D.

RICHARD E. HAYNES DISTINGUISHED PROFESSORSHIP FOR CLINICAL CANCER PREVENTION

Lorenzo Cohen, Ph.D.

CLIFTON D. HOWE DISTINGUISHED PROFESSORSHIP IN PULMONARY MEDICINE

Burton F. Dickey, M.D.

TEXAS 4000 DISTINGUISHED PROFESSORSHIP

Kerr-Anh Do, Ph.D.

HELEN SHAFER FLY DISTINGUISHED PROFESSORSHIP OF ANAesthesiology, IN HONOR OF BERTHA DAvis-CLARK, M.D.

Thomas W. Feeley, M.D.

ABELL-HANGER FOUNDATION DISTINGUISHED PROFESSORSHIP

Bonnie S. Glisson, M.D.

THE HAMILL FOUNDATION DISTINGUISHED PROFESSORSHIP IN HONOR OF DR. RICHARD G. MARTIN, SR.

Kelly K. Hunt, M.D.

GLORIA LUFTON TENNISON DISTINGUISHED PROFESSORSHIP IN LUNG CANCER RESEARCH

Ritsuko Komaki Cox, M.D.

RUBY E. RUTHERFORD DISTINGUISHED PROFESSORSHIP

Zhimin Lu, M.D., Ph.D.

JAMES E. ANDERSON DISTINGUISHED PROFESSORSHIP IN NUCLEAR MEDICINE

Hornor A. Macapinlac, M.D.

MONTELEONE FAMILY FOUNDATION DISTINGUISHED PROFESSORSHIP FOR RESEARCH OF BLADDER AND KIDNEY CANCERS

Surena Matin, M.D.

VIRGINIA H. COCKRELL DISTINGUISHED PROFESSORSHIP IN IMMUNOLOGY

Jeffrey Molldrem, M.D.

HUBERT L. AND OLIVE STRINGER DISTINGUISHED PROFESSORSHIP IN CANCER RESEARCH

Jeffrey N. Myers, M.D., Ph.D.

N. G. AND HELEN T. HAWKINS DISTINGUISHED PROFESSORSHIP FOR CANCER RESEARCH

Hui-Lin Pan, M.D., Ph.D.

ROBERT R. HERRING DISTINGUISHED PROFESSORSHIP IN CLINICAL RESEARCH

Shrayaskumar R. Patel, M.D.

KATHERINE RUSSELL DIXIE DISTINGUISHED PROFESSORSHIP IN PEDIATRICS

Alexander V. Prokhorov, M.D., Ph.D.

GERALD P. BODEY, SR. DISTINGUISHED PROFESSORSHIP IN INFECTIOUS DISEASE

Issam Raad, M.D.

DR. JOHN R. STROEHLING DISTINGUISHED PROFESSORSHIP IN GASTEROENTEROLOGY

G. S. Raju, M.D.

CHARLES M. MCBRIDE DISTINGUISHED PROFESSORSHIP IN SURGICAL ONCOLOGY

Merrick I. Ross, M.D.

EDGAR LEWIS CURTIS, SAVILLA ELIZABETH CURTIS AND ELEANOR LEWIS CURTIS DISTINGUISHED PROFESSORSHIP IN PEDIATRIC CANCER RESEARCH

Cindy L. Schwartz, M.D.

NAGUIB A. SAMAAN DISTINGUISHED PROFESSORSHIP IN ENDOCRINOLOGY

Steven I. Sherman, M.D.

BARNHART FAMILY DISTINGUISHED PROFESSORSHIP IN TARGETED THERAPIES

Sanjay S. Shete, Ph.D.

BETTYANN ASCHE MURRAY DISTINGUISHED PROFESSORSHIP IN OVARIAN CANCER RESEARCH

Anil K. Sood, M.D.

BARNTS FAMILY DISTINGUISHED PROFESSORSHIP IN CANCER RESEARCH

Maria E. Suarez-Almazor, M.D., Ph.D.

EDWARD ROTAN DISTINGUISHED PROFESSORSHIP IN CANCER RESEARCH

Jessica Tyler, Ph.D.

NYLENE ECKLES DISTINGUISHED PROFESSORSHIP IN BREAST CANCER RESEARCH

Naoto T. Ueno, M.D., Ph.D.

GRADY E. SAUNDERS, PH.D. DISTINGUISHED PROFESSORSHIP FOR MOLECULAR BIOLOGY

Richard D. Wood, Ph.D.

As of September 1, 2015
Endowed Professorships

**DOCTOR R. LEE CLARK PROFESSORSHIP**
Christian R. Abeel, D.V.M.

**HELEN BUCHANAN AND STANLEY JOSEPH SEEGER RESEARCH PROFESSORSHIP**
Salahadin Abdi, M.D., Ph.D.

**RANSOM HORE, JR. PROFESSORSHIP FOR CANCER RESEARCH**
Bharat B. Aggarwal, Ph.D.

**ASHBEL SMITH PROFESSORSHIP**
Michele Barton, Ph.D.

**THE KENNETH D. MULLER PROFESSORSHIP IN TUMOR GENETICS**
Mark Bedford, Ph.D.

**ASHBEL SMITH PROFESSORSHIP**
Diane Bodurka, M.D.

**ASHBEL SMITH PROFESSORSHIP**
Paul J. Chiao, Ph.D.

**MCCULLOUGH PROFESSORSHIP FOR CANCER RESEARCH**
Charles S. Cleeland, Ph.D.

**H-E-B PROFESSORSHIP IN CANCER RESEARCH**
Patrick M. Dougherty, Ph.D.

**BLANCHE BENDER PROFESSORSHIP IN CANCER RESEARCH**
Madeleine Ducic, M.D.

**KENNETH D. MULLER PROFESSORSHIP IN MELANOMA RESEARCH**
Adel K. El-Naggar, M.D., Ph.D.

**KATHRIN O’CONNOR RESEARCH PROFESSORSHIP**
Ziding Feng, Ph.D.

**DR. JOHN M. SKIBBER PROFESSORSHIP FOR SURGICAL ONCOLOGY**
Jeffrey Gershwenwald, M.D.

**ASHBEL SMITH PROFESSORSHIP**
Peng Huang, M.D., Ph.D.

**HUBERT L. AND OLIVE STRINGER PROFESSORSHIP IN MEDICAL ONCOLOGY**
Khandan Keyomarsi, Ph.D.

**FRANCES KING BLACK MEMORIAL PROFESSORSHIP FOR CANCER RESEARCH**
Dimitrios P. Kontoyiannis, M.D.

**JOHN E. AND DOROTHY J. HARRIS PROFESSORSHIP IN GASTROINTESTINAL CANCER RESEARCH**
Sunil Krishnan, M.D.

**FELIX L. HAAS PROFESSORSHIP IN BASIC SCIENCE**
Macus Tien Kuo, Ph.D.

**ELZA A. AND INA S. FREEMAN ENDOWED PROFESSORSHIP IN LUNG CANCER**
Jonathan M. Kurie, M.D.

**DR. JOHN MURRAY PROFESSORSHIP IN ORTHOPEDIC ONCOLOGY**
Valeria O. Lewis, M.D.

**HUBERT L. AND OLIVE STRINGER PROFESSORSHIP FOR CANCER TREATMENT AND RESEARCH**
Lei Li, Ph.D.

**UNITED ENERGY RESOURCES, INC. PROFESSORSHIP**
Xin Lin, Ph.D.

**JOHN O. GAINES FOUNDATION PROFESSORSHIP FOR CANCER RESEARCH**
Gabriel Lopez-Berestein, M.D.

**ROBERT F. FLY PROFESSORSHIP OF SURGICAL ONCOLOGY, IN HONOR OF R. LEE CLARK, M.D.**
David McConkey, Ph.D.

**FLORENCE MAUDE THOMAS CANCER RESEARCH PROFESSORSHIP**
Robert Z. Orlowski, M.D., Ph.D.

**JAY AND LORI EISENBERG ENDOWED PROFESSORSHIP**
Vali Papadimitrakopoulou, M.D.

**RUTH AND WALTER STERLING PROFESSORSHIP**
Nancy D. Perrier, M.D.

**A CONVERSATION WITH A LIVING LEGEND PROFESSORSHIP**
Yu Shen, Ph.D.

**ANISE J. SORRELL PROFESSORSHIP**
Peter F. Thall, Ph.D.

**MATTIE ALLEN FAIR PROFESSORSHIP IN CANCER RESEARCH**
Elizabeth L. Travis, Ph.D.

**DALLAS/FORT WORTH LIVING LEGEND PROFESSORSHIP**
Stephen E. Ulrich, Ph.D.

**BESSIE MCGOLDRICK PROFESSORSHIP IN CLINICAL CANCER RESEARCH**
Jean-Nicholas Vauther, M.D.

**DOUGLAS E. JOHNSON, M.D. PROFESSORSHIP**
Christopher G. Wood, M.D.

As of September 1, 2015
Ms. Phyllis S. Hoel and Mr. John Mascotte
Mr. and Mrs. Christopher T. Hoke
Maralessa and Alfie Holand
Mrs. Arlene M. Holden
Don L. and Julie Holden Foundation
Mr. and Mrs. John B. Holdsworth
Mr. and Mrs. Glen Z. Holender
Holiday Island Chamber of Commerce
Mr. and Mrs. Steve L. Holfield, Jr.
Mr. and Mrs. Britton Holland
Mr. and Mrs. John A. Holland
Dr. and Mrs. Warren Lee Holleman
Mr. and Mrs. Charles E. Holler
Mr. Stephen P. Holler
Mr. Steve Hollier
Mr. John C. Holloway
Ms. Patti Jones Holloway
Ms. Ellen L. Holman
Mr. and Mrs. Kenneth E. Holmes
Mr. and Mrs. Thomas J. Holmes, Jr.
Mr. and Mrs. Peter M. Holt
Holt Cat
Mr. and Mrs. Jason B. Holton
Holy Trinity Catholic Church
Mr. and Mrs. Joe Holyfield
Dr. and Mrs. Kenneth L. Homann
Ms. Michelle Honea
William E. and Audrine Honey Foundation, Inc.
Honeywell International
Dr. and Mrs. Waun Ki Hong
Ms. Winne P. Hood
Mr. and Mrs. Milton L. Hooper, Jr.
Mr. Carl H. Hoover
The Hope Foundation
Mr. Bob C. Hopkins
Mr. and Mrs. David L. Hopkins
Mr. Robert Horner
Horowitz Management, Inc.
Mr. and Mrs. Merritt Horrell, Jr.
Mrs. Dorothy Knox Houghton
Houseman-Wilkins Ophthalmological Foundation
Mr. Adam Houston
Mr. James R. Houston
Houston Endowment Inc.
Houston Jewish Community Foundation
Houston Jewish Healthcare Foundation
Houston Methodist Hospital
Houston Methodist Research Institute
Houstonia Foundation
Houston Endowment Inc.
Houston Health Park
Houstonian Hotel, Club & Spa
Mr. and Mrs. Bill J. Howard
Mr. and Mrs. Philip R. Howard
Mr. Will Howard
Howard Hughes Medical Institute
Dr. and Mrs. Richard J. Howe
Mr. and Mrs. Hiltunen, Jr.
Mr. and Mrs. Peter Paul Howell
Robert and Catherine Howell
Tom Howell
Mr. John K. Howery
Andrew and Ingrid Hoyt
Dr. and Mrs. Gaylord M. Hoyt
The HPIC and Anal Cancer Foundation
Mr. Peter Hsieh
Mr. Donald G. Hubbard
Mr. Edwin W. Hubbard
Mr. John Hubbard
Cheri Huber and Friends
Mr. and Mrs. Kirk J. Huber
Mr. and Mrs. Gerald S. Huchital
Mr. Donald Hudler
Mrs. Letha K. Hudson
Mr. and Mrs. Warren J. Hudson
Mr. and Mrs. Bert L. Huebner
Mr. and Mrs. Ronald E. Huebsch
Mrs. Sydney Huffman
Ms. Terry Huffman and Dr. Ralph Dittrman
Huffington Foundation
Ms. Catherine E. Huffman
Mr. and Mrs. Gary R. Huffman
Mr. and Mrs. Bodin A. Hugger, Sr.
Mr. Gerald E. Huggs
Mr. and Mrs. Dan Allen Hughes, Jr.
Mr. and Mrs. Kevin E. Hughes
Mrs. Paula Hughes
Mr. Timothy D. Hughes
Mr. and Mrs. James R. Hull
Mr. and Mrs. Jeffrey O. Hull
Mr. and Mrs. Walter J. Humann
Mr. and Mrs. Steve Humphrey
Mr. and Mrs. Richard F. Humphreys
Steve and Stephanie Humphreys
Dr. and Mrs. Leroy J. Humphries
Mrs. Carolyn Hunt
Mr. and Mrs. Hunter Hunt
Mr. and Mrs. T. Elwood Hunt
The Men and Women of Hunt Consolidated, Inc.
The Woody and Gayle Hunt Family Foundation
Mr. Garrett Hunter
Mr. and Mrs. Gerhart E. Hunter
Mr. and Mrs. James B. Hunter
Mr. and Mrs. Jasper E. Hunter
Mr. and Mrs. Ken Hunter
Mr. and Mrs. Robert C. Hunter
Mr. and Mrs. Richard O. Hunton Sr. (Hunton Group)
Susan and Martin Hurwitz
Mr. and Mrs. Syed S. Hussaini
Dr. Christopher W. Huston
Mr. and Mrs. Oliver C. Hutchaf
Mr. and Mrs. William L. Hutchison
Mr. and Mrs. Jason Hutt
Ms. Nina C. Hutton
William L. Hyde, Jr. and Claire C. Hyde
Dr. and Mrs. Geoffrey S. Ibbott
IIBC Bank
The IBC Network Foundation
IBE Trade Corp.
IBM Employee Services Center
IBM International Foundation
Mr. Robert Ideus
IHPBA Kenneth Warren Foundation Inc.
Barbara F. Imrrooth, Ph.D.
Impact Fulfillment Service, Inc.
Incoyte Corporation
Industrial Supply Rental
The Inflammatory Breast Cancer Advocacy and Research Foundation
Estate of Deanna B. Ingram
Mr. and Mrs. James A. Ingram
Ingram Park Auto Center
Mr. and Mrs. Mike Insellman
Insulation Products Corporation
InterActiveHealthCare, Inc.
International Myeloma Foundation
Intruder Alert Systems, Inc.
Invesco Cares
Dr. Katie D. Irani
Mr. Barry C. Irvine
Mr. Dale G. Isaac
Mr. Jerry Isackson
The Lawrence Israel Family Foundation
Sandy and Charles Israel, Aspen, Colorado
Mr. and Mrs. Verne G. Istock
Mr. and Mrs. Henry A. Itleson
Mr. and Mrs. Jose Ivo
The Ivy Foundation
Dr. Femi David Iwaloye

Patrick Zweidler-McKay, M.D., Ph.D., and graduate research assistant Marisa Hornbaker participated in a handprint ceremony to celebrate Childhood Cancer Awareness month in September. Zweidler-McKay, who is section chief of Pediatric Leukemia and Lymphoma, received a $250,000 research grant from Hyundai Hope on Wheels, a nonprofit that raises awareness of childhood cancer and donates funds to support research.

J.N. Bartfield Art Galleries, Inc.
Jack’s Ride
The Honorable and Mrs. Alphonso Jackson
Barbara Usian Jackson
Mr. and Mrs. Carl R. Jackson
Mr. and Mrs. James M. Jackson
Mr. and Mrs. John C. Jackson II
Mr. and Mrs. John P. Jackson
Mr. Rafe K. Jackson
Mr. Thomas I. Jackson
Jackson Spierg McCarthy & Townsend, LLP
Jackson Walker, L.L.P.
Jackson-Merkey Contractors, Inc.
Mr. Max W. Jacobs
Emma Jacobs Breast Cancer Foundation
Mr. and Mrs. Donald Jacobson
Mr. and Mrs. Norman K. Jacobson

Mr. Fred Herbert
Mr. Jeff Herbert
The Ira C. Herbert Family Foundation
Bob L. Herd Foundation
Dr. Carolyn Hernandez
Mr. and Mrs. Hector M. Hernandez
Mrs. Linda P. Hernandez
Mr. and Mrs. H. David Herndon
Mr. and Mrs. David T. Herr
The Herrera Law Firm
Mr. and Mrs. Donald A. Herron
Mr. R. Michael Hesketh-Prichard
Mr. and Mrs. Earl J. Hesterberg
Mr. and Mrs. Howard H. Hewitt
Hewlett-Packard Company Foundation
Estate of Robert Heyman
Ms. Jacquelyn Hibbler
Mrs. Kimberly B. Hbihler
Mr. and Mrs. Edward L. Hick, Jr.
Mr. Ivan N. Hidac
Mr. and Mrs. Alan Hicks
Gloria and Ed Hicks
Ms. Deborah J. Higbee
Mr. and Mrs. Shayne Higdon
Mr. Earl Higgins
Estate of Kathleen B. Higgins
Mr. and Mrs. Normann A. Higgins
Mr. Raymond A. Higgins
Mr. and Mrs. William G. Higgs
The Higgs Foundation
Highmount Capital
The Hildebrand Foundation
The Hildebrand Fund
Ms. Mary K. Hildebrandt
John P. and Mildred O. Hildebrandt Foundation
Mr. and Mrs. Randy Hiley
Al G. Hill, Jr.
Anne and Yenger Hill, III
Ms. Betty J. Hill
Mr. Bruce H. C. Hill
Mr. and Mrs. Gerald S. Hill
Lydia Hill
Margaret and Thad Hill
Ms. Susan Hill
Mr. and Mrs. David M. Hillberry
The Hillcrest Foundation
Ms. Cora L. Hilliard
Mr. and Mrs. Gerald Hillier
Mr. Steve Hillmer
Hills Prairie Livestock Auction Co.
Mr. and Mrs. Andrew S. Himoff
Mr. and Mrs. James S. Himoff
The Hindu Family
Mr. Gilbert C. Hine
Hines
Wendy and Jeff Hines
Dr. and Mrs. Randall D. Hinton
Mr. and Mrs. Robert O. Hirschi
Mrs. Frances Hitchcock
Ms. Paula C. Hix
Mr. and Mrs. Timo Hixon
Mr. and Mrs. John R. Hoag
Nancy and Jim Hoak
Roy Hobbs Foundation
Mr. and Mrs. Paul W. Hobby
Hobby Family Foundation
Mr. and Mrs. Laurence L. Hook
Margaret and Jerry Hodge
Mr. and Mrs. Mark C. Hodges
Mr. Zachary Gordon Hoffer
Mr. and Mrs. Evin Hofferek
Mr. Robert B. Hoffman
The Hoffman Foundation
Mr. and Mrs. Dan Hogan III
Mr. Ray P. Hogan
Mike Hogg Fund

J
Advance Team

The following people comprise a volunteer leadership board focused on advancing MD Anderson’s mission to eliminate cancer through community-based initiatives centered on basic science research, education and cancer prevention.

Mrs. Kasey Asarch
Mrs. Ashli R. Blurnenfeld
Mrs. Jenee J. Bobbora
Mrs. Amanda L. Bush
Ms. Caroline C. Cage
Mr. Brian Carney
Mr. John B. Connally IV
Ms. Nell F. Connally
Mrs. Andrea Crawmer
Mrs. Rachel Cruz-Auwarter*
Mrs. Jennifer Womble Daniels
Mr. Daniel T. Dudley
Mrs. Holly B. Deshields
Ms. Jennifer Womble Daniels
Mrs. Claire C. Thielke
Mr. J. C. Pace III
Ms. Kathryn Johnson
Mr. and Mrs. Paul H. Johnson
Mr. and Mrs. W. Barry Kahn
Ms. Susan Oliver Heard*
Mr. Bradford W. Heiser*
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Stanley M. Johnson
Ms. Dorothy S. Paterson
Mrs. Mary Kay Jane Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mrs. Mary Kay Jane Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones
Mr. and Mrs. Jeffrey A. Jones
Mr. and Mrs. Jon Rex Jones

*New member
The Sally M. Kingsbury Sarcoma Research

Mr. William S. (Bill) Kingsbury

Mr. Thomas M. King, Jr.

Estate of Sheppard W. King IV

Ms. Sheeran H. King

Mr. and Mrs. Luther King

Mr. and Mrs. Gregory C. King

Mr. and Mrs. Robert A. Kimmel

Kimberly-Clark Corporation

Mr. and Mrs. J. Reese Killion

Mr. Gary Komeran

Mr. and Mrs. Todd E. Lachermyer

Ms. Christine E. Lade

Mr. and Mrs. Bobby L. Lackey

Lackey Trucking, LLC

Ms. Cheryl LaCoss

Mr. and Mrs. Todd E. Lachenmyer

Mr. and Mrs. Robert A. Lacey

Ms. Pamela A. Lathem

Mr. Chester Latham

Ms. Pamela A. Latheh

Ms. Margaret A. Latimer

Mr. Trent T. Latshaw

Estate of Frederic G. Lauder

Mr. Ryan Laundermill

Mrs. Helen H. Laughery

Ms. Erica Laughlin

Mary Kay and Forrest Lauffer

Mr. and Mrs. John F. Lauffer

Ms. Yolanda M. Laurel and Dr. Richard D. Swogger

Mr. and Mrs. Ralph Lauren

The Ralph & Ricky Lauren Family Foundation, Inc.

Mr. Jeff Lautt

Mr. and Mrs. Kase L. Lawal

Mr. and Mrs. Bill L. Lawler

Ms. Melinda Lawrence

Mr. Steven Lawrence

The William Lawrence and Blanche Hughes Children’s Foundation

The Lawrence Foundation

Ms. Gale Lazarus

J. M. Lazarus Foundation

Lazy Two Cattle Company

The Honorable and Mrs. Howard H. Leach

Mr. and Mrs. Leon J. Leach

Mr. and Mrs. Timothy A. Leach

Mr. and Mrs. Ralph Leatherman

Mr. and Mrs. C. Leben

Mr. and Mrs. Marc LeBlanc

Mr. and Mrs. Roger S. LeBlanc

Mr. and Mrs. Joe Leblow

Mr. and Mrs. Lewis B. Leblow

Mr. Dwight J. Ledoux

Army and Gentry Lee

Mr. Chul-Jae Lee

Mr. Do Lee

Mr. and Mrs. Douglas Alan Lee

Mr. and Mrs. Eddie L. Lee

Mr. and Mrs. Edward T. Lee

Mr. and Mrs. James H. Lee

Dr. and Mrs. Jeffrey E. Lee

Mr. Robert Lee, Jr.

Dr. Norman E. Leeds in Honor of Ms. Bette G. Leedis

Dr. Peter J. Leeson

Liz and Eric Leffkosky

Dr. Randy J. Legeraki

Mr. and Mrs. David H. Lehman

Dr. Jeffrey Lehr

Mr. and Mrs. Jay S. Leibor

Mr. Jay LeJeune

Mr. Henry F. LeMeaux

Mr. Kenneth W. Lemons

Mr. and Mrs. Craig R. Lentzsch

Mr. Richard Lenzer

Ms. Marty L. Leonard

Ms. Marilyn L. Lerman

Ms. Mary L. Leszek

Mr. and Mrs. Richard L. Leszek

Mr. and Mrs. Gary T. Leszek

Mr. and Mrs. Walter T. Leszek

Mr. and Mrs. Rob Leslie

Mr. and Mrs. Ron Lesseraux

Mr. Earl L. Lester, Jr.

Ms. Mary Virginia Lester

The Lester Family Foundation

Mr. and Mrs. Robert Leutz

Leukemia & Lymphoma Society

Leukemia Research Foundation

Mrs. Wendy Leung

Mr. and Mrs. J. Waymon Leveil

Mr. and Mrs. Greg W. Levenson

Mr. Daniel Leventhal

Charles and Margaret Levin Family Foundation

Mrs. Lee Levit
Monroe Dunaway Anderson Society


Established in 1995, the Monroe Dunaway Anderson Society recognizes individuals and families who have selected the programs at MD Anderson to benefit from a planned gift such as a bequest, life insurance policy or other similar vehicle. Listed here are new members of the society who recently named the institution in their estate plans.

Dr. Madeleine Alcover
Mrs. Renza Moscatelli Baker
Dr. James R. Ballinger
Mr. Darrell W. Barrett
Mr. Hugh C. Berry, Jr.
Mrs. Raymona B. Bomar
Mr. John Brandt
Mr. and Mrs. Joel Brochstein
Ms. Roberta Bunch
Mr. Jerry J. Burgdorfer, Jr.
Ms. Hutis O. Carlson
Mr. John B. Crangle
Mr. Hall J Debusk
Mr. Jeff Drabing
Mr. Jon A. Ferris
Ms. Karen L. Getty
Mrs. Susan Hill
Ms. Nora Linares-Moeller and Mr. Mike Moeller
Mr. and Mrs. Dennis F. Loner
Mr. and Mrs. Stacy D. Long
Mr. and Mrs. Henry Longcrier
Longhorn, Inc.
Ms. Eva J. Longoria
Mr. and Mrs. Harry J. Longwell/Longwell Family Foundation
Mr. and Mrs. Cecil J. Looke
Dr. Frank W. Lopez
Lord and Taylor
Mr. Richard E. Lore, Sr.
Mr. and Mrs. Francisco A. Lorenzo
Mrs. Sara P. Loshak
Mr. and Mrs. Mitchell T. Lou
Mrs. Patricia M. Loucks
Loucks Family Foundation
Mr. Robert D. Loughney
Louisiana Machinery Co.
Mr. and Mrs. Jeff B. Love
The Jeff B. and Katherine B. Love Foundation
Mr. and Mrs. William T. Lovelady
Mrs. Alice B. Loveless
Ms. Jane Maury Lovitt
The Lowe Foundation
Mr. Guarini Lu
Mr. and Mrs. Sheldon Lubar
The Sheldon & Marianne Lubar Charitable Fund
The Lubrizol Foundation
Lushinger Family Foundation
Mrs. Seymour Luckoff
Ms. Janet M. Luz
Lumina Foundation
The Luminiscence Foundation, Inc.
Lund Money Inc.
Mr. Wallace L. Lundgren, Sr.
Lung Cancer Research Foundation
LUNGevity Foundation
Estate of Lois F. Lurin
Mrs. Betty Lunsford

Mrs. Laura McNemar
Ms. Sandra Mobly
Mrs. Page Davis Parker
Mr. Steve G. Rapfogel
Mrs. Beverly B. Rodriguez
Mr. John Rodriguez
Ms. Dianna Archer Semon
Mrs. Rose A. Sinkin
Mrs. Jessamine Slataper
Dr. Margaret P. Sullivan
Mr. and Mrs. Kenneth J. Valach
Ms. Jarnie L. Villegas
Mr. Winfred D. Weldon
Ms. Joan S. Werner
Mrs. Bette C. Whittow
Mr. and Mrs. Jack Zbar

Ms. Jean R. Lunt
Mr. Robert A. Lure
Connie and Bob Lure Foundation
Mr. and Mrs. Eric Luse
Mr. and Mrs. Ted W. Lusher
Lustgarten Foundation
Mr. and Mrs. Homer L. Luther, Jr.
Luther King Capital Management
Mr. Bill Lyttes
LVM Holdings LP
Mr. and Mrs. Khaish K. Ly
Mrs. Rosemary K. Lykos
Ms. Patricia S. Lyle
Mr. and Mrs. Jeffrey L. Lyman
Estate of Rachel Lyman
Lymphoma Research Foundation
LyondellBasell Industries
Mr. Allan R. Lyons
Lytle Arche Rounding, LLC

M2The Agency, Inc.
Mr. Tamotu Mabuchi
Mr. and Mrs. Jeffrey N. MacDowell
Mr. and Mrs. Roy W. Mace
The William Scott Mace Foundation
Dr. John W. MacGorman
Luis and Ana Marsho
Mr. Andrew Mackenzie
Mr. Nick Mackenzie
Employees of Macy’s
Macy’s Foundation
Mr. and Mrs. John Philip Madden
Mr. and Mrs. Robert R. Madden
Mr. and Mrs. Steven H. Madden
Mr. and Mrs. Bruce C. Maddux
Mr. and Mrs. Richard L. Madison
Mr. and Mrs. Andrew Maebius
Mr. and Mrs. Steve F. Marfige
Mr. and Mrs. Hubert E. Magee, Jr.
Louie E. Magne
Mr. Frank C. Maguire, Jr.
Mr. Jim Maher
Mr. and Mrs. Jeffrey S. Mahlmann
Mr. Wesley Mahone
Mr. Glen Makrizar Jr
Mr. Harry M. Main
Mr. and Mrs. S. Lewis Main
Main Family Foundation
Mr. Edward F. Malanda
Mr. and Mrs. Ed Malek
Marlene A. and Frederic V. Malek
Malibu Floors
Bob and Diane Malone
Mrs. Emily Malorzo
The Craig Malorzo Foundation
Dr. and Mrs. Manohar R. Manchanda
Mr. and Mrs. M. S. Mandell
The Honorable Robert A. Mandel
Mr. Anoop Mangat
Mangen Family Charitable Foundation
The Harry T. Mangurian, Jr. Foundation, Inc.
Ms. Dianne Mann
Mr. and Mrs. James I. Mann
Dr. and Mrs. Paul F. Mansfield
Mr. Robert N. Mansfield
Dr. and Mrs. Arnold O. Manske, Jr.
Ms. Hun-Chih Mao
Mr. and Mrs. James Maran
Employees of Marathon Oil
Marathon Oil Corporation
Marathon Petroleum Company, LP
Margo S. Marbut
March of Dimes Foundation
Ms. Jennifer Marcontell
The Anderson Assembly

Since its inception in 1989, The Anderson Assembly has recognized those whose support and financial contributions have enabled MD Anderson’s continued growth and progress. Listed here are members who have committed $1 million or more through cash gifts, documented cash pledges, irrevocable planned gifts and/or charitable remainder trusts to support MD Anderson programs.

Mr. and Mrs. Jerry Abbott
Addi’s Faith Foundation
Dr. Miriam & Sheldon G. Adelson Medical Research Foundation
Mr. and Mrs. Avinash C. Ahuja
Mr. and Mrs. Mark W. Albers
Joan and Stanford Alexander
Mr. and Mrs. Albert B. Alkek
American Brain Tumor Association
American Cancer Society
Amgen, Inc.
Homer Ammann Trust
Anadarko Petroleum Corporation
Estate of June Carol Anderson
M. D. Anderson Foundation
Mrs. Rita Anderson
Apache Corporation
James B. & Lois R. Archer Charitable Foundation
Lauren and John Arnold Foundation
AstraZeneca LP
Avon Foundation for Women
Mr. and Mrs. James A. Baker, III
Mr. and Mrs. Perry R. Bass
Mr. and Mrs. James A. Baker, III
Mr. and Mrs. Edward E. Crutchfield
Mr. and Mrs. William B. Finneran
Mr. and Mrs. George A. Finley, III
Mr. and Mrs. David H. Koch
Mr. and Mrs. Joseph D. Jamail, Jr.
Mr. and Mrs. M. G. and Lillie A. Johnson Foundation
Mr. and Mrs. Jerry Abbott
The J. Reed Danos Foundation
Mr. and Mrs. Jerry Abbott
The Clermont Foundation
Mr. and Mrs. Jason S. Blanton, Sr.
Mr. and Mrs. James C. Kennedy
Mr. and Mrs. Edward E. Crutchfield
Mr. and Mrs. C. Berdon Lawrence
Mr. and Mrs. Howard Lester
Leukemia & Lymphoma Society
Rochelle and Max Levit
Mr. and Mrs. Milton Levit and Family
Mr. and Mrs. Jack Lewis, Jr.
Mr. and Mrs. Thomas C. Liebman
VIVESTRONG
Mr. and Mrs. John T. Lockton, III
The Gillson Longenbaugh Foundation
The Longwell Family Foundation
Norma and Harry Longwell
Mr. and Mrs. Ben F. Love
Mr. Jho Lowl/Jynwel Charitable Foundation Limited
LUNGevity Foundation
The Lustgarten Foundation
Lymphoma Research Foundation
LyondellBasell Industries
The Harry T. Mangurian, Jr. Foundation, Inc.
Jed Manoucherian
Marathon Oil Corporation
The G. Harold and Leila Y. Mathers Charitable Foundation
M. D. Matthews Foundation
Lowry and Peggy Mays
Del and Dennis McCarthy
Red and Charline McCombs
John P. McGovern Foundation
The Robert and Janice McNair Foundation
Mr. and Mrs. Charles D. McVean
J. Ralph and Lillian H. Meadows
Melanoma Research Alliance
Mr. and Mrs. LeRoy Melcher
Mr. and Mrs. Allen A. Meyer
Estate of Anne W. McGraw
Midgley
Mr. and Mrs. George P. Mitchell
Estate of A. Clifford Mock
W. A. “Tex” and Deborah Moncrief, Jr.
Monteleone Family Foundation
Estate of Mary E. Montrose
Mr. Jerry J. Moore
Estate of Louise J. Moran
Estate of Frances Morse
The Honorable and Mrs. Robert A. Mosbacher, Sr.
Ralph E. and Virginia Mullin
Multiple Myeloma Research Foundation
Mr. and Mrs. James J. Mulva
Estate of Wanda L. Murr

Mr. and Mrs. Arthur Ciocca
CLL Global Research Foundation
The Cockrell Foundation
Mr. and Mrs. Gus Comiskey, Jr.
The Honorable and Mrs. Peter R. Coneway
ConocoPhillips
Conquer Cancer Foundation of the American Society of Clinical Oncology
Mr. and Mrs. Jack B. Corey
The James M. Cox, Jr. Foundation
Robert Page Crozer
Mr. and Mrs. Edward E. Crutchfield
The Cullen Foundation
The Cullen Trust for Health Care
Mrs. Delmer W. Dallas
Christopher and Susan Damico
Charles A. Dana Foundation
The Sidney and Charline Dauphin Foundation
Mr. William J. Doré, Sr.
John S. Dunn Research Foundation
Raymond A. Jr. and Roslyn S. Eckstein Foundation
El Paso Corporation
The Margaret and James A. Elkins, Jr. Foundation
The Ellwood Foundation
Entertainment Industry Foundation
Exxon Corporation
ExxonMobil Foundation
Diane Lokey Farb
Farmer Family Foundation
Mr. and Mrs. G. Steven Farris
The Fawrot Fund
Carolyn Grant Fay
Mr. and Mrs. David L. Feavel
Mr. and Mrs. George A. Finley, III
Mr. William B. Finneran
Ray C. Fish Foundation
Louis & Gloria Fanzer Charitable Trust
David and Judy Fleischer
Flight Attendant Medical Research Institute, Inc.
Maria & Raymond Floyd Family Foundation
Mr. and Mrs. Ford-Petrin
Mr. and Mrs. George E. Foreman
Freeport-McMoRan Copper & Gold Foundation
Estate of Frank H. Gabriel
Mr. and Mrs. James L. Gallogly
Pamela and Wayne Garrison
Mose A. Gimbel
Golfers Against Cancer
Mr. Harold V. Goodman
Mr. and Mrs. William H. Goodwin, Jr.
Mr. and Mrs. Steven L. Gordon
Mr. and Mrs. F. O’Neil Griffin
Estate of Dr. and Mrs. Ferenc Guzkey
Mr. and Mrs. Paul R. Haas
Hackett Family Foundation
Maureen and Jim Hackett Halliburton
The Hamill Foundation
The Hawn Foundation
Head for the Cure Foundation
The Hearst Foundations
Miss Lyda Hill
Hoffmann-LaRoche, Inc.
Estate of George S. Hogan/Scott Kochran, Trustee
Mike Hogg Fund
The Hoglund Foundation
Don L. and Julie Holden Foundation
Houston Endowment Inc.
Roy M. and Phyllis Gough Huffington
IBC Foundation
Interferon Foundation
Introgen Therapeutics, Inc.
Ben and Catherine Ivy Foundation
Mr. and Mrs. Joseph D. Jamail, Jr.
Judith and Weldon Jaynes
The Honorable Brenda L. Johnson and Mr. J. Howard Johnson
M. G. and Lillie A. Johnson Foundation, Inc.
Jane and John Justin Foundation
Mr. and Mrs. Michael Kadoorie
John Kanzier Cancer Research Foundation
Abraham J. and Phyllis Katz Foundation
Kavanagh Family Foundation
W. M. Keck Foundation
The John G. and Marie Stella Kenedy Memorial Foundation
Mr. and Mrs. James C. Kennedy
Khafifa Bin Zayed Al Nahyan Foundation
Killam Family Foundation
Kimberly-Clark Foundation
Sidney Kimmel Foundation
Kinder Foundation
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
Mr. and Mrs. Melvyn N. Klein
Estate of Ellen F. Knisely
Mr. and Mrs. David H. Koch
Estate of Lillian C. Koehler
Susan G. Komen Breast Cancer Foundation
Saranne and Livingston Kosberg
The State of Kuwait
Mr. and Mrs. William Kyte
Estate of Emma Lou Lancaster
Estate of Nathan W. Lassiter
Helen H. Laughery
Mrs. Theodore N. Law
Mr. and Mrs. C. Berdon Lawrence
Mr. and Mrs. Howard Lester
Leukemia & Lymphoma Society
Rochelle and Max Levit
Mr. and Mrs. Milton Levit and Family
Mr. and Mrs. Jack Lewis, Jr.
Mr. and Mrs. Thomas C. Liebman
VIVESTRONG
Mr. and Mrs. John T. Lockton, III
The Gillson Longenbaugh Foundation
The Longwell Family Foundation
Norma and Harry Longwell
Mr. and Mrs. Ben F. Love
Mr. Jho Lowl/Jynwel Charitable Foundation Limited
LUNGevity Foundation
The Lustgarten Foundation
Lymphoma Research Foundation
LyondellBasell Industries
The Harry T. Mangurian, Jr. Foundation, Inc.
Jed Manoucherian
Marathon Oil Corporation
The G. Harold and Leila Y. Mathers Charitable Foundation
M. D. Matthews Foundation
Lowry and Peggy Mays
Del and Dennis McCarthy
Red and Charline McCombs
John P. McGovern Foundation
The Robert and Janice McNair Foundation
Mr. and Mrs. Charles D. McVean
J. Ralph and Lillian H. Meadows
Melanoma Research Alliance
Mr. and Mrs. LeRoy Melcher
Mr. and Mrs. Allen A. Meyer
Estate of Anne W. McGraw
Midgley
Mr. and Mrs. George P. Mitchell
Estate of A. Clifford Mock
W. A. “Tex” and Deborah Moncrief, Jr.
Monteleone Family Foundation
Estate of Mary E. Montrose
Mr. Jerry J. Moore
Estate of Louise J. Moran
Estate of Frances Morse
The Honorable and Mrs. Robert A. Mosbacher, Sr.
Ralph E. and Virginia Mullin
Multiple Myeloma Research Foundation
Mr. and Mrs. James J. Mulva
Estate of Wanda L. Murr

70
Ms. Sara Brown Musselman
National Breast Cancer Foundation, Inc.
National Foundation for Cancer Research
The Robert R. and Kay M. Onstead Foundation
The Ovarian Cancer Research Fund
The John M. O’Quinn Foundation
Elsa U. Pardee Foundation
Ray Park and Family
Pennzoil-Quaker State Company
Phillips 66
Mr. T. Boone Pickens
Mr. Hanns Pielenz
Jack and Beverly Randall
The Randalls Foundation
Bernard and Audre Rapoport
Mr. and Mrs. James C. Roe
Ben, Julie, and Regina Rogers
Dr. Marnie Rose Foundation

**Estate of David Rosenstone**
Rotary Club of Houston Foundation
The Jerry and Maury Rubenstein Foundation
Damon Runyon Cancer Research Foundation
Mr. Andrew E. Sabin
Dr. Raymond and Beverly Sackler
Mr. and Mrs. Federico Sada
Samsung Electronics America, Inc.
The A. R. “Tony” and Maria J. Sanchez Family Foundation
SBC Foundation
Scherer Family Foundation
Scherling-Plouff Corporation
Estate of Gene Schulze
Estate of Dr. Sam Schwartzberg
Mr. Solon Scott, III
Scurlock Foundation
Peggy and Carl Sewell
Estate of Jeanne F. Shelby
Shell Oil Company Foundation
Cecil P. and Anna C. Simpson
Clara B. & W. Aubrey Smith Charitable Foundation
R. E. “Bob” and Vivian L. Smith
The William A. and Madeline Welder Smith Foundation

Mrs. Terry Sonneveld
Ron and Yatha Stading
Mr. and Mrs. Charles W. Stiefel
Stripes Convenience Stores
The Sunderland Foundation
T.L.L. Temple Foundation
Mr. and Mrs. David M. Talla
Dr. and Mrs. John C. W. Taylor
Tenneco Inc.
Texas 4000 for Cancer
Texas Federation of Business and Professional Women’s Clubs, Inc.
William G. and Dorothy K. Theisinger
Mr. and Mrs. Ron L. Thompson
Timken Foundation of Canton
Ting Tsung and Wei Fong Chao Foundation
Tony’s Prostate Cancer Research/Tony Masraff
Mrs. Shirley W. Toomim
Mr. and Mrs. Morton L. Topfer
Triumph Over Kid Cancer Foundation
Estate of Harold L. Tull
Beverly and John Turner
Herbert H. and Katharine Moore Unsworth

**Mr. Robert S. Miller**
Dr. and Mrs. Ronald G. Miller
Mrs. Shirley B. Miller
Dr. and Mrs. Stephen Miller
Mr. and Mrs. William D. Miller
Arnold and Suzanne Miller Charitable Fund
C. Wayne & Patricia J. Miller Foundation
Miller Historic Motorcars
Mr. and Mrs. Michael L. Millman
Mr. and Mrs. Danny Mills
Mr. F. H. Mills, Jr.
Mr. and Mrs. James R. Mills
W. Barry and Celia Miller
Mr. Maden Mimica
Mr. and Mrs. George W. Minor
Minor Industries
Mr. and Mrs. Forrest R. Mitchell
Mr. and Mrs. John W. Mitchell
Mr. Morris Mitchell
Mr. and Mrs. Leonard F. Mitschke
Dr. Elizabeth A. Mittendorf
Mr. and Mrs. Sam Mizrahi
M Mitr Constructions Inc.
Mobil Foundation, Inc.
Mobil Steel International, Inc.
Mr. and Mrs. Tom Mobley
Ms. Sandra K. Mobly
Ms. Frances Mosser
The Modern Group, Inc.
Modestus Bauer Foundation
Mr. and Mrs. Roger N. Moganey
Dr. and Mrs. Radhe Mohan
Ms. Julie Mohr
Mr. and Mrs. Randolph M. Moity, Sr.
Mr. and Mrs. John N. Molbeck, Jr.
Mr. and Mrs. Thomas D. Molzahn, Sr.
Mr. Joseph S. Monaghan, Jr.
Mr. and Mrs. Charles B. Moncrief
Brooke and Michael Monk
Mr. Jay Monroe

Mr. and Mrs. Thomas A. Monson
Mrs. Denise D. Monteleone
Monteleone Family Foundation
Mr. and Mrs. Terry R. Montesi
Mr. and Mrs. Ben C. Montgomery
Mr. Jimmy B. Montgomery
Mrs. Mary C. Montgomery
Susan and Bill Montgomery
Mr. and Mrs. William C. Montgomery
Montgomery County Medical Society
Montgomery Junior High School
Montgomery Trucking Co. LLC
Jeff and Sandy Monzinger
Cori Monzingo Foundation
Mr. and Mrs. Walker N. Moody
Mr. Frank S. Mooney
Mr. and Mrs. James R. Moore
Estate of Jerry J. Moore
Mr. and Mrs. John D. Moore
Lt. Colonel and Mrs. John F. Moore
Mrs. Marie O. Moore
Mr. Mason Moore
Mr. and Mrs. William Ross Moore
Mr. and Mrs. Lewis J. Moorman III
Mr. William R. Morales
Mr. John P. Moran
Estate of Louise J. Moran
Mr. Patrick J. Moran
Mr. and Mrs. Sidney S. Moran
P. J. Moran Foundation
Janet Mondecai
Mr. David M. Moreau
Ms. Emily H. Moreland
Mr. and Mrs. Howard Moreland
Morel Livestock Company, Inc.
Bill and Sara Morgan
Ms. Dolly C. Morgan
Morgan Stanley Charitable Spending Account
Morgan Stanley Global Impact Funding Trust, Inc.
Ms. Joan Morgenstern

Mr. and Mrs. Asha Murthy
Mr. and Mrs. Ravi Murthy
Dr. Asha Murthy and Dr. Ravi Murthy
Mrs. Lisa Mullins
Mr. and Mrs. C. Mullis, Jr.
Mr. and Mrs. David G. Mulock
Margaret P. Mulry
Multiple Myeloma Research Foundation
Miriam and Jim Mulva
Susan and Pat Mulvey
Mr. and Mrs. William T. Mumford
Mr. and Mrs. John E. Munday
Mr. and Mrs. Kenneth A. Munson
Mr. Myles Munson
Mr. and Mrs. Nick Munson
Mr. and Mrs. George W. Murfiee
Murfiee Engineering Company, Inc.
Mr. Spencer L. Murfiee III
Mr. George Munikan
Ms. Reba Murphey
Ms. Christina L. Murphy
Mr. and Mrs. Darrell Murphy
Ms. Erica Murphy
Mr. Larry Murphy
Ms. Linda A. Murphy
Dr. M. John Murphy
Ms. Martha W. Murphy and Mr. John W. “Jack” Lealh, Jr.
Mr. and Mrs. Richard J. Murphy
Mr. and Mrs. John A. Murray
Mrs. Sally C. Murray
Mr. Stephen B. Murray
Murray Law Firm
Dr. Asha Murthy and Dr. Ravi Murthy
Mr. and Mrs. Jeff Musgrove
Mr. and Mrs. Henry G. Musselman
Mr. Eimer T. Mussottom
Dr. Georgia Myers and Mr. S. C. Myers
Mr. and Mrs. Jeremy E. Myers
Mr. Lester W. Myers
Arthur B. & Marion V. Myers Trust Fund
Myriad Genetics, Inc.
Mr. James R. Myron
Elizabeth Mittendorf, M.D., Ph.D., associate professor of Breast Surgical Oncology.

Rosemary Herron is a 14-year breast cancer survivor and longtime Pink Ribbon Volunteer at MD Anderson’s Nellie B. Connally Breast Center. She also volunteers at MD Anderson in Sugar Land. Rosemary and her husband, Don, recently contributed $25,000 to support a HER2 vaccine research program, Injecting Hope. The program is led by Elizabeth Mittendorf, M.D., Ph.D., associate professor of Breast Surgical Oncology.

Mr. and Mrs. Shanti Neerukonda
Mr. and Mrs. Lee S. Neibert
Mr. and Mrs. DuA. Neikirk
Mr. and Mrs. Kenneth Neikirk
Mrs. Laura B. Neill
Mr. and Mrs. Donald Nelson
Mr. and Mrs. John C. Nelson
Dr. and Mrs. Ronnie E. Nelson
Tedd Nelson
Mr. and Mrs. Thomas B. Nenninger
Mr. and Mrs. Daniel Neronne
Nerenberg Foundation
Nerium Biotechnology, Inc.
Mr. and Mrs. Joseph H. Netherland, Jr.
Mr. and Mrs. Tom Netting
Mr. and Mrs. Lawrence A. Neubauer
The Neubauer Family Foundation
Mr. and Mrs. Christopher J. Neugebauer
Mr. and Mrs. Toby R. Neugebauer
Mr. and Mrs. Joseph R. Neuhaus, Jr.
Mr. and Mrs. Donald R. Neumeyer
Mr. and Mrs. Carl W. Neun
Neustadt Charitable Foundation
New Electric, Inc.
The New York Community Trust
New York Life Insurance Company
Mr. and Mrs. Sherwin S. Newar
Mr. and Mrs. David Newell
Mrs. Barbara F. Newman
Dr. Irene Newsham and Dr. Oliver Bogler
Ms. Valerie P. Newsom
Mr. Keith D. Newton
Ms. Amy T. Ng
Mr. Joe M. Nichols, Sr.
Mr. and Mrs. Warren H. Nicholson
The Stiles Nicholson Foundation
Mr. and Mrs. John T. Nickel
Mrs. Shelby Nickish
Mr. and Mrs. Jerome A. Nicolas
Mr. and Mrs. Dennis E. Nixon
NKK Switches
Noah’s Light Foundation
Kathy and Bill Noble
Noble Corporation plc
Mr. and Mrs. James W. Nobles, Jr.
Mr. and Mrs. William D. Noel
Mr. and Mrs. Jimmy W. Nokes
Mrs. Vickie T. Nolen
Mr. and Mrs. Karim K. Noonari
Mr. and Mrs. Richard Noppe
Mr. Andres S. Noriega, Jr.
Mr. and Mrs. Carlos Noriega
Norman High Volleyball Booster Club
Mrs. Esther R. Norris
Mr. and Mrs. Timothy J. Norris
Mr. and Mrs. Donald C. North
North America’s Building Trades Unions
Northern Trust
Mr. and Mrs. H. M. Northington, Jr.
Northtown Development Inc.
Northwest 45 Little League
Northwest Brotherapeutics, Inc.
Mr. Paul E. Norton
Carl Norton in memory of Shouling Liu Norton
Norton Rose Fulbright
Nosaj Inc.
Novartis Oncology
Novel Anti-Infective Technologies LLC
Mr. and Mrs. Wade T. Nowlin, Jr.
Mr. and Mrs. Wade T. Nowlin, Sr.
Mrs. Susan M. Noyes
NRG Oncology Foundation, Inc.
Diana and John Null
NuStar Logistics, L.P.
Mr. and Mrs. Thomas B. Nusz
Mr. and Mrs. William D. Oates
The Marilyn and Sonny Oates Foundation
Mr. Howard F. Oberg
Obie D. Tompkins High School
Mr. and Mrs. T. B. O’Brien
Mr. Thomas B. O’Brien
Occidental Petroleum Corporation
Occidental Petroleum Corporation Matching
Ms. Virginia O’Connell
Dr. Brendan D. O’Connor
Mrs. Lorraine Odasso
Mrs. Charles Oden
Mr. Jerry L. Oden
The Sydor and Olga Oden Foundation
Odfjell Tankers
Mrs. Mary C. Oдум
Mr. and Mrs. John H. Ogden
Mr. and Mrs. Charles M. Oglesby
Mr. and Mrs. James E. Oglesby
Beverly and Will O’Hara
Ms. Leslie A. Ohl
Mr. David E. Ohre
Mr. Patrick R. Okell
Dudley and Judy Oldham
Mark and Lynette Oxham
Mr. and Mrs. Alex H. Oliver
Mr. and Mrs. David E. Oliver
Mr. and Mrs. David M. Oliver, Jr.
Rodney and Mary Ann Oliver
The Honorable and Mrs. Lyndon L. Olson, Jr.
Mr. and Mrs. Rudolph K. Olson
Mr. and Mrs. Joseph E. Ommer
Mr. and Mrs. Alvin Oncken
Oncoceutics, Inc.
Mrs. Patty Cerf O’Neil
The Frank O’Neil Family Foundation
Mr. and Mrs. Brian E. O’Neil
Mr. and Mrs. James J. O’Neil
Steven and Rose O’Neil
OncoFoundation
ONEOK
Kay M. Onstead
Robert R. and Kay M. Onstead Foundation
Mr. and Mrs. Lawrence J. Oopalka
Operation Oligo Cure
Estate of Mildred M. Oppenheimer
The John M. O’Quinn Foundation
Orange County Building Materials, Inc.
Mr. Morris A. Orden
Mrs. Franca G. Orefice
Mr. and Mrs. Paul F. Orefice
The Orefice Foundation
Mr. Gerard V. Orelli
Dr. and Mrs. Bryant Orijako
Mr. and Mrs. Sanford H. Orkin
David A. and Cathy R. Orlando
Mr. Jason E. Ormsby
Joe and Joyce O’Rourke
 Orr Family Foundation
Mr. and Mrs. Jesse P. Orsini
Mr. and Mrs. Jose A. Ortega, Jr.
Mr. and Mrs. Pepe Ortega, Jr.
Dr. Richard M. Ostermeier
Mr. Ronald Osterberger
Dr. Richard M. Ostermeier
Mr. Tom J. Oswalt
Ms. Kathy Ott
William F. and Anne K. Outchark
Mrs. Jeanne Oudenhoven
Mr. and Mrs. John F. Oudt
Out Source Machine Co.
Overcome Non-Profit Inc.
Ovarian Cancer Research Fund, Inc.
Mrs. Anne Dale Owen
Mr. David K. Owen
Mr. Kenneth A. Owen
Dian Graves Owen Foundation
Mrs. Cindy G. Owens
Mr. and Mrs. Thomas J. Owens
Mr. and Mrs. Wilton L. Owens
Nancy Owens Memorial Foundation
Oxford Commercial
Mr. and Mrs. Henry J. Oxnard

P

P & L Cast Stone Inc.
Mr. and Mrs. Gary H. Peace
Mr. and Mrs. J. C. Peace III
The Peace Fund, Fort Worth
Pacific Consulting Group, Inc.
Padgett Stratton & Co. L.L.P.
Mr. and Mrs. Michael F. Padon
Mr. and Mrs. Carter F. Page
Mr. J. D. Page
Mr. and Mrs. Bruce Palfreyman
Mr. and Mrs. C. Robert Palmer
Mr. and Mrs. David D. Palmer
Ms. Renny Panfilioff
Ms. Natalie I. Papadim
Mr. and Mrs. Alan Z. Papernick
Pappas Restaurants, Inc.
Racial Tahoe Community Foundation
Mr. and Mrs. Robbye W. Parade
Mr. and Mrs. Dan K. Park
Mr. and Mrs. Kelly Park
Mr. Patrick Park
Rosey and Ray Park
Park East Synagogue
Mr. Arthur Parker
Ms. Barbara Parker
Mr. and Mrs. David Lyle Parker
Mr. and Mrs. David R. Parker
Mr. and Mrs. Jerre L. Parker
Mr. and Mrs. L. Edward Parker
Maggie Ryden Parker
Ms. Mary E. Parker
Estate of Page Davis Parker
Mr. and Mrs. Philip M. Parker
Mr. Robert A. Parker
Parker Drilling Company
Parker’s Building Supply
Mr. and Mrs. Donald V. Parks
The John C. and Carolyn Noonan Parmer Private Foundation
Mr. and Mrs. Brett Parrish
Mr. Jerry Parrish
Mr. and Mrs. Ronald L. Parrish
Mr. and Mrs. Alan Parrott
Morton and Susan Parsons
Mr. and Mrs. Charles A. Partain
Mrs. Elba Partridge
Mr. and Mrs. Paul Patschowski
Mr. and Mrs. Norman L. Pasas
Mr. and Mrs. Douglas Pascal
Mrs. Patrick J. Patek
Mrs. Bhatti N. Patel
Dr. Daisha M. Patel
Mr. and Mrs. Malcolm Paterson
Pathology Laboratories of Arkansas
The Patient-Centered Outcomes Research Institute
Mr. and Mrs. Leonard H. Paton
Mr. Harry S. Patten
Patten Law Firm PC
Mr. and Mrs. Harry E. Patterson, Jr.
John and Nora Patterson
Mr. Grier P. Patton
Mr. and Mrs. Robert C. Patton
Dr. Ted L. Patton
Mr. Suhas P. Pathwardhan
Ms. Janelle M. Pauer and Mr. Andrew E. Shirley
Dr. and Mrs. James A. Paulson
Ms. Ann L. Payne
Mr. and Mrs. Jarret Pazhanick
Mr. and Mrs. Arthur W. Peabody, Jr.
Peach Outreach
Mr. Guy P. Peacock
Mr. Paul A. Peacock
Mr. Christopher Pearce
Mr. and Mrs. Lee Roy Pearson III
Pecan Deluxe Candy Company
Mr. and Mrs. Patrick A. Peck
Mrs. Rodman S. Peddie
Pediatric Cancer Research Foundation
Mr. and Mrs. Roger Peery
Mrs. Kimmie C. Peet
Mr. and Mrs. Harry N. Pefanis
Mr. and Mrs. Howard Pena
Richard and Kaye Pendleton
Pendleton Foundation
Mr. and Mrs. Donor D. Penn
Pameila J. and James D. Penny
Mr. and Mrs. Robert D. Penny
Pericallis Children’s Chorus
John and Cherri Peper
Mr. Daniel Requeño
Mr. Troy B. Percival
Mr. C. G. Percy
The Percy Fund
Mr. Mark Pereira
Mr. Manuel A. Perez
Mr. Franklin T. Perkins
Colonel and Mrs. Peter L. Perkins
Mr. and Mrs. Richard D. Perkins
Permain Basin Area Foundation
Dr. and Mrs. James Perri
Mr. Leo F. Permon, Jr.
Mr. and Mrs. Chester Perry
Mr. Mills C. Perry
Mr. Sam R. Perry
Mr. Charles J. Perico
Mr. and Mrs. David Peskoff
Mr. and Mrs. Chris W. Petrie
Estate of Celina R. Petrie
Mr. and Mrs. Charles P. Peterman
Judge and Mrs. Jimmie C. Peters
Mr. and Mrs. M. Bookman Peters
Jeffrey and Candace Peterson
Dr. Judith A. Peterson and Dr. Donald N. Peterson
Ms. Mary Peterson
The Peterson Foundation
Mr. Alfred J. Petti-Clair, Jr.
Petroleum Club of Houston
Ms. Diana Pettross
Caroline Pettit and R. Richardson Pettit
June Pettus
Mr. John Ira Petty
Mr. and Mrs. Scott Pettry, Jr.
The Scott Pettry Foundation
Mr. and Mrs. Elliott Pew, Jr.
Mr. and Mrs. Carl Pfeiffer
Mr. David Phil
Ms. Marjorie L. Pflaum
Mr. and Mrs. Robert E. Phaneuf
Mrs. Jennie L. Phillips
Mr. and Mrs. John M. Phillips
Philips 66
The Waltz and Genevieve Philips Foundation
Phoenix Biotechnology, Inc.
The PhRMA Foundation
Mr. and Mrs. James M. Piccione
Beverly and Robert S. Pickelner
Mary Martha and John Picketts
Mr. T. Boone Pickens
Mr. and Mrs. William C. Pickens
Mr. and Mrs. W. E. Pielop III
Mr. and Mrs. W. Bernard Pieper
Mr. and Mrs. Edward K. Pier
Mr. Patrick R. Pierce
Mr. and Mrs. Robert R. Pierce
Ms. Sherry A. Pierce
Mrs. Trace Pierce
Mrs. Veronica Pierce
Mr. Jean Piggozi
Dr. Shirley A. Pike and Mr. James L. Pike
Mr. and Mrs. Bryan Pind快内
Pink Roses Foundation
The Pink Ribbon Shop
Ms. Patti Pinkston
Mr. and Mrs. Patrick Pinkschmidt
Mr. Walter Pipes
Mr. and Mrs. Gregory P. Pipkin
Mrs. Marilyn M. Piner
Pitc’h and Putt For A Cure
Ms. Phyllis Pitterman
Mr. and Mrs. Greg Pittzer
Dr. Carl Plager
PlanCapital Bank
Mr. and Mrs. Roger B. Plank
Mrs. Madeleine C. Plansky
Mr. and Mrs. Charles A. Plassmann
Plastic Surgery Educational Foundation
Platinum Partners
Mr. James Platt
Mr. Thomas R. Pledger
Mr. and Mrs. Edward A. Plummer
Mr. and Mrs. Daniel J. Podgurski, Jr.
Mr. and Mrs. Robert D. Poe
Dr. and Mrs. David F. Pohl
Ms. Deborah A. Polasek
Mr. David G. Potts
Mr. and Mrs. Joe E. Polk
Polk Mechanical Company, LLC
Colonel and Mrs. Arnold R. Pollard
Mr. and Mrs. Elton T. Pollock
Mr. and Mrs. David Pollock
Ms. Lenora Pool
Mr. William D. Pool
Lewis H. Pool Foundation
Mr. and Mrs. Bob Pool
Jon L. Poolie
Tula Pope
Ms. Mercedes S. Popejoy
Mr. and Mrs. Frank P. Popoff
Mr. and Mrs. Don E. Posey
Andrew & Lillian A. Posey Foundation
Mr. and Mrs. Mike Post
Mr. and Mrs. Michael J. Poulos
Mr. and Mrs. Gene Powell
Mr. Mark S. Powell
Mr. and Mrs. Richard Powell
Mr. William R. Powers
The John and Jane Powers Foundation
Tim and Katherine Powell
Mr. and Mrs. Tomasso Pozzi
Mr. and Mrs. Richard E. Prasek
Ms. Karen H. Prather
Mr. Anthony C. Pratt
Mrs. Susan S. Pratt
Mr. and Mrs. J. Dubac Preace
Mrs. Sherwood Preace
The Pink Roses Foundation
Mr. and Mrs. David E. Preng
Mrs. Sheila Prenowitz
Mr. and Mrs. Norman G. Presskitt
President Medical Services
Mr. and Mrs. Rodney L. Preut, Jr.
Prevent Cancer Foundation
The Honorable and Mrs. John Price
Mr. and Mrs. Kelly and Rebecca Price
Mr. Robert T. Price
Mr. William L. Price
John and Marca Price Family Foundation
Price Gregory International, Inc.
PricewaterhouseCoopers Foundation
PricewaterhouseCoopers LLP
Pride Foundation
Ms. Lori F. Press
Primera Companies
Primrose School of Breckinridge Park
Mrs. Ruth E. Priegle
Mr. Jonathan T. Probst
The Proctor & Gamble Fund
Prometheus Laboratories Inc.
Prostate Cancer Foundation
Mr. and Mrs. Bill Pruot
Estate of Jesse D. Puckett, Jr.
Mr. Gerry J. Pugil
Mrs. Freda E. Purkey
Purpose Institute, LLC
Mr. and Mrs. Wade Pursell
Mr. and Mrs. Ray Purzner
Mr. and Mrs. James H. Purvis
Mr. and Mrs. Kyle Purvis
Mr. and Mrs. Michael C. Puzio
Q

Qatar Foundation
Quality Electric Steel Castings, L.P.
Mr. Kenny R. Qualis
Mr. and Mrs. Steven J. Quamme
Quanex Foundation
Quantum Gas & Power Services, Ltd.
Colonel and Mrs. James Campbell Quick
Mr. and Mrs. Parker S. Quillen
Quilling, Selander, Cumminsley & Lownds PC
Mr. and Mrs. Edward Quinn
R

The R. C. Richardson Co.
The R. R. Family Foundation
Mr. and Mrs. Allen C. Rabe
Kathryn and Richard Rabinov
Roger Allan Raby
Dr. and Mrs. Mark Race
Ed Rachal Foundation
Ms. Mary Rachkind
Racing for Cancer
Radiological Society of North America
Susan and Alan Raffe
Mr. Roy M. Raffey, Jr.
Mr. C. E. Ragland
The Ragland Foundation
Mr. and Mrs. W. K. Raunbott, Jr.
Raising Cane’s Chickens Finkers
Mr. and Mrs. W. M. Ralls
Rally Foundation For Childhood Cancer Research
Mr. and Mrs. Ronald E. Rambin
Ms. Crystal E. Ramon-Miranda
Dr. Michelle Ramos and Mr. Ernest L. Ramos
Mr. and Mrs. James Ramsey
Ms. Kim E. Ramsey
Mr. Ray D. Ramsey
Ranchero Trust
Fairfax and Risher Randall
Jack P. and Beverly R. Randall
Roberta K. Randall Charitable Foundation
Edward and Ellen Randall Foundation

73
Mr. and Mrs. John Sarraf
Mr. and Mrs. Laurence R. Saslaw
Mr. and Mrs. Joshua J. Satterfield
Mr. and Mrs. Tom Saucier
Mr. and Mrs. Hugh H. Saum III
Mr. and Mrs. John T. Saunders, Jr.
G.B. & Charlotte A. Saunders Foundation, Inc.
Mr. and Mrs. Dan C. Savage
Mrs. Una Savoie
Mr. Shannon Savoy
Mr. and Mrs. Wayne Sayatovic
Dan E. and Ramona Scarlett
Ivy and Joe Scarpino
Mr. and Mrs. Donald J. Schade
Leah R. & Alfred E. Schafer Charitable Foundation
Mr. Martin L. Schaflle
Mr. and Mrs. Donald H. Schaffer
Mr. David R. Schehagen
Mr. Eric Schenk
Mr. and Mrs. William R. Scherer, Jr.
Mr. Carl M. Schexnayder, Sr.
Bob and Patricia Schefter
Mr. and Mrs. Bobbi E. Schiel
Schie B-R-G-P-B-U-F, Foundation Inc.
Dennis and Dorothy Schiffel
Mr. Michael J. Schimberg
Mr. Donald T. Schlattman
Dr. and Mrs. Russell H. Schlattman II
Mr. and Mrs. Thomas A. Schleigh, Jr.
Mr. and Mrs. Pierre M. Schlumberger
Mr. Robin Schmachtenberger
Mr. Arthur W. Schmidt
Mr. and Mrs. Christian A. Schmidt
Ms. Leslie A. Schmidt
Mr. and Mrs. Paul B. Schmidt
Mr. and Mrs. Richard W. Schmidt
The Honorable Harvey Schneider and Mrs. Marilyn Lee Schneider
Mr. and Mrs. Jay R. Schneider
Mr. and Mrs. Jeffry A. Schneider
Mr. and Mrs. Michael Schneider
Trey and Debi Schneider
Mr. and Mrs. David Schnell
Joan Weingarten Schnitzer
Mr. and Mrs. Kenneth L. Schnitzer, Jr.
Cynthia Schouler
Mr. and Mrs. Myron Scholes
Susan and David Scholes
Scholes Family Foundation
Mr. and Mrs. Jack W. Scholl
Mr. and Mrs. Kurt Schon
The Schon Charitable Foundation
Mr. and Mrs. John D. Schofield
Dr. and Mrs. John O. Schorge
Ms. Cheryl Schott
Mr. and Mrs. Bobby Schramme
Mr. and Mrs. Richard D. Schreiber
Mr. and Mrs. Bruce H. Schreppe
Mr. and Mrs. Michael T. Schuppert
Mr. and Mrs. Ted Schutz
LeRoy H. Schutz, Jr.
Mr. and Mrs. Leo R. Schuster, Jr.
Joan & Leo Schuster Charitable Trust
Mr. and Mrs. Jerry L. Schutza
Joan & Leo Schuster Charitable Trust
Mr. LeRoy H. Schulz, Jr.
Mr. and Mrs. Bruce H. Schremp
Mr. and Mrs. Richard D. Schreiber
Mr. and Mrs. Bobby W. Shoebridge
Mrs. Kelly Shoock
Shooting for a Cure
Ms. Toby Shor
Mr. and Mrs. Grady Lee Shrophoise
Ms. Jennifer L. Shufelt and Mr. Colter Harris
Mrs. George A. Shutt
Mrs. Nancy P. Shutt
Ms. Evelyn W. Sibley
Mrs. Barbara Sico
Mr. Paul J. Sides, Jr.
Mrs. Anna Sie
Anna and John J. Sie Foundation
Bobbi and Gary Siegel
Signature Real Estate Services, Inc.
SignMelUp.com
Mrs. Sue C. Sikas
Mr. and Mrs. Ronald Silber
The Robert and Christina Silberman Charitable Trust
Silicon Valley Community Foundation
Mr. and Mrs. William A. Silk, Jr.
Mr. and Mrs. George C. Sillier, Jr.
Dr. and Mrs. Bernard Silver
Ms. Heather Silver and Mr. Neil Grandhofer
Silver Eagle Distributors
Elise Silverman Trust
Mrs. Suzy Simar
Mr. James B. Simmons
Mr. and Mrs. Carl E. Simmons
Eileen C. L. Simmons and Family
Mr. and Mrs. John B. Simmons
Mr. and Mrs. Scott Simmons
Mr. Tony A. Simmons
Simmons & Company International
Mr. and Mrs. William S. Simon
Mr. Herbert D. Simons
Mrs. Jann Simons
Mr. and Mrs. Justin S. Simons
Ms. Sydney Simons
The Simons Family Foundation
Estate of Cecil P. Simpson
Mr. and Mrs. Elvin C. Simpson, Jr.
Ms. Ora Lee Sims
Dr. William E. Sims
Mr. Robert B. Singer
Ms. Mary Singh
Estate of Rose A. Sinkin
Mr. and Mrs. Howard Sinar, Jr.
SIR Foundation
Mr. and Mrs. Eric C. Singh
Mr. and Mrs. John J. Sailer
Ms. E. R. Sisson
SIUT North America, Inc.
Mr. and Mrs. Millard L. Skaggs
Mr. and Mrs. Michael B. Skalka
Mr. and Mrs. Damir S. Skerl
Mr. and Mrs. James W. Skidmore
Ms. Lillian Susan Skiles
Ms. Martise C. Skinner
Mr. and Mrs. Richard H. Skinner
Mr. and Mrs. Michael Skipski
Dr. Jared L. Sklar
Estate of Jessamine Slater
Mr. and Mrs. Denys R. Slater, Jr.
Mr. and Mrs. Paul M. Slater
Ms. Angela Slaughter
Mr. James Slaughter
Mr. and Mrs. Gene Sledge
Mr. and Mrs. Jack W. Sledge
Mr. and Mrs. William T. Stlick, Jr.
Gale and Jerry Singer
Mr. and Mrs. Melvin Sloan
Ms. Wendi E. Sloane and Dr. Steven D. Field
Small Army For A Cause, Inc.
Don and Lori Smart
Mr. and Mrs. Phil Smuadner
Judith B. Smuris
Ms. Alice U. Smith
Mrs. Ashley Smith
Mr. and Mrs. Billy A. Smith
Mr. Bruce C. Smith
Mr. and Mrs. Bubba Smith
Mr. Chadbourne B. Smith
Ms. Charis Smith
Mr. Charles Aubrey Smith, Jr.
Dr. David T. Smith
Mr. and Mrs. Dennis Smith
Ms. Dana Lynne Smith
Mr. Edwin Bomber Smith
Mr. F. Ford Smith, Sr.
Mr. and Mrs. Forrest M. Smith III
Gawlyn and Larry Smith
Mr. and Mrs. Gerald B. Smith
Mr. Greg A. Smith
Mr. and Mrs. Harvey W. Smith, Jr.
Dr. and Mrs. James A. Smith
Mrs. Jimmie Miller Smith
Mr. Kenneth James Smith
Mr. and Mrs. L. R. Smith
Mr. Landon T. Smith
Larry J. and Marsha Smith
Mr. Lawrence L. Smith
Mr. and Mrs. Robin Smith
Ms. Mary Smith
Mr. and Mrs. Michael A. Smith
Onnie Leach Smith
Mr. and Mrs. Paul H. Smith
Mr. Randlow Smith
Mr. and Mrs. Robert L. Smith
Mr. Russell Smith
Mr. Stephen F. Smith
Mr. and Mrs. Steven M. Smith
Mr. Stuart H. Smith
Ms. Sue Smith
Mr. Terence J. Smith
Mr. and Mrs. W. Brett Smith
Mr. and Mrs. Warren H. Smith
Mr. and Mrs. William F. Smith
Vivian L. Smith Foundation
The William A. and Madeline Welder Smith Foundation
Mr. and Mrs. Mark S. Smock
Mrs. Barbara Hanah Smolowitz
Mr. and Mrs. Robert G. Sneed
Mr. and Mrs. Thomas M. Snell
Mr. and Mrs. Curran Sneses
Mr. and Mrs. Kevin R. Snodgrass
Estate of Janet M. Snow
Mr. and Mrs. Dudley Snyder
Mr. and Mrs. Harold B. Snyder
Dr. James L. Snyder
Mr. John C. Snyder
Ms. Rebecca Snyder
Ms. Rosanna Snyder
G. Whitney Snyder Charitable Fund
Mr. Robert Sobczak
Mrs. John F. Soderquist
Kristen Julian Sohr Cancer Research Fund
The Harry and Estelle Soicher Foundation
Mr. and Mrs. Richard S. Sokolow
Ms. Mariajo Solferino
The Somekh Family Foundation
Somerset High School Student Council

PARTNERS IN MAKING CANCER HISTORY
Mr. and Mrs. Bob Tidwell
Mr. and Mrs. Don Tidwell
Timken-Sturgis Foundation
Mr. Terrence N. Tingley
Mr. Phillip D. Tippo
Lous Tiseo
Dr. Teresa M. Todd and Dr. David L. Todd
Todd Family Charitable Foundation
Mr. and Mrs. Eric W. K. Tom
Mr. and Mrs. Don Tomlin
Mr. and Mrs. Hank Tomlinson
Phuong Tonthat
Too’n Totum Food Stores, LLC
Mr. and Mrs. Morton L. Topfer
Topfer Family Foundation
Ms. Judith Yates Tor
Tory’s Tacos
Mr. and Mrs. Shane Torr
Mr. and Mrs. Donald E. Torres
Mr. and Mrs. Joe V. Toroncic, Jr.
Dr. Victor Tottafuki
Fiona and Dr. Robert S. Tott
W. F. Touchstone, Jr.
Mr. William Touchstone, Jr.
Jean and Seven Townsend
Mrs. Sachiko Toya
Toyota Motor Sales, U.S.A., Inc.
Tradition Financial Services
Mr. Mark Traficante
Tral-Tex, Inc.
Mr. and Mrs. L. A. Train
Ms. Jean M. Trainor
Mr. and Mrs. Joseph L. Trapolino, Jr.
Ms. Eileen Trautmann
Mr. and Mrs. Don Traweek
Mr. and Mrs. Travis Taylor, Jr.
Mrs. Betty Treadaway
Tres Aguillas Management, LLC
Mr. Maurice Tria
Triangle Community Foundation, Inc.
Mr. Richard Triece
Mr. and Mrs. Michael D. Trice
Mrs. Jamarie E. Trebel
Mr. and Mrs. George L. Trimble III
Mrs. Margaret C. Trimble
Trinity Materials
Trinity Title of Texas
Ms. Mary J. Trinkle
Tro Electric Ltd.
Triple-S Steel Holdings, Inc.
Triumph Over Kid Cancer Foundation
Ms. Cynthia Crowell Troop
Mr. and Mrs. Harley Troipn
Mr. and Mrs. Byron Trott
Trott Family Foundation
Mr. Edward R. Troy
Mr. and Mrs. Brian K. Tuby
Leslie and John Truedoe
The Taylor Truedoe Cycle for Life Foundation
Mr. Robert E. Tse
True Companion Animal Hospital
True Firm Foundation
Mr. and Mrs. Dean B. Trutt
Truman Heartland Community Foundation
Mr. and Mrs. Jerry Trumps
Kirk and Julie Russell
Mr. Joseph J. Tryba
Leah Tucker
Drs. Mark and Tina Tucker
Stephanie and Brad Tucker
Mr. and Mrs. Robert B. Tudor III
The Tuffli Family Foundation
Mr. and Mrs. Robert W. Tuly
Tulsa Community Foundation
Mr. Gatlan L. Turk
Ms. Elizabeth Turley
Mr. and Mrs. Douglas E. Uhkiru
Mr. and Mrs. James I. Uhlein
Mr. and Mrs. Billy Ulm
The Ulm Foundation
Mr. and Mrs. Walter Umphrey
Ms. Jeanne S. Umstead
Unaka Foundation
Mr. and Mrs. Timothy J. Unger
United Association of Plumbers & Pipefitters
United Seafood, Inc.
United Way of Broward County, Inc.
United Way of Central New Mexico
United Way of Galveston County
United Way of Greater Houston
United Way of Metro Chicago
United Way of Tri-State
Uniting Against Lung Cancer (currently part of the Lung Cancer Research Foundation)
The University of Wisconsin
Nick and Nancy Usplak
Mr. and Mrs. Donnie R. Urbovynko
U.S. Bolt Manufacturing, Inc.
U.S. Chamber of Commerce and Related Entities
US - Israel Binational Science Foundation
Mr. and Mrs. Bob Utter

Chris and Jess R. Turner
Mr. and Mrs. David O. Turner
Mr. John A. Turner
Mr. and Mrs. Lawrence A. Turner
Ms. Carol A. Turni
Mr. and Mrs. Douglas B. Varga
Ms. Cheryl Vasquez
Daphne Vaughan
Mr. and Mrs. George Vaughan
Mr. Gerald E. Vaughan
Susan and Gene Vaughan
Mr. and Mrs. Robert C. Vaughn
The Vaughn Foundation
Mr. and Mrs. Paul G. Veale, Jr.
Mr. and Mrs. C. Richard Vermillion, Jr.
Mr. and Mrs. Michael Verostek
Mr. Charles H. Vernini
Vertex Financial Corp.
Ms. Mary Shelton Simpson Vesceo
Mr. Samuel H. Vester, Jr.
Mr. and Mrs. John E. Vick
Mr. Sidney-Victory, Jr.
Vietnam Education Foundation
Mrs. George F. Vistor
The Village School
Mrs. Jamie L. Villas
Mr. and Mrs. Gerald J. Vilmont
Mr. Clarence Vinikarek
A.P. “Skip” Viragh
Mr. Mark S. Viragh
VISA International
Visconti Properties LLC
Mr. and Mrs. Gregory A. Vogt
Mr. John C. Vogt
Volunteer Management LLC
Mr. and Mrs. Michael J. Vorst
Mrs. Wilma Voss
Vs. Cancer Foundation
Vynkier Enclosure Systems, Inc.
Mr. and Mrs. Walter Weathers III
WCOV-TV
WCA Waste Corporation
Samuel Waxman Cancer Research Foundation
Mr. and Mrs. R. G. Watson
Mrs. Martha Watson
Howard Watson
Mr. and Mrs. Samuel H. Vester, Jr.
Mr. and Mrs. Thomas L. Vickers
Mr. and Mrs. William C. Ward
Mrs. Emily C. Ware
Mr. Herb Ware
Richard Ware
The Ware Foundation
Mr. Chauncey Edward Warner
Mr. and Mrs. John A. Warner
Mr. and Mrs. Alfred C. Warrington IV
Mr. and Mrs. Steven H. Wasserman
Mr. and Mrs. John M. Ward
Mr. and Mrs. William C. Ward
Mr. and Mrs. Robert H. Ware
Mr. and Mrs. Tony G. Watkins
Mrs. Ann Brennand Watson
Mr. Eddie Watson
Howard Watson
Mr. and Mrs. Martha Watson
Mr. and Mrs. R. G. Watson
Ms. Marilynn Kay Watts
Mr. and Mrs. Perry M. Waughtal
Samuel Waxman Cancer Research Foundation
WCA Waste Corporation
WCCO-TV
Mr. and Mrs. Jim C. Weatherly
Mr. and Mrs. Walter Weathers III
Mr. and Mrs. Andy Weaver
Mr. and Mrs. James Conrad Weaver

Robert Earl Keen provided the entertainment as more than 1,000
MD Anderson supporters raised over $305,000 to fund the fight against
cancer at the 29th annual Polo on the Prairie in Albany, Texas. Effects
of the severe drought ruled out polo play, but that didn’t deter hosts Henry
Musselman and his wife, Melinda, who dubbed the event “Party” on
the Prairie.

Mr. and Mrs. Walter Weathers III
Mr. and Mrs. Robert W. Warach
Mr. Albert J. Ward, Jr.
Mr. and Mrs. Buford Ward
Mr. and Mrs. John M. Ward
Mr. and Mrs. William C. Ward
Mr. and Mrs. Robert H. Ware
Mr. and Mrs. Tony G. Watkins
Mrs. Ann Brennand Watson
Mr. Eddie Watson
Howard Watson
Mr. and Mrs. Martha Watson
Mr. and Mrs. R. G. Watson
Ms. Marilynn Kay Watts
Mr. and Mrs. Perry M. Waughtal
Samuel Waxman Cancer Research Foundation
WCA Waste Corporation
WCCO-TV
Mr. and Mrs. Jim C. Weatherly
Mr. and Mrs. Walter Weathers III
Mr. and Mrs. Andy Weaver
Mr. and Mrs. James Conrad Weaver

Mr. and Mrs. Walter Weathers III
Mr. and Mrs. Robert W. Warach
Mr. Albert J. Ward, Jr.
Mr. and Mrs. Buford Ward
Mr. and Mrs. John M. Ward
Mr. and Mrs. William C. Ward
Mr. and Mrs. Robert H. Ware
Mr. and Mrs. Tony G. Watkins
Mrs. Ann Brennand Watson
Mr. Eddie Watson
Howard Watson
Mr. and Mrs. Martha Watson
Mr. and Mrs. R. G. Watson
Ms. Marilynn Kay Watts
Mr. and Mrs. Perry M. Waughtal
Samuel Waxman Cancer Research Foundation
WCA Waste Corporation
WCCO-TV
Mr. and Mrs. Jim C. Weatherly
Mr. and Mrs. Walter Weathers III
Mr. and Mrs. Andy Weaver
Mr. and Mrs. James Conrad Weaver
Fiscal Year 2015
financial and statistical data
## Sources of revenue (unaudited)

<table>
<thead>
<tr>
<th>Sources of Revenue</th>
<th>FY 2011</th>
<th>FY 2012</th>
<th>FY 2013</th>
<th>FY 2014</th>
<th>FY 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient Revenue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gross patient revenue (Includes inpatient, outpatient and professional services)</td>
<td>$5,544,009,390</td>
<td>$6,144,132,636</td>
<td>$6,582,112,827</td>
<td>$6,994,996,215</td>
<td>$7,567,179,285</td>
</tr>
<tr>
<td>Deductions from gross patient revenue¹</td>
<td>2,813,830,643</td>
<td>3,185,346,342</td>
<td>3,403,247,816</td>
<td>3,659,313,782</td>
<td>3,935,319,324</td>
</tr>
<tr>
<td><strong>Net patient revenue</strong></td>
<td>$2,730,178,747</td>
<td>$2,958,786,294</td>
<td>$3,178,865,011</td>
<td>$3,335,682,434</td>
<td>$3,631,859,960</td>
</tr>
<tr>
<td><strong>Restricted grants and contracts, philanthropy</strong></td>
<td>$436,638,273</td>
<td>$426,455,579</td>
<td>$565,144,559</td>
<td>$421,761,275</td>
<td>$402,702,183</td>
</tr>
<tr>
<td>State-appropriated general revenue</td>
<td>168,730,376</td>
<td>170,383,019</td>
<td>154,562,093</td>
<td>185,393,182</td>
<td>187,350,746</td>
</tr>
<tr>
<td>Auxiliary income²</td>
<td>33,232,458</td>
<td>36,957,473</td>
<td>40,674,618</td>
<td>41,502,690</td>
<td>44,808,473</td>
</tr>
<tr>
<td>Other income³</td>
<td>52,954,731</td>
<td>56,151,131</td>
<td>75,564,178</td>
<td>99,702,455</td>
<td>107,422,200</td>
</tr>
<tr>
<td>Investment and other non-operating income</td>
<td>239,483,083</td>
<td>87,098,290</td>
<td>180,428,432</td>
<td>328,881,907</td>
<td>121,624,475</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td>$3,661,217,668</td>
<td>$3,735,831,786</td>
<td>$4,135,238,891</td>
<td>$4,412,923,943</td>
<td>$4,495,768,037</td>
</tr>
</tbody>
</table>

¹ Amounts discounted from established rates as a result of agreements with third-party payors, including Medicare, Medicaid and insurance companies. Also includes deductions associated with indigent care and bad debt.

²Funds received from parking fees, valet services, dining facilities, hotel charges, gift shop sales and vending-machine sales

³Includes tuition and student fees, Children’s Art Project sales, management fees and other sources
# Sources of revenue (unaudited)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient Revenue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gross patient revenue (Includes inpatient, outpatient and professional services)</td>
<td>$5,544,009,390</td>
<td>$6,144,132,636</td>
<td>$6,582,112,827</td>
<td>$6,994,996,215</td>
<td>$7,567,179,285</td>
</tr>
<tr>
<td><strong>Deductions from gross patient revenue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2,813,830,643</td>
<td>3,185,346,342</td>
<td>3,403,247,816</td>
<td>3,659,313,782</td>
<td>3,935,319,324</td>
</tr>
<tr>
<td><strong>Net patient revenue</strong></td>
<td>$2,730,178,747</td>
<td>$2,958,786,294</td>
<td>$3,178,865,011</td>
<td>$3,335,682,434</td>
<td>$3,631,859,960</td>
</tr>
<tr>
<td><strong>Restricted grants and contracts, philanthropy</strong></td>
<td>$436,638,273</td>
<td>$426,455,579</td>
<td>$505,144,559</td>
<td>$421,761,275</td>
<td>$402,702,183</td>
</tr>
<tr>
<td><strong>State-appropriated general revenue</strong></td>
<td>$168,730,376</td>
<td>$170,383,019</td>
<td>$154,562,093</td>
<td>$185,393,182</td>
<td>$187,350,746</td>
</tr>
<tr>
<td><strong>Auxiliary income</strong></td>
<td>$33,232,458</td>
<td>$36,957,473</td>
<td>$40,674,618</td>
<td>$41,502,690</td>
<td>$44,808,473</td>
</tr>
<tr>
<td><strong>Other income</strong></td>
<td>$52,954,731</td>
<td>$56,151,131</td>
<td>$75,564,178</td>
<td>$99,702,455</td>
<td>$107,422,200</td>
</tr>
<tr>
<td><strong>Investment and other non-operating income</strong></td>
<td>$239,483,083</td>
<td>$87,098,290</td>
<td>$180,428,432</td>
<td>$328,881,907</td>
<td>$121,624,475</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td>$3,661,217,668</td>
<td>$3,735,831,786</td>
<td>$4,135,238,891</td>
<td>$4,412,923,943</td>
<td>$4,495,768,037</td>
</tr>
</tbody>
</table>

**Uses of revenue (in millions)**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Instruction, academic support and public service</td>
<td>$153,409,591</td>
<td>$164,580,132</td>
<td>$209,633,502</td>
<td>$195,968,981</td>
<td>$225,871,577</td>
</tr>
<tr>
<td>Patient care</td>
<td>$1,704,851,239</td>
<td>$1,880,230,560</td>
<td>$2,013,554,826</td>
<td>$2,055,617,566</td>
<td>$2,369,972,993</td>
</tr>
<tr>
<td>Facilities and depreciation</td>
<td>$427,461,242</td>
<td>$460,445,328</td>
<td>$471,935,938</td>
<td>$486,793,306</td>
<td>$508,973,014</td>
</tr>
<tr>
<td>Institutional support, auxiliary and other⁴</td>
<td>$248,601,648</td>
<td>$260,844,123</td>
<td>$305,390,616</td>
<td>$312,865,408</td>
<td>$155,828,553</td>
</tr>
</tbody>
</table>
| Allocation to capital plan  
(For future projects to replace and improve facilities and technology) | $606,311,739  | $402,895,083  | $546,059,455  | $729,743,695  | $566,878,529  |

**TOTAL EXPENSES** | $3,661,217,668 | $3,735,831,786 | $4,135,238,891 | $4,412,923,943 | $4,495,768,037 |

### Uses of revenue (in millions)

- **Research**: $688.2 (14.7%)
- **Instruction, Academic Support and Public Service**: $225.9 (5.0%)
- **Patient Care**: $2,370.0 (52.7%)
- **Facilities and Depreciation**: $509.0 (11.3%)
- **Institutional Support, Auxiliary and Other⁴**: $155.8 (3.5%)
- **Allocation to Capital Plan**: $557.0 (12.6%)  
  (For future projects to replace and improve facilities and technology)

### Gross revenue by payor classification (in millions)

- **Medicare**: $2,207.0 (29.2%)
- **Medicaid**: $147.2 (1.9%)
- **Managed Care**: $4,704.0 (62.2%)
- **Indigent**: $75.8 (1.0%)
- **Other (International/Self Pay/Other)**: $433.1 (5.7%)

---

⁴Includes support for parking, food and gift shop services, as well as general institutional support (e.g. information technology, human resources, administration, development activities, etc.)
Clinical profile

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital admissions</td>
<td>25,230</td>
<td>26,726</td>
<td>27,905</td>
<td>27,761</td>
<td>28,167</td>
</tr>
<tr>
<td>Patient days</td>
<td>180,354</td>
<td>191,735</td>
<td>202,553</td>
<td>202,636</td>
<td>202,483</td>
</tr>
<tr>
<td>Average daily census</td>
<td>504</td>
<td>536</td>
<td>569</td>
<td>571</td>
<td>574</td>
</tr>
<tr>
<td>Average length of stay</td>
<td>7.1</td>
<td>7.2</td>
<td>7.3</td>
<td>7.3</td>
<td>7.2</td>
</tr>
<tr>
<td>Average number of inpatient beds</td>
<td>594</td>
<td>616</td>
<td>635</td>
<td>654</td>
<td>665</td>
</tr>
<tr>
<td>Outpatient clinic visits, treatments, procedures</td>
<td>1,190,568</td>
<td>1,281,489</td>
<td>1,338,706</td>
<td>1,363,008</td>
<td>1,440,684</td>
</tr>
<tr>
<td>Pathology/laboratory medicine procedures</td>
<td>10,937,213</td>
<td>11,619,591</td>
<td>11,718,405</td>
<td>12,005,766</td>
<td>12,334,917</td>
</tr>
<tr>
<td>Diagnostic imaging procedures</td>
<td>515,999</td>
<td>497,660</td>
<td>501,887</td>
<td>523,297</td>
<td>530,590</td>
</tr>
<tr>
<td>Surgery hours</td>
<td>63,230</td>
<td>66,241</td>
<td>70,221</td>
<td>69,506</td>
<td>69,987</td>
</tr>
<tr>
<td>Total active clinical protocols</td>
<td>1,048</td>
<td>1,078</td>
<td>1,065</td>
<td>1,101</td>
<td>1,197</td>
</tr>
</tbody>
</table>

Workforce

20,722 total employees
1,714 faculty
906 onsite trained volunteers
2,224 offsite myCancerConnection trained survivor volunteers
145,452 volunteer hours

MD Anderson provided more than $186.2 million in uncompensated care to Texans with cancer in FY15. *This figure includes unreimbursed costs of care for patients who either have no insurance or are underinsured, or whose care was not fully covered by government-sponsored health programs.
Total philanthropic gift support by type

<table>
<thead>
<tr>
<th>Cash gifts</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporations</td>
<td>$11,561,214</td>
</tr>
<tr>
<td>Foundations</td>
<td>31,879,345</td>
</tr>
<tr>
<td>Individuals</td>
<td>45,129,641</td>
</tr>
<tr>
<td>Organizations</td>
<td>5,228,055</td>
</tr>
<tr>
<td>Trusts and estates</td>
<td>3,753,821</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>$97,552,076</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pledge gifts</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporations</td>
<td>$8,410,928</td>
</tr>
<tr>
<td>Foundations</td>
<td>20,006,229</td>
</tr>
<tr>
<td>Individuals</td>
<td>18,086,352</td>
</tr>
<tr>
<td>Organizations</td>
<td>12,214,275</td>
</tr>
<tr>
<td>Trusts and estates</td>
<td>98,700,886</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>$157,418,670</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gifts-in-kind</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporations</td>
<td>$195,073</td>
</tr>
<tr>
<td>Foundations</td>
<td>1</td>
</tr>
<tr>
<td>Individuals</td>
<td>37,180</td>
</tr>
<tr>
<td>Organizations</td>
<td>24</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td><strong>$232,278</strong></td>
</tr>
</tbody>
</table>

| TOTAL               | $255,203,024  |

Total philanthropic gift support by purpose (in millions)

- **$14.7** | Annual/unrestricted/undesignated | 5.8%
- **$10.2** | Education/prevention/patient assistance | 4.0%
- **$230.3** | Research | 90.2%

1. These dollars fund institutional peer-reviewed research.
2. Donor-targeted gifts to research conducted in all mission areas.
Sources of research expenditures

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>External funding for research</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Federal grants, contracts</td>
<td>$236,413,656</td>
<td>$196,753,104</td>
<td>$182,970,502</td>
<td>$158,986,303</td>
<td>$161,170,908</td>
</tr>
<tr>
<td>Private industry grants, contracts</td>
<td>$59,582,449</td>
<td>$68,413,794</td>
<td>$65,579,036</td>
<td>$75,307,463</td>
<td>$81,076,353</td>
</tr>
<tr>
<td>Philanthropy, foundations</td>
<td>$98,150,749</td>
<td>$100,794,491</td>
<td>$101,642,898</td>
<td>$147,016,586</td>
<td>$172,412,727</td>
</tr>
<tr>
<td><strong>Total external funding</strong></td>
<td>$394,146,854</td>
<td>$365,961,389</td>
<td>$350,192,436</td>
<td>$381,310,352</td>
<td>$414,659,988</td>
</tr>
<tr>
<td><strong>State funding allocated for research</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>State-appropriated general revenue</td>
<td>$14,767,719</td>
<td>$11,618,126</td>
<td>$11,776,785</td>
<td>$13,636,669</td>
<td>$13,658,113</td>
</tr>
<tr>
<td>Tobacco settlement receipts</td>
<td>10,654,928</td>
<td>8,854,774</td>
<td>5,837,249</td>
<td>11,175,016</td>
<td>10,227,690</td>
</tr>
<tr>
<td>CPRIT</td>
<td>8,670,289</td>
<td>19,546,278</td>
<td>24,262,525</td>
<td>$25,072,890</td>
<td>$32,049,453</td>
</tr>
<tr>
<td><strong>Total state funding</strong></td>
<td>$34,092,936</td>
<td>$40,019,178</td>
<td>$41,876,559</td>
<td>$49,884,575</td>
<td>$55,935,256</td>
</tr>
<tr>
<td><strong>Internal funding allocated for research</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospital operating margins</td>
<td>$175,424,228</td>
<td>$215,527,886</td>
<td>$192,770,342</td>
<td>202,607,346</td>
<td>198,607,568</td>
</tr>
<tr>
<td>Institutional grants*</td>
<td>20,239,439</td>
<td>26,032,444</td>
<td>95,730,271</td>
<td>102,391,157</td>
<td>111,374,655</td>
</tr>
<tr>
<td><strong>Total internal funding</strong></td>
<td>$195,663,667</td>
<td>$241,560,330</td>
<td>$278,500,613</td>
<td>$304,998,503</td>
<td>$309,982,223</td>
</tr>
<tr>
<td><strong>TOTAL RESEARCH EXPENDITURES</strong></td>
<td>$623,903,457</td>
<td>$647,540,897</td>
<td>$670,569,608</td>
<td>$736,193,430</td>
<td>$780,577,467</td>
</tr>
</tbody>
</table>

*Philanthropic donations to the institution internally designated to support research and PRS funds internally allocated to support research activities. Source - THECB Report (Research Finance)

**Education profile**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical residents, fellows</td>
<td>1,141</td>
<td>1,187</td>
<td>1,231</td>
<td>1,276</td>
<td>1,507</td>
</tr>
<tr>
<td>Research trainees</td>
<td>1,629</td>
<td>1,714</td>
<td>1,743</td>
<td>1,853</td>
<td>1,890</td>
</tr>
<tr>
<td>Observers, visitors, special programs</td>
<td>429</td>
<td>431</td>
<td>507</td>
<td>452</td>
<td>752</td>
</tr>
<tr>
<td>Nursing trainees</td>
<td>2,320</td>
<td>2,531</td>
<td>1,306*</td>
<td>1,238</td>
<td>1,352</td>
</tr>
<tr>
<td>Student programs participants</td>
<td>1,102</td>
<td>1,317</td>
<td>1,396</td>
<td>1,204</td>
<td>817</td>
</tr>
<tr>
<td>School of Health Professions students</td>
<td>248</td>
<td>316</td>
<td>291</td>
<td>318</td>
<td>303</td>
</tr>
<tr>
<td><strong>TOTAL TRAINEES</strong></td>
<td>6,869</td>
<td>7,496</td>
<td>6,474</td>
<td>6,341</td>
<td>6,621</td>
</tr>
</tbody>
</table>

*Total includes academic credit clinical placement only. Previous data included outreach and CPRIT education programs.
LOCATIONS
MD Anderson has Houston-area locations in the Texas Medical Center, Bay Area, Katy, Sugar Land, The Woodlands, Bellaire and West Houston (diagnostic imaging), Memorial City (surgery) and The Woman’s Hospital of Texas (gynecologic oncology). MD Anderson physicians also provide cancer care to Harris County’s underserved patients at Lyndon B. Johnson Hospital. In addition, there are two research campuses in Bastrop County, Texas. The institution also has developed a network of national and international locations.

MD ANDERSON CANCER NETWORK®
www.mdanderson.org/cancernetwork

PARTNER MEMBERS
• Banner MD Anderson Cancer Center (Gilbert, Arizona)
• MD Anderson Cancer Center at Cooper (Camden, New Jersey)
• MD Anderson Cancer Center at Summit Medical Group (Berkeley Heights, New Jersey)
• Baptist MD Anderson Cancer Center (Jacksonville, Florida)

CERTIFIED MEMBERS
• 14 health systems and hospitals in 12 states

ASSOCIATE MEMBERS
• Hospital Israelita Albert Einstein (São Paulo, Brazil)
• MD Anderson Cancer Center Madrid (Spain)

AFFILIATE MEMBERS
• MD Anderson Radiation Treatment Center at American Hospital (Istanbul, Turkey)
• MD Anderson Radiation Treatment Center at Presbyterian Kaseman Hospital (Albuquerque, New Mexico)

Julie Penne, interim director, External Communications

EDITOR
Andy Olin, program director, External Communications

DESIGNER
Michael Clarke

Photography by Wyatt McSpadden.
Additional photography by Adolfo Chavez III (inside front cover), Eric Kayne (pages 12 and 27) and Nick de la Torre (pages 17, 23, 30 and 43).

Conquest is published by the MD Anderson Cancer Center Board of Visitors on behalf of MD Anderson.
All correspondence should be addressed to the Communications Office - Unit 700, MD Anderson Cancer Center, 6900 Fannin St., Houston, Texas 77030-3800, 713-792-3457.
Email: ConquestMagazine@mdanderson.org. Articles and photos may be reprinted with permission.

For information on supporting programs at MD Anderson, please contact Patrick Mulvey, vice president, Development, 713-792-3450, or visit the myGiving website at www.mdanderson.org/gifts/q0215.

For information on patient services at MD Anderson, call askMDAnderson at 877-632-6789, or log on to www.mdanderson.org/ask.

© 2016 The University of Texas MD Anderson Cancer Center
Not printed at state expense. Printed with soy-based ink.

Visit the Conquest website at www.mdanderson.org/conquest.